1
Status: Approved , Date: 16 December 2019Janssen Research & Development *
Clinical Protocol
A Multicenter, Open -Label Trial of Intravenous Golimumab, a Human Anti- TNFα 
Antibody, in Pediatric Subjects W ith Active Polyarticular Course Juvenile Idiopathic 
Arthritis Despi[INVESTIGATOR_40917]-VIVA
Protocol CNTO148JIA3003 ; Phase 3
Amendment INT -4
SIMPONI®(golimumab ) for Intravenous Use
*Janssen Research & Development is a global organization that operates through different legal entities in 
various countries. Therefore, the legal entity acting as the Sponsor for Janssen Research & Development 
studies may vary, such as, but not limited to Janssen Biotech, Inc.; Janssen Products, LP; Janssen 
Biologics, BV; Janssen- Cilag International NV; Janssen, Inc; Janssen Infectious Diseases BVBA; Janssen 
R&D Ireland; or Janssen Research & Development, LLC. The term “Sponsor” is used throughout the 
protocol to represent these various legal entities; the Sponsor is identified on the Contact [CONTACT_23756].
This study  will be conducted under US Food & Drug Administration I NDregulations 
(21 CFR Part 312).
Status: Approved
Date: 16 December 2019
Prepared by: [CONTACT_12945] & Development, LLC
EDMS No: EDMS- ERI-71227414, 6.0
GCP Compliance: This study will be conducted in compliance with Good Clinical Practice, and applicable regulatory 
requirements .
Confidentiality Statement
The information in this document contains trade secrets and commercial information that are privileged or confidential and ma y 
not be disclosed unless such disclosure is required by [CONTACT_784]. In any event, persons to whom the 
information is disclosed must be informed that the information is privileged or confidential and may not be further disclosed by 
[CONTACT_476]. These restrictions on disclosure will apply equally to all future information supplied to you that is indicated as privileged or 
confidential.
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
2
Status: Approved ,Date: [ADDRESS_42652] OF IN -TEXT T ABLES A ND FIGU RES ................................................................................................ 5
PROTOCOL A MENDMENTS ....................................................................................................................... 6
SYNOPSIS .................................................................................................................................................. 64
TIME AND EVENTS SCHE DULES ............................................................................................................ 69
ABBREVIA TIONS ...................................................................................................................................... 77
1. INTRODUCTION ................................................................................................................................ 79
1.1. Background .................................................................................................................................... 79
1.1.1. Juvenile Idiopathic Arthritis ......................................................................................................... 79
1.1.2. Golim umab C linical Studies in Rheumatoid Arthritis and Juvenile Idiopathic Arthritis ............... 80
[IP_ADDRESS]. Intravenous Golimumab in Adult Rheumatoid Arthritis ........................................................... 81
[IP_ADDRESS]. Subcutaneous Golimumab in Juvenile Idiopathic Arthritis ...................................................... 84
1.2. Overall Rationale for t he Study ...................................................................................................... 86
2. OBJECTIVES A ND HYPOT HESIS ................................................................................................... 87
2.1. Objectives ...................................................................................................................................... 87
2.2. Hypothesis ..................................................................................................................................... 87
3. STUDY DESIGN A ND RA TIONA LE................................................................................................ .87
3.1. Overview of Study Design .............................................................................................................. 87
3.1.1. Week 0 Through Week 28.......................................................................................................... 89
3.1.2. Week 28 Through Week 52........................................................................................................ 89
3.1.3. Week 52 Through Week 252 (Long -term Extension) ................................................................ .89
3.1.4. After Week 252 (Extended Treatment Period) ........................................................................... 90
3.1.5. End of Study Definition ............................................................................................................... 90
3.2. Study Design Rationale .................................................................................................................. 90
3.2.1. Blinding, Control, Study Phase/Periods, Treatment Groups ...................................................... [ADDRESS_42653] POPUL ATION.................................................................................................................. 91
4.1. Inclusion Criteria ............................................................................................................................ 92
4.2. Exclusion Criteria ........................................................................................................................... 97
4.3. Prohibitions and Restrictions ....................................................................................................... 100
5. TREA TMENT A LLOCA TION AND BLINDING ............................................................................... 101
6. DOSA GE A ND A DMINISTR ATION................................................................................................ 101
6.1. Golim umab................................................................................................................................... 101
6.2. Methotrexate ................................................................................................................................ 102
7. TREA TMENT COMPLIA NCE .......................................................................................................... 102
8. PRESTUDY A ND CONCOMI TANT THERA PY.............................................................................. 102
9. STUDY EVA LUATIONS .................................................................................................................. 104
9.1. Study Procedures ......................................................................................................................... 104
9.1.1. Overview ................................................................................................................................... 104
9.1.2. Screening Phase ...................................................................................................................... 105
9.1.3. Treatment Phase: Week 0 Through Week 28.......................................................................... 106
9.1.4. Treatment Phase: After Week 28 Through Week 52............................................................... 107
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
3
Status: Approved ,Date: 16 December [ZIP_CODE].1.5. Long- Term Extension Phase: Afte r Week 52 Through W eek 252 ........................................... 107
9.1.6. Extended Treatment Period ...................................................................................................... 108
9.2. Efficacy ......................................................................................................................................... 108
9.2.1. Evaluations ............................................................................................................................... 108
[IP_ADDRESS]. Joint Evaluation ..................................................................................................................... 108
[IP_ADDRESS]. American College of Rheumatology Pediatric Response ..................................................... 109
[IP_ADDRESS]. Physician Global Assessment of Disease Activity ................................................................ .110
[IP_ADDRESS]. Childhood Health Assessment Questionnaire ....................................................................... 110
[IP_ADDRESS]. C-reactive Protein .................................................................................................................. 111
[IP_ADDRESS]. Juvenile Arthritis Disease Activity Score (JADAS) ................................................................ 111
9.2.2. Endpoints .................................................................................................................................. 111
9.3. Pharmacokinetics and Immunogenicity ....................................................................................... 112
9.3.1. Evaluations ............................................................................................................................... 112
9.3.2. Analytical Procedures ............................................................................................................... 112
9.3.3. Pharmacokinetic Parameters ................................................................................................... 113
9.3.4. Immunogenicity Assessments (Antibodies to Golimumab) ...................................................... [ADDRESS_42654] COMPLETION/W ITHDRA WAL..................................................................................... [ADDRESS_42655] Information ...................................................................................................................... 120
11.2. Sample Size Determination ......................................................................................................... 121
11.3. Efficacy  Analyses ......................................................................................................................... 121
11.4. Pharmacokinetic Analy ses........................................................................................................... 122
11.5. Immunogenicity Analyses ............................................................................................................ 122
11.6. Pharmacokinetic/Pharmacodynamic Analyses ............................................................................ [ADDRESS_42656] ug.............................................................................................. 129
14.2. Packaging .................................................................................................................................... 130
14.3. Labeling ........................................................................................................................................ 130
14.4. Preparation, Handling, and Storage ............................................................................................. 130
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
4
Status: Approved ,Date: [ADDRESS_42657] ................................................. 132
16.2.3. Informed Consent ..................................................................................................................... 134
16.2.4. Privacy of Personal Data .......................................................................................................... 135
16.2.5. Long- Term Retention of Samples for Additional Future Res earch .......................................... 135
16.2.6. Countr y Selection ..................................................................................................................... 135
17. ADM INISTRA TIVE REQUI REM ENTS ............................................................................................ 136
17.1. Protocol Amendments .................................................................................................................. 136
17.2. Regulatory Documentation .......................................................................................................... 136
17.2.1. Regulatory Approval/Notification .............................................................................................. [ADDRESS_42658] Identification, Enrollment, and Screening Logs .............................................................. 137
17.4. Source Documentation ................................................................................................................. 137
17.5. Case Report Form Completion .................................................................................................... 138
17.6. Data Quality Assurance/Quality Control ...................................................................................... [ADDRESS_42659] Retention ......................................................................................................................... 139
17.8. Monitoring .................................................................................................................................... 140
17.9. Study Com pletion/Termination ..................................................................................................... 141
17.9.1. Study Com pletion ..................................................................................................................... 141
17.9.2. Study Termination ..................................................................................................................... 141
17.10. On-Site Audits .............................................................................................................................. 141
17.11. Use of Information and Publication .............................................................................................. 141
REFERENCES .......................................................................................................................................... 144
ATTACHMENT 1 QUA NTIF ERON®-TB GOLD TESTING ....................................................................... 146
ATTACHMENT 2 TUBERCU LIN SKIN TESTING ................................................................................... 149
ATTACHMENT 3 HEPA TITIS B VIRUS (HBV) SCREENING ................................................................ .151
ATTACHMENT 4: A NTICI PATED EVENTS ............................................................................................ 152
ATTACHMENT 5: SLIT L AMP EVA LUATIONS ...................................................................................... 153
ATTACHMENT 6: EXTEND ED TREA TMENT PERIOD .......................................................................... 154
INVESTIGA TOR A GREEME NT............................................................................................................... 161
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
5
Status: Approved ,Date: [ADDRESS_42660] OF IN -TEXT TA BLES A ND FIGU RES
TABLES
Table 1: Screening Through W eek 52.................................................................................................... 69
Table 2: From  Week 60 Through Week 156 (Long -term Extension) ...................................................... 73
Table 3: From  Week 164 Through W eek 252 (Continuation of Long -term Extension) .......................... 75
Table 4: Approximate Volume of Blood t o be Collected From Each Subject Through W eek 252 ....... 105
FIGURES
Figure 1: Schematic Overview of the Study ............................................................................................. 88
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
6
Status: Approved ,Date: [ADDRESS_42661] recent amendment.
Amendment 4 (16December 2019 )
The overall reason for the amendment: The ov erall reason sfor th isamendm ent are: 1) toallow  continued 
treatment of subjects in the long -term extension (LTE) phase of the study (Week 52 through Week 252) that more 
closely resembles a real -world setting, collects critical safety information, and reduces the burden to subjects ,and 2) 
to add details regarding an Extended Treatment Period (ETP) whichallow ssubjects who are <18 years of age who 
are benefit ingfrom treatment to continue to receive golimumab after Week 252 if the drug is not commercially 
available .
Applicable Section(s) Description of Change(s)
Rationale: To change the collection of concomitant medications during the LTE to review and documentation of 
concomitant medications in source with update to the concomitant medications case report form ( CRF )page to 
include only those medications that are associated with adverse events ( AEs) and serious adverse events (SAEs) .
Corresponding text was updated in Section 8 (Prestudy and Concomitant Therapy).
Time and Events 
Schedule s
Table [ADDRESS_42662] and document in source ;update 
concom itant medication CRF page to include only those medications that are 
associated with AEs and SAEs (ie, used to treat event or suspected in causing event) .
8. Prestudy and 
Concomitant TherapyPrestudy JIA medications administered before the first dose of study agent must be 
recorded at screening. All co ncomitant therapi[INVESTIGATOR_40918] [ADDRESS_42663] on the CRF page only those concom itant 
medications that are associated with AEs and SAEs (ie, used to treat event or 
suspected in causing event) .
All therapi[INVESTIGATOR_014] (prescription or over -the-counter medications, including vaccines, vitamins, 
herbal supplements; non -pharmacologic therapi[INVESTIGATOR_40919]) different from the study drug must be recorded in the CRF through 
Week52. Recorded information will include a description of the type of the drug, 
treatment period, dosing regimen, route of administration, and its indication. Modification 
of an effective pre -existing therapy should not be made for the explicit purpose of e ntering 
a subject into the study .
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
7
Status: Approved ,Date: 16 December 2019Applicable Section(s) Description of Change(s)
Rationale: To change the frequency of review of systems ,QuantiFERON®-TB Gold test ,and the collection of vital 
signs before, during, and after an infusion in the LTE to at the discretion of the investigator to more close ly follow 
standard medical practice. Corresponding text was updated in Section 9.4 (Safety Evaluations).
Time and Events 
Schedule s
Table 2 and 3Revie w of systems ,QuantiFERON®-TB Gold test , and requirement for collection of vital 
signs before, during, and after the infusion have been updated to indicate that they are to 
be performed at the discretion of the investigator during the LTE.
Footnote d. d. Vital signs should be taken pre- infusion; at 15 and 30 minutes (15 -minute intervals 
during the infusion ); and at 60 and 90 minutes (during the 1 -hour observation period 
following the infusion).
Footnote f . f.Testing is not required for subjects w ith a history of latent TB and ongoing treatment for 
latent TB or documentation of having completed adequate tr eatment
Time and Events 
Schedule s
Table 2
Footnote d .d. Perform  at the discretion of the investigator.
Time and Events 
Schedule s
Table 3
Footnote e.e. Perform  at the discretion of the investigator.
9.4. Safety 
Evaluations 
(Vital Signs)Vital signs should be taken pre -infusion; at 15 and 30 minutes (15 -minute intervals during 
the infusion); and at 60 and 90 minutes (during the 1 -hour observation period following 
the infusion) through Week 52 . After Week 52, vital signs should be taken at the 
discreti on of the investigator.
9.4. Safety 
Evaluations 
(Physical 
Examination )Physical examinations, including a skin exam at every physical examination and Tanner 
staging at least every 6 months for sexual maturity will be performed (through Week 52 
only) according to the Time and Events Schedule. Revie w of systems will be performed at 
all visits through Week 52 to evaluate for new symptomatology and if necessary, full 
physical examination may be performed at investigator discretion. After Week 52, review 
of system s will be performed at investigator discretion. Any clinically significant 
abnormalities persisting at the end of the study will be followed by [CONTACT_40966] a clinically stable endpoint.
9.4. Safety 
Evaluations
(Early Detection of 
Active Tuberculosis )To aid in the early detection of TB, reactivation, or new TB infection during study 
participation, subjects must be evaluated for signs and symptoms of active TB at scheduled 
visits (refer to Time and E vents Schedule) or by [CONTACT_40967] 8 
to 12 w eeks through Week 252. After Week 252, TB evaluation will be carried out at 
investigator discretion and according to local and country guidelines for 
immunosuppressed patients .The follow ing series of questions is suggested for use 
during the evaluation.
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
8
Status: Approved ,Date: 16 December 2019Applicable Section(s) Description of Change(s)
9.4. Safety 
Evaluations 
(Early Detection of 
Active Tuberculosis)Annual QuantiFERON®-TB Gold (and tuberculin skin) testing at Week [ADDRESS_42664] radiograph, a repeat 
QuantiFERON®-TB Gold test, a repeat tuberculin skin test in countries in which the 
QuantiFERON®-TB Gold test is not approved/registered, and, if possible, referral to a 
physician specializing in TB to determine the subject’s risk of developi[INVESTIGATOR_40920] w arranted. The QuantiFERON®-TB Gold test (and 
tuberculin skin test) does not need to be repeated for subjects with a history of latent TB, 
and ongoing treatment for latent TB, or documentation of having completed adequate 
treatment for TB. If the QuantiFERON®-TB Gold test result is indeterminate, the test 
should be r epeated as outlined in Section 9.1.2. Subjects should be encouraged to return 
for all subsequent scheduled study visits according to the protocol.
Rationale: To remove Tanner staging during the LTE since this exam may place investigators and subjects in a n 
unnecessary uncomfortable situation ,may be particularly burdensome for subjects , and no safety concerns have 
been identified.
Time and Events 
Schedules
Table 2
Footnote e.e.c.Includes skin examination at every physical examination and Tanner staging 
approximately every 6 months .
Time and Events 
Schedules
Table 3
Footnote f.f.c.Includes skin exam and Tanner staging .
Rationale: To decrease the frequency of routine laboratory analyses and antinuclear antibodies ( ANA )/anti-dsDNA 
antibodies collected during the LTE. With decreased laboratory sampling, Footnote c. w as added to Table [ADDRESS_42665] is decr eased w ith the implementation of 
Protocol Amendment 4.
Time and Events 
Schedule s
Table 2 and 3The frequency of collection of routine laboratory analyses during the LTE has been 
decreased from every 24 w eeks to once yearly. The collection of ANA/anti -dsDNA 
antibodies has been changed from occurring every  [ADDRESS_42666] during the study ; with imple mentation of Protocol Amendment 4, the volume 
of blood collected will be decreased.
Rationale: To change the frequency of collection of chest x -rays during the LTE to at the discretion of the 
investigator.
Time and Events 
Schedules
Table [ADDRESS_42667] x -ray screening should be performed at the discretion of the investigator and
asper local and country regulations for initiation of children with JIA who are receiving
immunosuppressive agents in children with JIA and who are at risk of TB.
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
9
Status: Approved ,Date: 16 December 2019Applicable Section(s) Description of Change(s)
Time and Events 
Schedules
Table [ADDRESS_42668] x -ray screening should be performed at the discretion of the investigator 
andasper local and country regulations for initiation of children with JIA who are 
receiving immunosuppressive agents in children with JIA and who are at risk of TB.
Rationale: To change the frequency of uveitis and slit lamp evaluations during the LTE to at the discretion of the 
investigator and per s tandard of care. Corresponding text was updated in Section 9.4 (Safety Evaluations) and 
Attachment 5 (Slit Lamp Evaluations).
Time and Events 
Schedules
Table 2 and 3Evaluation of uveitis ha sbeen updated to indicate that the evaluation is to be performed at 
the discretion of the investigator during the LTE.
Time and Events 
Schedules
Table 2
Footnote h.h. Evaluations (based on physical examination and interview) should be performed by [CONTACT_40968] [ADDRESS_42669]/optometrist during the study at the discretion of the investigator and 
per standa rd of care intervals (based on JIA subtype, ANA test results, age at JIA onset, 
and JIA duration) as specified in Attachment 5 .
Time and Events 
Schedules
Table 3
Footnote i.i.h.Evaluations (based on physical examination and interview ) should be performed by [CONTACT_40969] [ADDRESS_42670]/optometrist during the study at the discretion of the investigator and 
per standard of care intervals (based on JIA subtype, ANA test results, age at JIA onset, 
and JIA duration) as specified in Attachment 5 .
9.4. Safety 
Evaluations (Uveitis 
Evaluations)All subjects will be assessed for new -onset uveitis at screening and at least every [ADDRESS_42671]/optometrist during the study through Week 52 at intervals (based on JIA 
subtype, ANA test results, age at JIA onset, and JIA duration) as specified in 
Attachment 5. After Week 52, slit lamp evaluations will be perform ed at the discretion 
of the investigator and per standard of care.
Attachment 5: Slit 
Lamp EvaluationsThrough Week 52, a All subjects are required to have slit lamp evaluations performed by
[CONTACT_4674]/optometrist during the study at intervals (based on JIA subtype, ANA 
test results, age at JIA onset, and JIA duration) as specified in the table below . After 
Week 52, slit lam p evaluations will be perform ed at the discretion of the investigator 
and per standard of care. The date of the screening visit and the ANA test results during 
screening (as applicable depending on the JIA subtype) should be used to determine when 
the first slit lamp evaluation should be performed during the stu dy. The interval for the slit 
lamp evaluations may be adjusted thereafter based on the subject’s ANA test results and 
JIA disease duration after screening. However, once a subject tests positive for ANA at 
any time during the study (and regardless if the s ubject subsequently tests negative for 
ANA), the subject should be considered ANA positive when determining the frequency of 
slit lamp evaluations.
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
10
Status: Approved ,Date: 16 December 2019Applicable Section(s) Description of Change(s)
Rationale: To change the length of infusion reaction evaluation from at least 60 minutes to at the discreti on of the 
investigator. Corresponding text was updated in Section 9.4 (Safety Evaluations).
Time and Event 
Schedules
Table [ADDRESS_42672] 60 minutes
after the administration of study agent for symptoms of an infusion reaction.
9.4. Safety 
Evaluations (Infusion 
Reaction Evaluations)An infusion reaction is any unfavorable or unintended sign that occurs during the infusion 
or within [ADDRESS_42673] should be treated at 
the inve stigator’s discretion.
9.4 Safety 
Evaluations (Allergic 
Reactions)Through out the study Week [ADDRESS_42674] be observed carefully for symptoms of an 
allergic reaction (eg, urticaria, itching, hives) for at least [ADDRESS_42675] be observed carefully for symptoms of 
an allergic reac tion at the discretion of the investigator after completion of the 
infusion. If mild or moderate allergic reaction is observed, acetaminophen or NSAIDs and 
diphenhydramine at approved pediatric doses may be administered.
Rationale: To remove efficacy assessments from the LTE and add requirement for investigators to sign an annual 
attestation form regarding subject’s receipt of continued benefit of treatment. The attestation form will be 
maintained in the subject’s source documents . As no efficacy assessments will be collected during the LTE, 
instructions regarding Childhood Health Assessment Questionnaire ( CHAQ )collection are no longer needed.
Time and Event 
Schedule s
Table [ADDRESS_42676] been removed from visits during the LTE.
Time and Event 
Schedules
Table 2 
Footnote k.k. JIA assessments include the following:  Physician Global Assessment of Disease 
Activity, Childhood Health Assessment Questionnaire (CHAQ), and duration of morning 
stiffness.   CHAQ should be com pleted before any tests, procedures, or other 
consultations for that visit to prevent influencing subjects’ perceptions. Investigator 
will com plete an annual attestation form  to document that subject is benefiting from  
treatm ent.
Time and Event 
Schedules
Table 3
Footnote l.l.k.JIA assessments include the following:  Physician Global Assessment of Disease 
Activity, Childhood Health Assessment Questionnaire (CHAQ), and duration of morning 
stiffness.   CHAQ should be com pleted before any tests, procedures, or other 
consultations for that visit to prevent influencing subjects’ perceptions. Investigator 
will com plete an annual attestation form  to document that subject is benefiting from  
treatm ent.
Time and Event 
Schedules
Table 2 and 3
Footnote l.l. CHAQ to be completed by [CONTACT_40970]; preferably the same parent or 
caregiver should complete at every visit. Subjects who are 15 to <18 years of age at study 
entry may complete the assessment jointly with the parent/caregiver.
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
11
Status: Approved ,Date: 16 December 2019Applicable Section(s) Description of Change(s)
3.1.3. Week 52 
through Week 252 
(Long -term 
Extension )During the LTE, all subjects will continue to receive golimumab q8w  (±1 week) through 
Week 244. For children who have completed the full trial period of 252 w eeks and for 
whom drug is proven beneficial but is not commercially available for p JIA indication (or 
patient does not qualify for insurance to pay for the drug) IV golimumab will continue to 
be provided by [CONTACT_1034] , as described in Section 3.1.[ADDRESS_42677]’s source documents by [CONTACT_40971] a yearly basis via an attestation form documented in the CRF every 16 w eeks; 
infusions and safety measurements will be done every 8 weeksat the investigative site 
according to the Tim e and Events Schedule .
9.1.5. Long -Term  
Extension Phase: 
After Week [ADDRESS_42678] safety, efficacy , PK, and immunogenicity evaluation s performed 
according to the Time and Events Schedules (Table 2 and Table 3). After Week 52, 
disease activity will be m onitored and assessed by [CONTACT_431]. Investigators will fill 
out an annual attestation form to document that a subject is benefiting f rom 
treatm ent.Subjects who discontinue study agent administration prior to Week [ADDRESS_42679] study agent infusion (Section 10.2).
9.2.1. Evaluation s The Time and Events Schedule summarizes the frequency and timing of efficacy 
measurements applicable to this study (Table 1 , Table 2, and Table 3 ). After Week 52, 
investigators will com plete an attestation form  annually to docum ent that the subject 
is be nefit ingfrom  treatment.
[IP_ADDRESS]. Evaluations 
(Joint Evaluation)It is preferable that the consistent joint assessor who performs the baseline joint 
assessments for a subject also performs the joint assessments for that subject for all 
subsequent visits t hrough the final efficacy assessment at Week [ZIP_CODE].
Rationale: To update the instructions regarding visits outside the recommended acceptable visit window after 
Week 52 in order to more closely resemble a real -world setting and reduce the burden to subjects .
9.1.1. Overview The Time and Events Schedules summarize the frequency and timing of efficacy, PK, 
immunogenicity, and safety measurements applicable to this study (Table 1, Table 2, and 
Table 3). All scheduled study visits should occur within ±3 days of the intended visit
through Week 28 and ±[ADDRESS_42680] be recorded in source 
documents. After Week 252, study procedures will be perform ed as described in 
Attachm ent 6.
Rationale: To update the assessments performed at unscheduled visits based on the changes to Time a nd Events 
Schedule.
9.1.1. Overview At every unscheduled visit, the investigator w ill perform the following evaluations:
 Revie w of systems (after Week 52, at the discretion of the investigator)
 Vital signs (after Week 52, at the discretion of the investigator)
 TB questionnaire
 Adverse events
 Revie w of concomitant medications (after Week 52, medications should be 
reviewed and docum ented in source; m edications used to treat or associated with 
AEs and SAEs should be recorded on the CRF)
 Safety laborat ory evaluations (after Week 52, at the discretion of the investigator)
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
12
Status: Approved ,Date: 16 December 2019Applicable Section(s) Description of Change(s)
Rationale: To clarify the responsibilities of the investigator during the LTE based on the changes to Time and 
Events Schedule.
9.1.5. Long -Term  
Extension Phase: 
After Week 52 
through Week 252Review of system s, collection of vital signs, QuantiFERON®-TB Gold testing, uveitis 
evaluations (including slit lamp evaluations), and chest x -ray screening will be 
perform ed at the discretion of the investigator, refer to the Time and Events 
Schedules (Table 2 and Table 3). It is the responsibility of the investigator to carry 
out all assessments per standard of practice and to update the CRF with all 
inform ation related to AEs and SAEs (eg, concom itant medications).
Rationale: To update the assessments performed at the final safety follow -up visit based on the changes to Time 
and Events Schedule.
Time and Events 
Schedule s
Table [ADDRESS_42681] infusion (Section 10.2). Collection of vital signs, review of
symptoms, and uveitis evaluation are performed at the final safety follow -up visit at 
the discretion of the investigator.
Time and Events 
Schedule s
Table [ADDRESS_42682] infusion (Section 10.2). Collection of vital signs, review of 
symptoms, and uveitis evaluation are performed at the final safety follow -up visit at
the discretion of the investigator.
10.2. Discontinuation 
of Study TreatmentSubjects who discontinue study agent infusions but do not terminate study participation 
will have the following assessments performed at the final safety follow -up visit:
•Safety evaluation sincluding (vital signs, review of systems, AE revie w, TB 
evaluation , uveitis evaluation and the collection of a blood sample for routine laboratory 
analyses ,anddetermination of the presence of ANA/anti -double -stranded 
deoxyribonucleic acid (dsDNA) antibodies ,and antibodies to golimumab ).; after 
Week 52, other safety evaluations are perform ed at the discretion of the investigator 
(vital signs, review of systems, uveitis evaluation).
•Concomitant medication review (after Week 52, medica tions should be reviewed 
and documented in subject’s source records; medications used to treat or associated 
with AEs and SAEs should be recorded in the source document as well as the CRF) .
•Efficacy evaluations (joint assessments, JIA assessments, and co llection of blood 
sample for CRP) through Week 52 only .
•Blood samples drawn for measurement of golimumab concentration for all subjects at 
the final safety follow -up visit.
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
13
Status: Approved ,Date: 16 December 2019Applicable Section(s) Description of Change(s)
Rationale: To add an E TPin order to allow  subjects <18 years of age who are demonstrating benefit from treatment 
with golimumab to continue treatment after Week 252 if the drug is not commercially available. An additional 
database lock at the end of the E TPis planned, which will be the final database lock for the study.
Synopsis (Overview 
of Study Design)All subjects will receive 80 mg/m2golimumab as an IV infusion (over 30±10 minutes) at 
Weeks 0, 4, and q8w  (±3 days) through Week 28 and q8w  (±1 week) thereafter (maximum 
single dose 240 mg [maximum body surface area (B SA) 3.0 m2x 80 mg/m2]). Commercial 
MTX is to be administered at a stable dose of 10 -30mg/m2/week in subjects with BSA 
<1.67 m2 or a stable minimum dose of 15 mg/week in subjects with BSA ≥1.67 m2through 
Week 28 (unless lower doses of MTX are administered for documented safety reasons or 
unless documented country or site regulations prohibit dose of 15 mg/week or above in 
subjects with BSA ≥1.67 m2). Subjects who complete the study at Week [ADDRESS_42683] the 
option to enter into the long -term extension (LTE ) phase of the study. During the LTE, all 
subjects will continue to receive 80 mg/m2IV golimumab q8w  (±1 w eek; maximum single 
dose 240 mg) through Week 244. All subjects who complete the Week 244 visit are 
expected to participate in the safety follow -up visit at Week 252. Subjects <[ADDRESS_42684] the option to continue to receive golimum ab (80 m g/m2q8w) in the 
Extended Treatment Period (ETP). The first dose of golimuma b in the ETP is 
administered at Week [ADDRESS_42685] been completed. Golimumab 
after Week 252 (for subjects who have completed the full [ADDRESS_42686]) will be provided in the Extended 
Treatment Period until the drug will be is approved and marketed for use in pJIA in the 
country of the subject or for as long as proven beneficial to the child (in cases where 
commercial drug is not accessible to the subject).
Since this is an o pen-label study with all subjects receiving the same BSA -based dose of 
IV golimumab, an external Data Monitoring Committee will not be established.
The end of the study is defined as the last follow -up assessment for the last subject in the
LTEETP .
Synopsis (Dosage and 
Administration, 
Golimumab)During the ETP, subjects will continue to receive 80 m g/m2golimumab IV infusions 
q8w starting at Week 252.
Time and Events 
Schedule
Table 3
Footnote d.d. The ETP starts at Week 252. These procedures should only be com pleted for 
subjects who enter the ETP .
3.1. Overview  of 
Study DesignAll subjects will receive 80 mg/m2golimumab (maximum single dose 240 mg) as an IV 
infusion given over 30±10 minutes at Weeks 0, 4, and every 8 w eeks (q8w ; ±3 days) 
through W eek 28 and then q8w (±1 w eek) thereafter through Week 244. Body surface area 
will be calculated based on the subject’s height and body weight measured at each visit, 
and the BSA -based dose of golimumab w ill be adjusted as needed to maintain the dose at 
80 mg/m2. Subjects will also receive commercial MTX w eekly through Week 28 at the 
same BSA -based dosage (10 to 30 mg/m2per w eek of MTX in subjects w ith BSA 
<1.67 m2, or a minimum of 15 mg/week in subjects w ith BSA ≥1.67 m2) as at time of 
study entry as outli ned in Section 6.2. At Week 252, subjects who m eet the inclusion 
criteria for the optional Extended Treatment Period (E TP) may continue treatm ent 
with golimumab (80 m g/m2q8w) after com pletion of the Week 252 assessments.
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
14
Status: Approved ,Date: 16 December 2019Applicable Section(s) Description of Change(s)
3.1.1. Week 0 through 
Week 28After all subjects complete the Week 28 visit, the database will be locked to assess PK, 
safety and efficacy. An additional safety, efficacy, and PK database lock is currently 
planned for Week 52. Final Adatabase lock w ill be performed at Week 252 , and a fin al 
database lock will be performed at the end of study .
3.1.3. Week 52 
through Week 252 
(Long -term 
Extension)The final Adatabase lock will occur beat Week 252.
3.1.4. After Week 252 
(Extended Treatment 
Period)Subjects < [ADDRESS_42687] in the
long-term extension ETP.
3.2.1. Blinding, 
Control, Study 
Phase/Periods, 
Treat ment GroupsThis is a single -arm, open -label study to evaluate the PK of IV golimumab in subjects with 
pJIA, w ith all subjects receiving the same BSA- based dose of IV golimumab through 
Week 52. Subjects w ho complete the study at Week [ADDRESS_42688] the optio n to enter into 
the LTE phase of this study through Week 252. After Week 252, subjects who m eet 
specific criteria (see Attachment 6) will have the opportunity to continue treatm ent 
with golimumab in the ETP.
5. Treatment 
Allocation and 
BlindingThis is an open -label study . All subjects will receive golimumab 80 mg/m2at Week 0, 
Week 4, and q8w  (± 3 days) through W eek 28 and q8w  (± 1 week) up to W eek [ADDRESS_42689] has 
completed the Week 252 assessments.
8. Prestudy and 
Concomitant TherapyAfter Week 252, concom itant m edications are documented as described in 
Attachm ent 6.
9.1.1. Overview The Time and Events Schedules summarize the frequency and timing of efficacy, PK, 
immunogenicity, and safety measurements applicable to this study (Table 1, Table 2, and 
Table 3). All scheduled study visits should occur within ±3 days of the intended visit
through Week 28 and ±[ADDRESS_42690] be recorded in source documents. After 
Week 252, study procedures will be perform ed as described in Attachment 6.
9.1.6. Extended 
Treatment Period9.1.6. Extended Treatment Period
Subjects who enter the ETP after c ompletion of the Week 252 assessments will 
continue to receive 80 m g/m2golim umab IV q8w.
The frequency and timing of assessments during the ETP are provided in 
Attachm ent6.
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
15
Status: Approved ,Date: 16 December 2019Applicable Section(s) Description of Change(s)
10. Subject 
Com pletion/
Withdraw alSubject completion/withdrawal during the ETP is described in Attachment 6.
14.4. Preparation, 
Handling, and StoragePreparation, handling, and storage of study agent during the ETP is described in 
Attachm ent 6.
14.5 Drug 
AccountabilityDrug accountability during the ETP is described in Attachment 6.
Attachment 6. 
Extended Treatment 
PeriodWith the addition of the Extended Treatment Period, information was added to the 
protocol to detail the eligibility, requirements, and procedures of the Extended Treatment 
Period.
Rationale: To remove the use of a Data Revie w Committee as the study is open -label, golimumab has been 
marketed since 2009, and an internal Sponsor safety monitoring team revie ws safety concerns in addition to routine 
medical monitoring. 
11.9. Data Monitoring 
CommitteeThis is an open -label study, with all subjects receiving the same dosage of IV golimumab. 
Therefore, an external Data Monitoring Committee will not be utilized. Safety data will be 
routinely evaluated by [CONTACT_1758]’s medical monitor and Sponsor’s internal Safety 
Managem ent Team as needed and an internal Data Review Committee as defined in the 
DRC charter . In addition, the data may be reviewed by [CONTACT_40972].
Rationale: Minor errors w ere noted
Throughout the 
protocolMinor grammatical, formatting, or spelling changes were made.
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
16
Status: Approved ,Date: 16 December 2019Amendment INT-3(28February 2017 )
The overall reason for the amendment: 1) to change the inclusion criteri on regarding C -reactive protein (CRP) ; 
2)to provide clarification on the methotrexate (MTX) dose to be used during the study; 3) to modify the 
requirements and intervals for slit lamp evaluations; 4) to remove the term  “emancipated ”to describe a juvenile ; 
5)to remove unnecessary wording regarding blinding ; 6) to indicate that a local laboratory maybe used for the 
QuantiFERON®-TB Gold test .
Applicable Section(s) Description of Change(s)
Rationale: With approximately half the planned number of subjects enrolled in the study to date, the study 
population exhibits a range of C-reactive protein ( CRP )levels that would support the planned population 
pharmacokinetics ( PK)analysis. At the same time, the Sponsor has received consistent feedback from the Steering 
Committee and investigators that otherwise qualified subjects have failed screening because their CRP 
was<0.1 mg/dL. Given these facts, the i nclusion criterion has been revised to allow approximately 30% of the study 
population to have a screening CRP of <0.1 mg/dL in order to enhance enrollment in the study without affecting the 
Sponsor’s abilit y to fulfil lthe objectives of the study.
Synopsis ,Objectives The primary objective of this study is to assess the pharm acokinetics (PK) following 
intravenously administered golimumab in subjects (ages 2 to less than 18 years) with pJIA 
manifested by ≥5 joints with active arthritis and C-reactive protein (CRP) of ≥0.1 mg/dL
despi[INVESTIGATOR_40921] (MTX) therapy for ≥[ADDRESS_42691] ≥5 joints with active arthritis as defined by [CONTACT_40973] (ACR) criteria at screening and enrollment .and must have a screening CRP 
of ≥0.1 mg/dL .
2.1 Objectives The primary objective of this study is to assess the PK following intravenously 
administered golimumab in subjects (ages 2 to less than 18 years) w ith pJIA m anifested by 
≥5 joints with active arthritis and CRP of ≥0.1 mg/dL despi[INVESTIGATOR_40922] ≥[ADDRESS_42692] a screening CRP of ≥0.1 mg/d Lwith the exception of 
approximately 30% of the study population.
Rationale:   Text has been revised to clarify the appropriate MTX dose for subjects according to their body surface 
area (BSA) measurement.
Synopsis ,Overview
of Study DesignCommercial MTX is to be administered at a stable dose of 10-30 mg/m2/week in subjects 
with BSA <1.67 m2or a stable mini mum dose of 15 mg/week in subjects with BSA 
≥1.67 m2through Week 28(unless lower doses of MTX are adm inistered for 
documented safety reasons or unless documented country or site regulations prohibit 
dose of 15 mg/week or abov e in subjects with BSA ≥1.67 m2), lower doses of MTX are 
administered ) through Week 28. For patients with BSA greater than 1.67 m2, a minimum 
fixed dose of 15 mg/week is required .
Synopsis , Dosage and 
AdministrationSubjects will receive commercial MTX atleast through Week 28at the same BSA -based 
dose (10 to 30 mg/m2per week for subjects with BSA <1.[ADDRESS_42693] 15 mg/week 
for subjects with BSA ≥1.67 m2) as at time of study entry at least through Week 28 .
3.1 Overview  of 
Study DesignSubjects willalso receive commercial MTX weekly through Week 28at the same BSA -
based dosage (10 to 30 m g/m2per week of MTX in subjects with BSA <1.67 m2, with or
a minimum of 15mg/week in subjects with BSA ≥1.67 m2) as at time of study entry 
through Week 28 as outlined in Section 6.2.
…………………………………………………………………………………………….
(Legend for Figure 1) All subjects receive 80 mg/m2golimumab IV infusion at Weeks 0,4, and every8 weeks 
thereafter through Week 244. Subjects will receive and 10 to 30 mg/m2per week of
commercial methotrexate at the same weekly dose as at time of study entry at least
through Week 28.
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
17
Status: Approved ,Date: 16 December 2019Applicable Section(s) Description of Change(s)
4.[ADDRESS_42694] active pJIA despi[INVESTIGATOR_40923], intramuscular, or 
subcutaneous MTX for ≥2 months before screening at a weekly dose of ≥10mg/m2. 
Subjects currently on MTX must receive a stable dose (between 10 to 30 mg/m2 per week) 
of MTX for ≥4weeks before screening . For subjects with BSA <1.[ADDRESS_42695] be between 10 to 30 mg/m2per week and stable for ≥4 weeks before screening.
For sSubjects with BSA ≥1.[ADDRESS_42696] receive abe a minimum of 15 
mg/week and must be stable for ≥4 weeks before screening . of MTX unless documented 
country or site regulations prohibit use of 15 mg of MTX per week in subjects with BSA 
≥1.67 m2.In situations where there is documented intolerance of doses >10 mg/m2weekly 
(for subjects with BSA <1.67 m2)or ≥15 mg/week (for subjects with BSA ≥1.67 m2); or 
where docum ented country or site regulations prohibit use of ≥15 mg of MTXper 
week in subjects with BSA ≥1.67 m2, subjects may be entered into the trial on a lower 
dose of MTX.
6.2 Methotrexate Subjects will receive commercial MTX through Week 28at the same BSA -based dose 
(10 to 30 mg/m2per week for subjects with BSA <1.[ADDRESS_42697] 15 mg/week for 
subjects with BSA ≥1.67 m2)(10 to 30 mg/m2per week) as at time of study entry through 
Week 28 . Absolute dose should remain stable from baseline through Week 28.
………………………………………………………………………………
After Week 28, changes in MTX admin istration are permitted (eg, increase or 
decrease in dosage, change in route of administration, or discontinuation).
8. Prestudy and 
Concomitant TherapySubjects must have received MTX at a weekly dose of ≥10 mg/m2for ≥2 months before 
screening. For subjects with BSA <1.[ADDRESS_42698] be between 10 to 
30mg/m2 per week and stable for ≥4weeks before screening. For sSubjects with BSA 
≥1.[ADDRESS_42699] be a minimum of 15 mg/week of MTX and must be stable 
for ≥4weeks before screening. The dose must have been stable and between 10 to 30 
mg/m2weekly (or at least 15mg/week in subjects with BSA ≥1.67 m2) for ≥4 weeks 
before screening.
9.1.3. Treatment 
Phase: Week 0 
through Week 28Subjects will also receive commercial MTX weekly at thesame BSA -based dosage (10 to 
30 mg/m2 per week) as at time of study entry at least through Week 28 and commercial 
folic acid ≥5 mg weekly or folinic acid (at half the MTX dose) given the day after the 
MTX dose (Section 6.2). In children <12 years of age, the administration of folic acid or 
folinic acid w ill be at the discretion of the physician.
9.1.4. Treatment 
Phase: After Week 28 
through Week 52Subjects may also receive commercial MTX weekly at the same BSA -based dosage (10 to 
30 mg/m2 per week) as at time of study entry and commercial folic acid ≥5 mg weekly or 
folinic acid if administered (at half the MTX dose; Section 6.2) given the day after the 
MTX dose; however, increases, decreases or discontinuations of MTX, other DMA RDs, 
corticosteroids ,and/or NSAIDs are permissible after Week 28.
Rationale:  Text has been revised to clarify the nature of uveitis examinations and that, in addition to uveitis 
examinations performed at least every [ADDRESS_42700]/optometrist during the study based on current clinical 
recommendations as specified in Attachment 5.
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
18
Status: Approved ,Date: 16 December 2019Applicable Section(s) Description of Change(s)
Time & Events 
Schedules, Table 1h.Evaluations (based on physical examination and interview) should be performed by 
[CONTACT_40974] [ADDRESS_42701]/ optometrist 
during the study at intervals (based on JIA subtype, ANA test results, age at JIA 
onset, and JIA duration) as specified in Attachment 5.Subjects who test ANA positive 
at screening will be required to undergo slit lamp evaluation by a qualified 
ophthalmologist to evaluate for subclinical uveitis in the screening period, before first 
study drug administration, as well as at least every 3 months subsequent.
Time & Events 
Schedules, Table 2 
and Table 3h.Evaluations (based on physical examination and interview) should be performed by 
[CONTACT_40974] [ADDRESS_42702]/ optometrist 
during the study at intervals (based on JIA subtype, ANA test results, age at JIA 
onset, and JIA duration) as specif ied in Attachment 5.   Subjects who test ANA positive 
at screening will be required to undergo slit lamp evaluation by a qualified 
ophthalmologist at least every 3 months.
9.4 Safety 
Evaluations (Uveitis 
Evaluations)All subjects will be formally assessed for new -onset uveitis at screening and at least every 
[ADDRESS_42703]/optom etrist during the study at intervals (based on JIA subtype, 
ANA test results, age at JIA onset, and JIA duration) as specified in Attachment 5.  
Subjects who test antinuclear antib odies (ANA) positive at screening will be required to 
undergo slit lamp evaluation by a qualified ophthalmologist to evaluate for subclinical 
uveitis in screening period as well as at least every 3 months subsequent as specified in the 
Time and Events Sche dules (Table 1, Table 2, and Table 3).
If a subject develops uveitis during the study, the subject’s continued participation in the 
study is at the discretion of the investigator and Sponsor . and a qualified ophthalmologist .
Attachment 5: Slit 
Lamp Evalu ations(Attachment added that outlines requirements and intervals for slit lamp evaluations based 
on JIA subtype, ANA test results, age at JIA onset, and JIA duration.)
Rationale:  The term “emancipated” to describe a juvenile has been deleted because it does not have global 
application and text has been added to indicate that the CHAQ may be completed jointly with the parent/caregiver .
Time & Events
Schedules, Table 1, 
Table 2, and Table 3l.CHAQ to be completed by [CONTACT_40970]; preferably the same parent or 
caregiver should complete at every visit. Subjects who are emancipated juveniles (ages 15 
to <18 years of age)at study entry may complete the assessment sjointly with the 
parent/caregiver themselves .
4.[ADDRESS_42704] is an emancipated juvenile.
[IP_ADDRESS] Childhood 
Health Assessment 
Questionnaire 
(Parent/Subject 
Assessment of 
Overa ll Well -being)Subjects who are emancipated juveniles (ages 15 to <18 years ) of ageat study entry may
complete allthe CHAQ assessments jointly with the parent/caregiver themselves . 
Preferably, the same individual (eg, parent, caregiver, or subject) who completes the 
assessment sat the start of the study should complete the assessment sthroughout the study.
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
19
Status: Approved ,Date: 16 December 2019Applicable Section(s) Description of Change(s)
Rationale:  Unnecessary text regarding blinding has been removed to avoid confusion. 
3.1 Overview  of 
Study DesignUnblinded s Safety data will be routinely evaluated by [CONTACT_1758]’s medical monitor.
5. Treatment 
Allocation and 
BlindingAs this is an open -label study, blinding procedures are not applicable. Subjects and 
investigational study sites will remain unblinded. Sponsor personnel who will be involved 
with data analyses will be identified before the interim analyses.
11.9 Data Monitoring 
CommitteeUnblinded sSafety data will be routinely evaluated by [CONTACT_1758]’s medical monitor and an 
internal Data Review Committee as defined in the DRC charte r.
Rationale: Wording w as added to indicate that of a local laboratory may be used for the QuantiFERON®-TB Gold 
test.
ATTACHMENT 1 
QUANTIFERON®-
TB GOLD TESTINGThe central laboratory will analyze and report results for each subject, and sites will be 
informed of the results. Under certain circumstances as approved by [CONTACT_1034], a 
local laboratory m ay be used to process the QuantiFERON®-TB Gold test sample 
and/or analyze the results . 
Rationale: Minor errors w ere noted
Throughout the 
protocolMinor grammatical, formatting, or spelling changes were made.
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
20
Status: Approved ,Date: 16 December 2019Amendment INT -2(11 July 2016)
The overall reason for the amendment: The overall reason s for the amendment are: 1) to change the criteria used 
to determine subject eligibility toenhance enrollment in the study ; 2)to provide clarification and additional detail s
regarding the efficacy and safety evaluations to be used during the study ;3) toclarify the timing ofchanges that can 
be made to background medications ;4) removal ofthe ultrasound substudy ;and 5) inclusion of anticipated events 
due to progression of the disease in the overall safety analy ses for the study.
Applicable Section(s) Description of Change(s)
Rationale: Published Juvenile idiopathic arthritis (JIA) treatment guidelines such as the ACR guidelines 
(2011 American College of Rheumatology Recommendations for the Treatment of Juvenile Idiopathic Arthritis: 
Initiation and Safety Monitoring of Therapeutic Agents for the Treatment of Arthritis and Systemic Features) 
recommend the initiation of treatm ent with a TNF αinhibitor after 3 months of methotrexate (MTX )treatment for 
patients with active JIA despi[INVESTIGATOR_40924]. How ever, the Sponsor has received consistent feedback from the 
Steering Committee and investigators that this duration of MTX treatment is too long and is inconsistent with typi[INVESTIGATOR_40925]. JIA is a cause of serious functional disability, and the goal of treatment for pediatric patients with 
the disease is to gain disease control as quickly  as possible. The required duration of M TX therapy before screening 
was shortened from ≥3 months to ≥2 months to still allow adequate time for patients to demonstr ate failure or 
inadequate response to MTX therapy, but to also provide this vulnerable patient population with an opportunity to 
enroll in a clinical trial and receive treatment that may provide symptomatic relief of their disease.
Synopsis ,Objective sand 
HypothesisThe primary objective of this study is to assess the pharmacokinetics (PK) of following
intravenously administered golimumab in subjects (ages 2 to less than 18 years) with 
polyarticular JIA(pJIA)manifested by ≥5 joints with active arthr itis and C-reactive 
(CRP )of ≥ 0.1 m g/dL despi[INVESTIGATOR_40921] (MTX) therapy for ≥32months.   
Synopsis, Subject 
PopulationSubjects must have active pJIA despi[INVESTIGATOR_40923], intramuscular or 
subcutaneous MTX (for ≥32months before screening) at a weekly dose of ≥10 mg/m2.
2.1. Objectives, Primary 
ObjectiveThe primary objective of this study is to assess the PK following intravenously 
administered golimumab in subjects (ages 2 to less than 18 years) w ith pJIA manifested 
by ≥5 joints with active arthritis and CRP of ≥0.1 mg/dL despi[INVESTIGATOR_40922] 
≥32months.
4.1.Inclusion Criteria 
(Criterion #4)Failure or inadequate response to at least a 32-monthcourse of MTX before screening.
4.1.Inclusion Criteria 
(Criterion #7)Subjects must have active p JIA despi[INVESTIGATOR_40923], intramuscular, or 
subcutaneous MTX (for ≥32months before screening and on a stable dose for 4 w eeks 
as noted in Section 8)at a w eekly dose of ≥10mg/m2. 
8.Prestudy and 
Concomitant TherapySubjects must have received MTX at a w eekly dose of ≥10 mg/m2for ≥32months
before screening.
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
21
Status: Approved ,Date: 16 December 2019Applicable Section(s) Description of Change(s)
Rationale:  The secondary objectives were correct edto include PK evaluations .
Synopsis , Objective and 
Hypothesis;The secondary objectives of this study are to evaluate IV golimumab in subjects w ith 
pJIA w ith respect to PK, efficacy (relief of signs and symptoms, physical function, and
quality of life), safety ( adverse events [ AEs] , serious AEs [SAEs ], and assessment of 
laboratory parameters), and immunogenicity (antibodies to golimumab).
2.[ADDRESS_42705] to PK, efficacy (relief of signs and symptoms, physical function, and
quality of life), safety (AEs, SAEs, and assessment of laboratory parameters) and 
immunogenicity (antibodies to golimumab).
Rationale:  To align the description of the study design in the Sy nopsis with that in the body of the document.
Synopsis, Overview of 
Study DesignThis is a Phase 3, open -label, single -arm, multicenter study to evaluate the PK, safety, 
and efficacy of IV golimumab in subjects w ith active pJIA despi[INVESTIGATOR_40926]/or corticosteroids and/or non -steroidal anti -inflammatory agents and/or 
prior use of anti -TNFα agents (up to 30% of total population) .
Synopsis, Overview of 
Study DesignApproxim ately At least [ADDRESS_42706] 100 subjects remain in the study at Week 52 .
Rationale:  The Synopsis was revised to clarify the evaluations and endpoints of the study and to align the 
presentation of this information with that in the body of the document. 
Synopsis The efficacy evaluations/endpoints were separated from the PK evaluations/endpoints 
and clarified.  The safety evaluations and analyses were moved an d are now  presented 
before the i mmunogenicity evaluations and analyses.
Rationale:  To clarify the stable dose of MTX that subjects should be receiving for ≥4weeks before screening .
4.1.Inclusion Criteria 
(Criterion #7)Subjects currently on MTX (weekly 10 to 30 mg/m2), must receive a stable dose 
(between 10 to 30 mg/m2) per w eek of MTX for ≥4 weeks before screening.
Rationale: To clarify that MTX is to be administered to subjects through Week 28 of the study.
Synopsis, Overview of 
Study DesignAll subjects will receive 80 mg/m2golimumab as an IV infusion (over 30 ±10 minutes) 
at Weeks 0, 4, and every 8 weeks ( q8w;(± 3 days) through Week 28 and q8w  (± 1 
week) thereafter (maximum single dose 240 mg [maximum body surface area ( BSA )
3.0 m2x 80 mg/m2]),along with c . Commercial MTX is to be adm inistered at a dose 
of 10 -30 mg/m2/week (unless for documented safety reasons, low er doses of MTX are 
administered) through Week 28 .
Rationale: Clarification that the MTX dose and route of administration should remain stable through the Week 28 
“visit ,” not the Week 28 “safety and efficac y database lock .”
Synopsis, Dosage and 
Administration
MethotrexateEvery effort should be made to ensure that subjects remain on the same dose and route 
of administration of MTX through theWeek 28 visit safety and efficacy database lock , 
unless intolerance or AEs due to MTX occur. 
6.2. Methotrexate Every effort should be made to ensure that subjects remain on the same dose and route 
of administration of MTX through the Week 28 visitsafety and efficacy database lock , 
unless intolerance or AEs due to MTX occur (Section 8) .
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
22
Status: Approved ,Date: 16 December 2019Applicable Section(s) Description of Change(s)
Rationale: JADAS has been deleted from Time &Events schedule s, Tables 1, 2, and 3,because it is not a specific 
assessment that the physician performs rather it is a calculation based on the Physician Global Assessment, 
parent/child ratings of well -being and pain, joint assessments, and CRP.   
Time and Events 
Schedules, Tables 1, 2, 
and 3JADAS was removed from the Time and Events Schedules.
Rationale: The JADAS physician assessed remission was deleted from the efficacy endpoints because it is 
considered to be exploratory in nature and not necessary for the evaluation of efficacy in this study.   
[IP_ADDRESS] Juvenile Arthritis
Disease Activity Score 
(JADAS)JADAS physician assessed remission is defined as a total JADAS score of ≤2.
9.2.2 Endpoints, Other 
Endpoints
11.3 Efficacy Analyses, 
Other Efficacy Endpoints•The proportion of subjects who achieve JADAS 10, 27, and 71 remission over time .
Rationale: It has been decided not to initiate the exploratory ultrasound substudy as a result of concerns over the 
feasibility of enrolling a sufficient number of subjects in the substudy due to the lack of interest from sites
participating in the substudy or the inability of sites to participate due to operational reasons.
Synopsis, Ultrasound 
SubstudyPower Doppler Sonography (PDUS) is a non -invasive ultrasound technique to assess 
inflammation at the joint level in rheumatoid arthritis (RA). At selected sites, subjects 
over the age of [ADDRESS_42707] been enrolled in the study and are currently receiving 
study treatment may undergo PDUS and High Frequency gray scale Ultrasound 
(HFUS) of the 2ndand 3rdmetacarpophalangeal joints, wrist, knee and ankle. Up to 5 
exams will be performed at Weeks 0, 4, 12, 24, and 52 using a standardized protocol, 
described in a separate manual. Reading of the PDUS and HFUS will be performed by 
[CONTACT_40975] .
9.6 Ultrasound Substudy At selected sites, a total of approximately 20 subjects over the age of 4 years who are 
enrolled in this study and are currently receiving study treatment may undergo pow er 
ultrasounds of their metacarpophalangeal 2 and 3 joints (examining dorsal and volar 
surfaces), w rist (dorsal long midline, tendons), knee (suprapatellar long and parapatellar 
images; entheseal evaluations), and ankle (tibula/talar, subtalar medial and lateral 
surfaces, tendon examinations). Up to 5 ultrasound a ssessments may be conducted at 
Weeks 0, 4, 12, 28, and 52. The primary objective of the substudy is to examine Pow er 
Doppler response measured as the Pow er Doppler Sum Score at 6 months compa red 
with the score at baseline. Additional details will be presen ted in the ultrasound 
substudy Protocol.
15. Study -Specific 
Materials Ultrasound substudy (only  for sites participating in the ultrasound sub study )  
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
23
Status: Approved ,Date: 16 December 2019Applicable Section(s) Description of Change(s)
Rationale: A footnote was added to the Time and Events schedules (Tables 1, 2, and 3) to describe when vital signs 
should be taken at visits when study agent infusion is administered. Corresponding text was added to Section 9.4 
(Safety Evaluations).   
Time and Events 
Schedules , Tables 1, 2, 
and 3
Footnote d
9.4 Safety Evaluations ,
Vital Signsd.Vital signs should be taken pre -infusion; at 15 and 30 m inutes (15 -minute 
intervals during the infusion); and at 60 and 90 m inutes (during the 1 -hour 
observation p eriod following the infusion).
Pulse/ heart rate , respi[INVESTIGATOR_697], temperature, and blood pressure measurements will 
be performed according to the Time and Events Schedules (Table 1, Table 2, and 
Table 3).
Vital signs should be taken pre -infusion; at 15 and 30 m inutes (15 -minute intervals 
during the in fusion); and at 60 and 90 m inutes (during the 1 -hour observation 
period following the infusion).
Rationale: Patients are excluded from the study if they had been treated with therapeutic agents that deplete B or 
Tcells during the [ADDRESS_42708] evidence of persistent depletion of 
the targeted lymphocyte after receiving any of these agents. Lymphocyte subset analys es wereincluded in the Time 
and Events Schedule for subjects who received these agents >[ADDRESS_42709] is being considered for enrollment who previously received treatment with an agent 
that depletes B or T cells > [ADDRESS_42710] been treated w ith natalizumab, efalizumab, or therapeutic 
agents that deplete B or T cells (eg, rituximab, alemtuzumab, or visilizumab) during 
the ≥[ADDRESS_42711] study agent administration.
Rationale: Based on general knowledge about the tests for latent TB (QuantiFERON®-TB Gold and tuberculin skin 
tests), it is not recommended to repeat these tests in patients with a history of latent TB and ongoing treatment for 
latent TB or documentation of having completed adequate treatment. Therefore, a footnote has been added to 
Tables 1, 2, and 3 and text was added to Section 9.4 to indicate that QuantiFERON®-TB Gold (and tuberculin skin) 
testing does not need to be repeated during the study for subjects with a history of latent TB and ongoing treatment 
for latent TB or documentation of hav ing com pleted adequate treatment. 
Time and Events 
Schedules , Tables 1, 2, 
and 3
Footnote f.f.Testing is not required for subjects with a history of latent TB and ongoing 
treatm ent for latent TB ,or documentation of having completed adequate 
treatm ent.
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
24
Status: Approved ,Date: 16 December 2019Applicable Section(s) Description of Change(s)
9.4 Safety Evaluations ,
Early Detection of Active 
TuberculosisAnnual QuantiFERON®-TB Gold (and tuberculin skin )testing is not required for 
subjects with a history of latent TB andongoing treatm ent for latent TB ,or 
documentation of having completed adequate treatm ent for TB.
Subjects who experience close contact [CONTACT_40976] a repeat chest radiograph, a repeat QuantiFERON®-TB 
Gold test, a repeat tuberculin skin test in countries in which the QuantiFERON®-TB 
Gold test is not approved/registered, and, if possible, referral to a physician 
specializing in TB to determine the subject’s risk of developi[INVESTIGATOR_40927] w hether 
treatment for latent TB is warranted. The QuantiFERON®-TB Gold test (and 
tuberculin skin test )does not need to be repeated for subjects with a history of 
latent TB and ongoing treatment for latent TB, or documentation of having 
completed adequate treatm ent for TB. If the QuantiFER ON®-TB Gold test result is 
indeterminate, the test should be repeated as outlined in Section 9.1.2. Subjects should 
be encouraged to return for all subsequent scheduled study visits according to the 
protocol.
Rationale: The inclusion criterion for subject s who require a chest x-ray prior to the first administration of study 
agent has been modified to reflect that this is dependent on country or local guidelines rather than country and site 
guidelines.  Similarly, Footnote f. in Tables 1, 2, and 3, has been modified to clarify that chest x-ray screening for 
each subject is to be conducted per local and country regulations, not per site and country regulations.
Time and Events 
Schedules , Tables 1, 2, 
and [ADDRESS_42712] 
radiograph (posterior -anterior view) must have been taken within [ADDRESS_42713], w ith 
no evidence of curren t active TB or old inactive TB.
Rationale: Visit window s were added to the Time and Events Schedules (Table 1, Table 2, and Table 3) to provide 
clarification of timing of study visits.  
Time and Events 
Schedules , Table 1, 
Table 2, and Table 3In Table 1, -6 weeks wa s added to the Screening Period.  A footnote was added to 
Table 1, Table 2 and Table 3 to indicate that the visit window from Week 0 through 
Week 28 is  ±3 days of the intended visit and ±1 w eek after Week 28 . 
Rationale:  A column was added totheTime and Events Schedules , Tables 1, 2, and 3,to specify the assessments 
that should be performed at the Final Safety Follow -up Visit.  
Time and Events 
Schedules , Table 1, 
Table 2, and Table 3A final safety follow -up visit was added to eac h table and the following footnote w as 
moved to the column:   
b.a. All subjects who discontinue study agent administration before Week [ADDRESS_42714] infusion (Section 10.2) .
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
25
Status: Approved ,Date: 16 December 2019Applicable Section(s) Description of Change(s)
Rationale:  Clarifications were made to the Time and Events Schedules (Tables 1, 2, and 3),regarding the efficacy 
evaluations. Specifically, morning stiffness, the Physician Global Assessment of Disease Activity and CHAQ were
grouped under “JIA assessments”; the footnote regarding the timing of PRO assessments was revised to clarify that 
the CHAQ should be conducted prior to any tests, procedures, or other consultations for that visit; and the redundant 
sentence in the footnot e for the CHAQ was deleted.  
Time and Events 
Schedules , Tables 1, 2, 
and 3Joint assessments /morning stiffness
Physician Global Assessment of Disease Activity JIA assessments
CHAQ
Time and Events 
Schedules , Tables 1, 2, 
and 3
Footnote kk.All visit-specific PRO assessments should be conducted before any tests, procedures, 
or other consultations for that visit to prevent influencing subjects’ perceptions.
k.JIA assessments incl ude the following:  Physician Global Assessment of Disease 
Activity , Childhood Health Assessment Questionnaire (CHAQ), and duration of 
morning stiffness.  CHAQ should be completed before any tests, procedures, or 
other consultations for that visit to prevent influencing subjects’ perceptions.
Time and Events 
Schedules ,Tables 1, 2, 
and 3
Footnote ll. i.CHAQ to be completed by [CONTACT_40970]; preferably the same parent 
or caregiver should complete at every visit. Subjects who are emancipated juveniles 
(ages 15 to <18 years) at study entry may complete the ass essments themselves. Ideally 
the same individual (eg, parent, caregiver, or subject) w ho completes the assessments at 
the start of the study should complete the assessments throughout the study
Rationale: Change made to footnote oin Table [ADDRESS_42715] not be collected at a regularly scheduled visit (eg. Week 8).
Table 1.
Footnote o
9.1.3 Treatment Phase:  
Week 0 through Week 28o m.One additional sample for serum golimumab concentration for population 
PKwill be collected from all subjects at any time betw een Weeks 0 and 8 other than at 
the time of the Week 0, Week 4, and Week 8 visits; this sample must be collected at 
least [ADDRESS_42716] not be collected
at a regularly scheduled visit (eg. Week 8).
In addition, 1 One additional sample for serum golimumab concentration for 
population PK will be collected from all subjects at any time betw een Weeks 0 and 8 
other than at the time of the Week 0, Week 4, and W eek 8 visits; this sample must be 
collected at least [ADDRESS_42717] not 
be collected at a regularly scheduled visit (eg, Week 8) .
Rationale: Figure 1 was revised to clarify that subjects will receive MTX through Week 28 instead of Week 52; 
after Week 28, changes in MTX are permitted.
3.1. Overview  of Study 
DesignFigure 1: Schematic Overvie w of the Study
Rationale: To be consistent in listing the background medications that may be used by [CONTACT_40977].
3.1.1. Week 0 through 
Week 28No changes should be made to background medications (ie, MTX, other DMARDs, 
corticosteroids, and NSAIDs ) in terms of increases or decreases in dosage beyond the 
parameters provided in Section 8 (eg, no more than 10 mg/day prednisone or no more 
than 0.20 mg/kg/day, whichever is low er) and/or route of administration between 
Weeks 0 and 28, unless there is a safety concern (eg, elevated liver function tes ts), 
which requires changes to background medications.
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
26
Status: Approved ,Date: 16 December 2019Applicable Section(s) Description of Change(s)
Rationale: Editorial change smade to be consistent in listing the background medications that may be used by 
[CONTACT_40978] 28.
3.1.2. Week 28 through 
Week 52As noted beginning at after Week 28, subjects w ill be permitted to change /addMTX, 
other DMARD s,(including agents besides MTX), MTX corticosteroid s, and NSAID s
useas outlined in Section 8.
Rationale: To clarify when subjects will bepermitted to make change sto background medications (ie, after 
Week 28) during the long-term extension phase of the study ; editorial changes have been made to be consistent in 
listing the background medications that may be used by [CONTACT_40979] ; "approximately "
has been added to indicate when the follow -up visit should occur (ie, approximately [ADDRESS_42718] ).
3.1.3. Week 52 through 
Week 252 (Long -term 
Extension)As noted above beginning atafter Week 28 , subjects w ill be permitted to change /add
MTX, other DMARD s, MTX, corticosteroid s, and NSAID suse, including increases or 
decreases in BSA- based dosing (where appropriate) for these classes of agents as 
outlined in Section 8.
Those subjects who discontinue study agent at any time before Week [ADDRESS_42719] 
administration of study agent.
Rationale: Clarification of how the PK and PD data collected during the study will be used. There are no changes to 
the primary endpoints/outcomes in this study.
3.2.3. Rationale The Sponsor w ill utilize PK /PDdata generated from the proposed open -label 
CNTO148JIA3003 study to extrapolate to adult PK and efficacy data from the 
CNTO148ART3001 study in RA, which was the pi[INVESTIGATOR_40928] (SIMPONI ARIA/ and SIMPONI for 
Intravenous Use) for adult patients with RA. Additionally, efficacy (PD) data will be 
collected to explore the assessment of supportive exposure -response.
Rationale: Clarification of the definition of a joint with active arthritis when using ACR criteria to determine the 
number of joints with active arthritis.
4.[ADDRESS_42720] ≥5 joints with active arthritis at screening and at Week 0 as defined 
by [CONTACT_19665] (ie, a joint with either swelling, or in the absence of swelling, 
limited range of m otion associated with pain on m otion or tenderness).
Rationale: To correct the error in the stated inclusion criterion for the serum ALT upper limit of norm alfor the 
central laboratory for enrollment of boys 10 to 18 years of age.
4.1 Inclusion Criteria ,
Criterion 15.e.Serum transaminase levels not exceeding 1.2 x the upper limit of normal for the central 
laboratory:
–Alanine aminotransferase (ALT)
o≤41 IU/L (girls, ages 2 to 18)
o≤41 IU/L (boys, ages 2 to <10)
o≤4252IU/L (boys, ages 10 to 18)
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
27
Status: Approved ,Date: 16 December 2019Applicable Section(s) Description of Change(s)
Rationale: Investigators have provided feedback that requiring subjects to present documentation of immunization 
may limit the opportunity for this vulnerable patient population to enroll in a clinical trial and receive treatment that 
may provide symptomatic relief of their disease.  Therefore, the inclusion criterion has been modified to permit 
subjects without documentation of their immunizations with an opportunity to enroll in the trial provided that the 
investigator has evaluated the subject to confirm that the subject is up to date with all immunizations per the current 
local immunization guidelines for immunocompromised subj ects.
4.[ADDRESS_42721] present documentation of immu nizations (eg, medical record or 
vaccination card) .
17.4 Source 
Documentation• Subject verified report of vaccination or vaccination card
Rationale: Patients with JIA treated with a biologic medication may need to switch to another medication. Ideally, 
the first medication would be washed out prior to starting the second medication, since overlappi[INVESTIGATOR_40929], such as infections. The Sponsor has received consistent 
feedback from investigators that the biologics washout periods in the CNTO 148JIA3003 study are too long and are a 
deterrent to enrollment. The Sponsor has carefully assessed the half-lives of biologic agents thatsubjects may have 
previously been treated and ha sshortened the washout periods (ie, Criterion 6, Criterion 11, and Criterion 14) , while 
at the same time, maintaining a long enough period of time betw een different administered medications to protect 
subjects from exposure to overlappi[INVESTIGATOR_40930].
4.[ADDRESS_42722] has received IL -1ra (anakinra) within [ADDRESS_42723] dose of study agent.
Rationale: The target patient population for this study is patients with polyarticular JIA who have active disease 
despi[INVESTIGATOR_40924]. Anti-TNF α agents are typi[INVESTIGATOR_40931], however , other biologics may be used to treat the disease.  The Sponsor has received consistent feedback 
that the prohibited medications are a deterrent to enrollment in the study .  The Sponsor has carefully assessed the 
half-lives of known IL-[ADDRESS_42724] 
study agent adm inistration .
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
28
Status: Approved ,Date: 16 December 2019Applicable Section(s) Description of Change(s)
Rationale: The target patient population for this study is patients with polyarticular JIA who have active disease 
despi [INVESTIGATOR_40924]. Anti-TNF α agents are typi[INVESTIGATOR_40931], and published JIA treatment guidelines such as the ACR guidelines (2011 American College of 
Rheumatology Recommendations for the Treatment of Juvenile Idiopathic Arthritis: Initiation and Safety 
Monitoring of Therapeutic Agents for the Treatment of Arthritis and Systemic Features) recommend switching to a 
second anti-TNF α agent for patients who continue to have active JIA despi[INVESTIGATOR_40932]-TNF α 
agent. Factors besides lack of efficacy (including inconvenience and pain with administration) may also result in 
changes in treatment. The Sponsor has received consistent feedback that excluding patients who have received 
>1anti-TNF αfrom this study is a deterrent to enrollment. Juvenile idiopathic arthritis is a cause of serious 
functional disability , and the goal of treatment for pediatric patients with the disease is to gain disease control as 
quickly as possible. Criterion [ADDRESS_42725] been previously treated w ith no more than 1 2therapeutic agents 
targeted at reducing TNFα prior to study entry per Inclusion Exclusion Criterion 1912
(Section 4.14.2). Subjects may not have initiated or been treated w ith prohibited 
therapeutic agents as outlined in Exclusion Criteria 1 through 20 (Section 4.2).
Rationale: Previously , patients who were treated with a JAK inhibitor were not eligible for enrollm ent in the study , 
and the Sponsor has received feedback that this is a deterrent to enrollment. Subjects with JIA treated with a 
biologic medication may need to switch to another medication to gain disease control to prevent serious functional 
disability . The Sponsor has carefully assessed the half-lives of JAK inhibitors with which subjects may have been 
treated and has modified Exclusion Criterion [ADDRESS_42726] hasever received a Janus Kinase (JAK) inhibitor , including but not limited to 
tofacitinib ,within [ADDRESS_42727] dose of study agent.
Rationale: Editorial change s weremade to be consistent with the time period of prohibited sperm donation and 
pregnancy planning.
4.3.Prohibitions and
Restrictions ,
#4If sexually active with a girl of childbearing potential and has not had a vasectomy, 
boys must use a double barrier method of birth control during the study and for 
6months after receiving the last administration of study agent, including the LTE 
phase of the study. Boys must not donate sperm and must agree not to plan a pregnancy 
or father a child during the study and within for6 months follow ing the last 
administration of study agent, including the LTE phase of the study.
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
29
Status: Approved ,Date: 16 December 2019Applicable Section(s) Description of Change(s)
Rationale:  A clarification was made to the collection of prior medications beginning at screening and concomitant 
medication collection beginning with the first dose of study drug.
8. Prestudy and 
Concomitant TherapyConcomitant therapi[INVESTIGATOR_40933] [ADDRESS_42728] dose of the study drug. 
Rationale: Correction of the cross -reference made in text regarding the number of anti-TNF α agents that subjects 
are allow ed to have been treated w ith prior to study entry which are in Exclusion Criterion [ADDRESS_42729] been on stable doses of these 
medications prior to study entry per Inclusion C riteria 8 and 9 (Section 4.1). Subjects 
may have been previously treated w ith no more than 12therapeutic agents targeted at 
reducing TNFα prior to study entry per Inclusion Exclusion Criterion 1912
(Section 4.14.2). Subjects may not have initiated or been treated w ith prohibited 
therapeutic agents as outlined in Exclusion Criteria 1 through 20 (Section 4.2).
Rationale: For consistency, changes were made to list of background medications that may be adjusted and 
clarification added that these adjustments are allowed after Week 28.
8. Prestudy and 
Concomitant TherapyNo changes should be made to background medications (ie, MTX, other DMARDs, 
corticosteroids, and NSAIDs ) in terms of increases or decreases in dosage (eg, no more 
than 10 mg/day prednisone or no more than 0.20 mg/kg/day, whichever is lower) and/or 
route of administration between Weeks 0 and 28, unless there is a safety concern (eg, 
elevated liver function tests), which requires changes to background medications . 
Beginning at After Week 28, subjects w ill be permitted to change/add MTX, a new
other DMARD s, MTX ,corticosteroid sand NSAID suse,including increases or 
decreases in dosage, changes of route of administration, or discontinuations from these 
classes of agents.
Rationale: To clarify that the CHAQ is the PRO assessment that should be conducted prior to any tests, procedures, 
or other consultations for that visit
9.1.1. Overview The Childhood Health Assessment Questionnaire All visit -specific PRO assessments
(CHAQ) should be conducted before any tests, procedures, or other consultations for 
that visit to prevent influencing subjects’ perceptions. For additional details, refer to the 
PRO user manual.
Rationale: Clarification of the total volume of blood to be collected from each subject through the course of the 
study .  The total blood volume that was reflected in Table [ADDRESS_42730] for the study is approximately 
146149.4 mL ( Table 4). Repeat or unscheduled samples may be taken for safety 
reasons or for technical issues with the samples.
Rationale: Added a cross -reference to Section 4.[ADDRESS_42731] undergo testing for TB (Attachment 1 and Attachment 2) at screening 
and their medical history assessment must include specific questions about a history of 
TB or know n personal exposure to individuals with active TB .  The subject should be 
asked about past testing for TB, including chest radiograph results and responses to 
tuberculin skin or other TB testing (see Section 4.1) .
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
30
Status: Approved ,Date: 16 December 2019Applicable Section(s) Description of Change(s)
Rationale: Clarification regarding perm issible changes in, or discontinuations of, other anti-rheumatic medications 
after Week 28 in subjects who continue to receive study agent through Week 52; clarification as to when subjects 
who discontinue or withdraw from study participation before W eek [ADDRESS_42732] infusion of study agent.
9.1.4. Treatment Phase: 
After Week 28 through 
Week 52Beginning at After Week 28, eligible subjects w ill continue to receive 80 mg/m2 
golimumab administered as IV infusions over 30±10 minutes at Week 28 and q8w  
(±1week) through Week 52 (Section 6.1 ). Subjects may also receive commercial MTX 
weekly at the same BSA- based dosage (10 to 30 mg/m2per week) as at time of study 
entry through Week 28 and commercial folic acid ≥5 m g weekly or folinic acid if 
administered (at half the MTX dose; Section 6.2) given the day after the MTX dose, 
however, increases, decreases or discontinuations of MTX, othe r DMARDs,
corticosteroids and/or NSAIDs are permissible after Week 28. All changes and reasons 
for changes for these medications nee d to be documented in the eCRF.
Rationale: Clarification that end of treatment assessments should be obtained approximately [ADDRESS_42733] prematurely discontinues study treatment.
9.1.4 Treatment Phase: 
After Week 28 through 
Week 52 ,
End of Treatment/Early 
Withdraw alIf a subject discontinues study agent before Week 52, the subject should return 
approximately [ADDRESS_42734] administration of study agent for a final safety 
follow -up visit (Section 10.2). If a subject w ithdraws from stu dy participation before 
Week 52, every effort should be made to obtain end -of-treatment assessments prior to 
the subject’s withdraw al of consent.
10.[ADDRESS_42735] infusion of study 
agent at the final safety follow -up visit.
Rationale: Clarification that during the long-term extension phase of the study , subjects who discontinue before the 
end of the study without withdraw ing consent should return for final evaluations within approximately [ADDRESS_42736] infusion of study agent .
9.1.5. Long -Term  
Extension Phase: After 
Week [ADDRESS_42737] study agent infusion (Section 10.2).
Rationale: Clarifications on the evaluations that should be performed at th e Final Safety Follow -up visit.
10.2 Discontinuation of 
Study Treatment Safety evaluations (vital signs, review of systems, AE review , study agent 
infusion reaction evaluation , TB evaluation, uveitis evaluation, and the collection 
of a blood sample for routine laboratory analyses and determination of the 
presence of ANA/anti -double -stranded deoxyribonucleic acid (dsDNA) antibodies 
and antibodie s to golimumab).
 Efficacy evaluation s (egjoint assessment s, pain assessment, Parent/Subject 
Assessment of Overall Well -Being and Physician ’s Global Assessments of 
Disease Activity, and CHAQ , JIA assessments, and collection of blood sample 
for CRP ).
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
31
Status: Approved ,Date: 16 December 2019Applicable Section(s) Description of Change(s)
Ratio nale: Removed the subsection for the “Parent/Subject Assessment of Overall Well-being ”in Section [IP_ADDRESS] 
and included it in Section [IP_ADDRESS], Childhood Health Assessment Questionnaire, since the “Parent/Subject 
Assessment of Overall W ell-being ” is part of the Childhood Health Assessment Questionnaire.
[IP_ADDRESS]. American 
College of Rheumatology 
Pediatric Response
Parent/Subject 
Assessment of Overall 
WellbeingParent/Subject Assessment of Overall Well- being
The Parent/Subject Assessment of Overall Well -being is a 10 cm visual analog scale 
(VAS).  Parents/subjects are to complete the VAS that asks them to consider all the 
ways arthritis impacts their child/themselves and then indicate how  the child is doing.  
The anchors of the scale are “very well” to “very p oor”.  Lower scores indicate better 
well-being .  The process for including this measure in the core set of variables for the 
assessment of children has been captured in the literature.5  
Subjects who are emancipated juveniles (ages 15 to <18 years) at study entry may 
complete the assessments themselves.  The same individual (eg, parent, caregiver, or 
subject) who completes the assessments at the sta rt of the study should complete the 
assessments throughout the study.
Rationale: Correction of the number scale units for the Physician ’sGlobal Assessment of disease activity for 
inactive disease.
[IP_ADDRESS]. American 
College of Rheumatology 
Pediatric Response ,
Inactive Disease Physician ’sGlobal Assessment of dDisease aActivity indicating no active disease 
(<0.5cm 5mm)
Rationale: Correction of the number scale units for the visual analog scale (VAS) used in the Physician Global 
Assessment of Disease Activity .
[IP_ADDRESS]. Physician Global 
Assessment of Disease 
ActivityThe Physician Global Assessment of dDisease aActivity is a 10 cm 100 mm  VAS.
Rationale: Clarification of the construct and ordinal scores to be used to assess functioning and task performance 
with the Childhood Health Assessment Questionnaire (CHAQ); correction of the number scale units for the VAS 
used to assess the subject’ s pain and overall well-being; paragraph 1 of “ Parent/Subject Assessment of Overall W ell-
being ” was removed from Section 9.2.1. 2and was included in Section [IP_ADDRESS] since this assessment is a component 
of the CHAQ; paragraph 3 of Section [IP_ADDRESS], Childhood Health Ass essm ent Questionnaire, was deleted because it 
was redundant to paragraph 2 which is now part of the subsection ,“Parent/Subject Assessment of Overall Well-
being .”
[IP_ADDRESS]. Childhood 
Health Assessment 
Questionnaire
Parent/Subject 
Assessment of Pain
Parent/Subject 
Assessment of Overall 
Well -beingThe functional status of subjects will be assessed by [CONTACT_40980] ( CHAQ ).19  Parents/subjects will are to complete this questionnaire
20-question instrument tothatassess esthe degree of difficulty the subject child has in 
accomplishing tasks in 8 functional areas (dressing and grooming, arising, eating, 
walking, hygiene, reaching, grippi[INVESTIGATOR_007], and activities of daily living).  Responses in each 
functional area are scored from as0,indicating “ (Wwithout anyANY difficulty )”, 
1(with som e difficulty) , 2 (with much difficulty) , to 3 (unable to do) , or 4 (not 
applicable). indicating “With MUCH Difficulty” to perform a task in that area (lower 
scores are indicative of better functioning) with an ‘unable to do’ and ‘not applicable’ 
response options as well .  Lower scores are indicative of improved functioning and 
task performance in specific functional areas.
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
32
Status: Approved ,Date: 16 December 2019Applicable Section(s) Description of Change(s)
Additionally, the CHAQ includes 2 VAS questions —one used to assess the 
subject’s level of pain, and one used to assess the subject’s overall well -being.
Properties of the CHAQ measure have been evaluated and its validity assessed.19  The 
CHAQ has been shown to be responsive to disease change.19  A decrease of 0.188 has 
been determined to be a meaningful clinical improvement.1
Subjects who are emancipated juveniles (ages 15 to <18 years) at study entry may 
complete the assessments themselves.  The same individual (eg, parent, caregiver, or 
subject) who completes the assess ments at the start of the study should complete the 
assessments throughout the study. 
Parent/Subject Assessment of Pain
Visual Analog Scale for p Pain w ill be assessed as average pain experienced by [CONTACT_40981] .  The scale that ranges from “no pain” 
(0mmcm ) to “very severe pain” (10 0 mmcm).  This assessment should be completed 
by [CONTACT_7903] (caregiver) /subjects prior to the tender and swollen joint examination.  
Parent/Subject Assessment of Overall Well- being
The Paren t/Subject Assessment of Overall Well -being is a 0 -100 mm  VAS. 
Parents/subjects will complete the VAS that asks the m to consider all the ways 
arthritis impacts their child/themselves and then indicate how the subject is doing. 
The anchors of the scale are “ very well” (0 mm) to “very poor (100 mm)”. Lower 
scores indicate better well -being. The process for including this measure in the 
core set of variables for the assessment of children has been captured in the 
literature.5
Subjects who are em ancipated juveniles (ages 15 to <18 years) at study entry m ay 
complete all the CHAQ assessments themselves.  Preferably, the sam e individual 
(eg, parent, caregiver, or subj ect) who com pletes the assessments at the start of the 
study should complete the assessments throughout the study.
Rationale: To align the text in Section 9.3.4 regarding the evaluation of samples for antibodies to golimumab for 
consistency with the Time and Events Schedule (Tables 1, 2, and 3).
9.3.4. Immunogenicity 
Assessments (Antibodies 
to Golimumab)Antibodies to golimumab will be evaluated in serum samples collected from all 
subjects according to the Time and Events Schedule (ie, Weeks 0, 4, 8, 12,28, 52, 100, 
148, 196, and 244).
Rationale: Editorial changes only regarding subjects with severe infusion reactions that involve bronchospasms 
with wheezing and/or dyspnea.
9.4 Safety Evaluations ,
Allergic ReactionsSubjects with severe reactions following an infusion resulting that result in 
bronchospasm swith wheezing and/or dyspnea requiring and require ventilatory 
support, or symptomatic hypotension with a decrease in systolic blood pressure greater 
than 40 mm mercury (Hg), will not be permitted to receive any additional study agent 
infusions. In the case of such reactions, appropriate medical treatment should be 
administered.
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
33
Status: Approved ,Date: 16 December 2019Applicable Section(s) Description of Change(s)
Rationale: Editorial changes made to clarify that the DRC charter defines how the DRC will revie w safety.  The 
DRC charter does not define the Steering Committee’s review of safety data.
11.9. Data Monitoring 
CommitteeUnblinded safety data will be routinely evaluated by [CONTACT_1758]’s medical monitor and 
an internal Data Revie w Committee as defined in the DRC charter.  In addition, the 
data m ay be reviewed by [CONTACT_40982] .
Rationale: Addition of language to clarify that events meeting the definition of a serious adverse event will be 
report ed, as w ell as those events that are anticipated as related to the progression of the disease under study.
12.3.1. All Adverse 
EventsAll events that meet the definition of a serious adverse event w ill be reported as serious 
adverse events, regardless of whether they are protocol -specific assessments. 
Anticipated events will be recorded and reported as described in Attachment 4.
Rationale: The Parent/Subject Assessm ent of Overall Well-being and the VAS for pain were removed from the list 
of assessments that are recorded into an electronic device because these are part of the CHAQ.  Duration of morning 
stiffness was added as one ofthe assessments that are recorded into an electronic device.  Text was added to clarify 
that these assessments should be not recorded on paper first.  
17.4. Source 
DocumentationThe following parent/subject -and investigator -completed scales and 
assessments designated by [CONTACT_40983]: joint assessments, 
CHAQ, parent/subject assessment of overall well-being, pPhysician gGlobal 
aAssessment of dDisease aActivity, and duration of morning stiffness .and 
visual analog scale for pain. These assessments should not be recorded on 
paper first . 
Rationale: Addition of language to include events that meet the definition of a serious adverse event, and 
anticipated events which may occur during the study as part of the safety analyses for the study; clarification of 
which anticipated events (drug or disease related) are to be captured in the Case Report Form (CRF), reported to the 
sponsor (serious or non-serious), may or may not be exempt for reporting to Health Authorities, the role of the 
Anticipated Event Review Committee, and analysis of anticipated events for safety evaluation and monitoring.
ATTACHMENT 4 
ANTICIPATED 
EVENTSAn anticipated event is an adverse event (serious or non -serious) that commonly 
occurs as a consequence of the underlying disease or condition under investigation 
(disease related) or background regimen.
For the purposes of this study, the following events will be considered anticipated 
events:
Events related to the progression of the disease under study.
These events will be captured on the CRF and in the database, and will be 
reported to the sponsor as described in Section 12.3.1, All Adverse Events. Any 
event that m eets serious adverse event criteria will be reported to the sponsor 
within the appropriate tim eline as described in Section 12.3.2, Serious Adverse 
Events. These anticipated events are exempt from expedited reporting as 
individual single cases to Health Authorities. However, if based on an aggregate 
review, it is determ ined that an anticipated event is possibly related to study drug, 
the sponsor will report these events in a n expedited manner.
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
34
Status: Approved ,Date: 16 December 2019Applicable Section(s) Description of Change(s)
Anticipated Event Review Committee (ARC)
An A RCwill be established to perform  reviews of pre -specified events at an 
aggregate level. The ARC is a safety committee within the sponsor’s organization 
that is independent of the sponsor’ s study team . The ARC will m eet to aid in the 
recommendation to the sponsor’s study team  as to whether there is a reasonable 
possibility that an anticipated event is related to the study drug.
Statistical Analysis
Details of statistical analysis of anticipated events, including the frequency of 
review and threshold to trigger an aggregate analysis of anticipated event will be 
provided in a separate Anticipated Events Safety Monitoring Plan (ASMP).
Rationale: Minor errors w ere noted and corrected.
Throughout the
protocolMinor grammatical, formatting, or spelling changes were made.
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
35
Status: Approved ,Date: 16 December 2019Amendment INT -1(12August 2014 )
The overall reason for the amendme nt:The protocol has been revised to add safety information from golimumab 
studies in adults and pediatric patients and to address recommendations from PRINTO and PRCSG.
Applicable Section(s) Description of Change(s)
Rationale: Clarification of approved therapi[INVESTIGATOR_40934].
Section 1.1.[ADDRESS_42738] been found in the serum of JIA patients with 
systemic onset disease, and these levels correlate w ith disease state. 
Currently approved biologic therapi[INVESTIGATOR_40935] (pJIA)
include etanercept, adalimumab ,abatacept ,and tocilizumab; canakinum ab has been 
approved for system ic JIA.
Rationale: Editorial changes were made.
Section 1.1.2 Golimumab 
Clinical Studies in 
Rheumatoid Arthritis and 
Juvenile Idiopathic 
ArthritisThe results of the CNTO148ART3001 study of IV golimumab in adults 
CNTO148JIA3001 study of SC golimumab in subjects with JIAand the results of the 
CNTO148JIA3001 study of SC golimumab in subjects with JIA CNTO148ART3001 
study of IV golimumab in adults are described below .
Rationale: Clarification of AEs and SAEs has been made
Section [IP_ADDRESS] 
Intravenous Golimumab 
in Adult Rheumatoid 
ArthritisThrough Week 16 (the placebo -controlled period prior to early escape) in 
CNTO148ART3001, 43.7% of subjects in the placebo group and 47.3% in the 
golim umab group had an AE; the highest incidence of AEs was in the infections 
and infestations SOC, 20.8% and 24.3% in the placebo and golimumab groups, 
respectively with upper respi[INVESTIGATOR_1092] (URTI) being the most 
frequently reported AE (5.6% and 5.1% in the placebo and golim umab groups, 
respectively ). Through Week 112, 79.1% of golimumab -treated subjects had an 
AE; the highest incidence of AEs was in the infections and infestations SOC 
(50.5%) and URTI was the most frequently reported AE (11.5%). 
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
36
Status: Approved ,Date: 16 December 2019Applicable Section(s) Description of Change(s)
The proportion of subjects who reported an AE was comparable betw een the 
golimumab + MTX and placebo + MTX groups through Week 16 (47.3% compared 
with 43.7%, respectively) and Week 24 (52.9% compared with 49.2%, respectively). 
The m ost commonly reported system organ class AEs through Week 16 were Infections 
and infestations (24.3 % and 20.8% in the golimumab + MTX and placebo + MTX 
groups, respectively), and were predominantly upper respi[INVESTIGATOR_1092], urinary 
tract infection, and nasopharyngitis.
Through Week 16 in CNTO148ART3001, 1.0% of subjects in the placebo group 
and 3.8% of subjects in the golim umab group had an SAE. The incidence of SAEs 
within each SOC was <1.0%, and no SAE occurred in more than 1subject. 
Through Week 112, 18.2% of golim umab-treated subjects had an SAE; the 
highest incidence of SAEs occurred in the infections and infestations SOC (5.5%) 
and musculoskeletal and connective tissue disorders SOC (3.4%) and the most 
frequently reported SAE was RA (2.1%).
Serious adverse events (SAEs) through Week 24 in the golimumab + MTX group were 
higher (4.1%) compared with the placebo + MTX group (2.0%) and were 
predominantly serious infections (1.0% in the golimumab + MTX group and 0.0% in 
the placebo + MTX group).
One subject in the placebo + MTX group died through Week 24 (presumed stroke due 
to hypertensive crisis; no autopsy performed).
Through Week 24, [ADDRESS_42739] 
was random ized to treatment with placebo + MTX, had never received 
golim umab, and died of a presumed cerebrovascular accident (stroke). Through 
Week 112, an additional 5 subjects died in the CNTO148ART3001 study. Two 
subjects randomized to treatm ent with placebo +MTX died, both after switching 
to golim umab2mg/kg +MTX; cause of death was sudden death (n=1) and 
complications of severe dehydration, Clostridium difficile colitis, and atrial 
fibrillation (n=1). Three subjects randomized to treatm ent with 2 mg/kg 
golim umab + MTX died in the study; reported cause of death was acute 
abdominal syndrome (later diagnosed as peritoneal tuberculosis [TB], n=1), 
presumed myocardial infarction (MI, n=1), and septic shock secondary to a 
pyogenic lung abscess due to Acinetobacter baumanii (n=1).
No malignancies were reported through Week 16 in CNTO148ART3001. Though 
not included in the tables which include only treatment -emergent events or the 
calculations of malignancy rates, there was 1 case of nontreatm ent-emergent lung 
adenocarcinom a reported in the placebo +MTX group before Week 16. Through 
the placebo -controlled period (Week 24), 1malignancy (breast cancer) was
reported in the golimumab group. Through Week 112, 5additional malignancies 
basal cell carcinoma, chronic lymphocytic leukemia in a subject with a family 
history of chronic lymphocytic leuke mia, cervix carcinom a in situ, Bowen’s 
Disease and basal cell carcinom a) were reported. No lymphomas were reported 
through Week 112.
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
37
Status: Approved ,Date: 16 December 2019Applicable Section(s) Description of Change(s)
Through Week 16 (the placebo -controlled period prior to early escape) in 
CNTO148ART3001, 43.7% of subjects in the placebo group and 47.3% in the 
golimumab group had an AE; the highest incidence of AEs was in the infections and 
infestations SOC, 20.8% and 24.3% in the placebo and golimumab groups, respectively 
with upper respi[INVESTIGATOR_1092] (URTI) being the most frequently reported AE 
(5.6% and 5.1% in the placebo and golimumab groups, respectively ). Through 
Week 112, 79.1% of golimumab -treated subjects had an AE; the highest incidence of 
AEs was in the infections and infestations SOC (50.5%) and URTI was the most 
frequently reported AE (11.5%).
The proportion of subjects who reported an AE was comparable betw een the 
golimumab + MTX and placebo + MTX groups through Week 16 (47.3% compared 
with 43.7%, respectively) and Week 24 (52.9% compared with 49.2%, respectively). 
The m ost commonly reported system organ class AEs through Week 1 6 were Infections 
and infestations (24.3% and 20.8% in the golimumab + MTX and placebo + MTX 
groups, respectively), and were predominantly upper respi[INVESTIGATOR_1092], urinary 
tract infection, and nasopharyngitis.
Serious adverse events (SAEs) throug h Week 24 in the golimumab + MTX group were 
higher (4.1%) compared with the placebo + MTX group (2.0%) and were 
predominantly serious infections (1.0% in the golimumab + MTX group and 0.0% in 
the placebo + MTX group).
No malignancies were reported through Week 16 in study CNTO148ART3001. 
There was 1 case of non -treatment -emergent lung adenocarcinom a reported in the 
placebo +MTX group prior to receiving study agent. Through the placebo -
controlled period (Week 24), 1malignancy (breast cancer) was reported in the 
golim umab group. Through Week 112, 5additional malignancies were reported, 
including basal cell carcinoma, chronic lymphocytic leukemia in a subject with a 
family history of chronic lymphocytic leukemia, cervix carcinom a in situ, Bowen’s 
Disease and basal cell carcinom a. No lymphomas were reported through 
Week 112.
Through Week 16 in CNTO148ART3001, 0.5% of subjects in the placebo group and 
2.5% of subjects in the golimumab group had an infusion reaction. Through Week 112, 
3.9% of golimumab -treated subjects had an infusion reaction and 0.4% of infusions 
were complicated by [CONTACT_40984]. It should be noted that all placebo infusions 
consisted of 0.9% normal saline alone rather than a true matched placebo. No serious 
infusion reactions requiring study agent discontinuation or anaphylaxis were noted. 
There was a case of anaphylaxis which was not associated with study drug.
For the most comprehensive nonclinical and clinical inform ation regarding 
Simponi (golimumab), refer to the latest version of the Investigator's Brochure 
and Addenda for S imponi (golimumab). 
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
38
Status: Approved ,Date: 16 December 2019Applicable Section(s) Description of Change(s)
The median peak serum golim umab concentration (ie, post-infusion golimumab 
concentration) of 41.56 µg/mL was observed at Week 4 following IV administration of 
2mg/kg golimumab at Week 0, Week 4, follow ed by q8w (±1 week ) administration. 
This peak is higher than that reported for SC golimumab administration of 50 mg every 
4 weeks (q4w ). The median trough serum golimumab concentration in subjects 
receiving IV golimumab at 2 mg/kg q8w with MTX was 0.28 µg/mL at Week 12 and 
0.22 µg/mL at Week 20; these levels are similar to those reported with SC golimumab 
50 mg. Overall exposure to golimumab in approximately 3 times that for SC 
golimumab 50 mg over a similar period of exposure.
Rationale: Major endpoints were not met and the study has been terminated and duly noted. Additionally, AEs have 
been described.
Section [IP_ADDRESS] 
Subcutaneous 
Golimumab in Juvenile 
Idiopathic ArthritisThe baseline disease characteristics of the 173 enrolled subjects constituted a 
population with moderate to severe JIA comparable with other clinical studies of anti-
TNF α agents in pJIA, with the exception of numerically lower mean and median 
CRP /ESR levels in CNTO148JIA3001.
The study did not meet its primary and major secondary endpoints as the proportion of 
subjects who were JIA ACR 30 responders at Week 16 and did not experience a flare 
of disease between Week 16 and Week 48 was not significantly different in subjects 
rando mized to continued golimumab treatment between Weeks 16 and 48 as compared 
with subjects randomized to receive placebo betw een Weeks 16 and 48 (59% versus 
52.6%, p=0.41). All sensitivity analyses and major secondary endpoints 
demonstrated the lack of statistically significant differences betw een treatment groups. 
The Sponsor terminated the long -term  extension of the study early as pre -specified 
efficacy endpoints were not met.
With regards to immunogenicity, 40.1% of subjects developed antibodies to golimum ab 
using the recently developed drug tolerant immunoassay analyses . The new drug 
tolerant immunoassay is more sensitive compared with assays used previously in adult 
golimumab RA studies and allows the detection of antibodies to golimumab despi[INVESTIGATOR_40936] e serum golimumab levels. Among subjects who were randomized and 
remained on golimumab 30 mg/m2SC + MTX, 30.8% developed antibodies to 
golimumab; antibody titers tended to be low. When evaluating the effects of 
immunogenicity on PK, efficacy, and safety, it was found that positive anti-golimumab 
antibody status significantly decreased steady -state trough golimumab concentrations 
when the titer levels were >1:100. However, the effect of antibodies on efficacy was 
less sensitive, requiring higher titers >1:1000 in order to correlate with apparent 
reductions in efficacy. Since only approximately 5% of subjects with JIA developed 
anti-golimumab antibodies with titers > 1:1000, it was determined that immunogenicity 
was not a contributing factor to not achieving lack of achievement ofthe prim ary 
endpoint in CNTO148JIA3001. Lastly, Additionally, positive anti-golimumab 
antibody status did not appear to be associated with a higher incidence of injection -site 
reactions.
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
39
Status: Approved ,Date: 16 December 2019Applicable Section(s) Description of Change(s)
The proportion of subjects who reported an AE through Week 48 was 87.9%. The m ost 
commonly reported sy stem organ class of AEs was Infections and infestations (67.1%), 
and were predominantly upper respi[INVESTIGATOR_40937]. There 
was no marked difference in AEs reported betw een Week 16 and Week 48 for subjects 
randomized to placebo (82.9%) and those randomized to continued golimumab 
treatment (78.2%), however it needs to be noted that all subjects in randomized 
withdrawal portion of the study were exposed to golimum ab for 16 week s before 
re-random ization. Serious adverse events were reported by 13.3% of subjects. The 
most commonly reported SAE was worsening of JIA (6.4%). Serious infections were 
reported in 2.9% of subjects (pneumonia, urinary tract infection, herpes zoster, upper 
respi[INVESTIGATOR_40938] n, and pyelonephritis), and there were no deaths, malignancies, 
or demyelination events through Week 48. There were no reports of active TB and no 
serious opportunistic infections. Through Week 48, the number of subjects with 
abnormal ALT measurements (and no concom itant treatment for latent TB, which 
may affect LFTs ) and no TB prophylaxis was 29.5% (51/167), 39 of the 51 subjects 
had elevations < [ADDRESS_42740].
There were twosubjects with ALT elevation to > [ADDRESS_42741] met 
the criteria for Hy’s Law consistent with hepatotoxicity. Subjects were not 
receiving TB prophylaxis; one of the subjects had baseline ALT which was already 
abnorm al. All subjects with LFT abnormalities were managed conservatively with 
changes in MTX dosing but one subject was discontinued for elevated LFTs.
The incidence of injections with injection -site reactions through Week 48 was 
0.8%; there was one SAE report of serum  sickness -like reaction in a patient 
randomized to placebo who resumed golimumab treatment.
Although the CNTO148JIA3001 study did not meet its endpoints, when JIA ACR 
response rates were presented analyzed as observed data through Week 48 (using 
Week 0 as baseline and comparing drug/placebo effect at each visit through Week 48) 
the study showed the potential for significant efficacy that could be attained with SC 
golimumab in children with pJIA. Therefore, it lends support to the study of IV 
golimumab in subjects with pJIA who have an inadequate response to MTX.
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
40
Status: Approved ,Date: 16 December 2019Applicable Section(s) Description of Change(s)
Rationale: Clarification of the prim ary objective has been made . Additionally, clarification on the prior use of 
agents has also been made.
Section 1.2 Overall 
Rationale for the StudyThe primary objective of this study is to characterize the PK of IV golimumab in pJIA, 
along with simultaneous evaluations of the safety and efficacy (reflected in proportion 
of subjects with JADAS minim al disease activity at Week 28) of IV golimumab in 
these subjects. This study will also include subjects with multiple subtypes of JIA, 
including juvenile PsA, as well as subjects with prior anti-TNF αexperience (up to 20
30% of the study population).
The study is designed to obtain PK data in response to BSA -based (80mg/m2,which is 
expected to be equivalent to the 2 mg/kg dose in adult RA patients weighing 70 kg)IV 
golimumab for subjects with pJIA who have inadequate response to MTX treatment as 
well as prior treatm ent with non-steroidal anti-inflammatory agents, 
corticosteroids and/or anti-TNFα agents, with the intent to demonstrate its similarity 
to the respon se seen with weight-based (2 mg/kg) doses of IV golimumab in adult RA 
subjects who have inadequate response to MTX treatment. The 80mg/m2dose for 
subjects with pJIA is based on the 2 mg/kg dose studied in CNTO148ART3001 in the 
adult RA population.
Ratio nale: Clarification of the primary objective has been made
Section 2.1 Objectives
Primary ObjectiveThe primary objective of this study is to assess the PK and JADAS minimal activity 
scores following intravenously administered golimumab in subjects (ages 2 to less than 
18 years) with pJIA manifested by ≥5 joints with active arthritis and CRP of 
≥0.1 mg/d L despi[INVESTIGATOR_40922] ≥3months at Week 28.
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
41
Status: Approved ,Date: 16 December 2019Applicable Section(s) Description of Change(s)
Rationale: Clarifications of duration of disease for enrollment in study and maximum single dose have be en made.
Section 3.[ADDRESS_42742] a 63-month history of pJIA, and active 
arthritis in ≥[ADDRESS_42743] population of approximately 10% aged 2 to up to 6 
years, approximately 20% aged 6 to up to 12 years, and approximately 70% aged 12 to 
less than 18 years.
All subjects will receive 80 mg/m2golimumab (maximum single dose 240mg) as an 
IV infusion given over 30±10 minutes at Week s 0, 4, and every 8 weeks (q8w; ± 3 
days ) through Week 28 and then q8w (± 1 week ) thereafter through Week 244. Body 
surface area will be calculated based on the subject’s height and body weight measured 
at each visit, and the BSA -based dose of golimumab will be adjusted as needed to 
maintain the dose at 80mg/m2. Subjects will also receive commercial MTX weekly at 
the same BSA -based dosage (10 to 30 mg/m2per week of MTX, with a minimum of 
15mg in subjects with BSA ≥1.67 m2) as at time of study entry through Week 28as 
outlined in Section 6.2.
Every effort should be made to maintain subjects at a dose of 80 mg/m2of golimumab
based upon BSA, and decreases below  or increases above 80 mg/m2 or shortening of the 
dosing interval (eg, from 8 weeks to 6 weeks) will not be permitted at any visit.
The schematic overview of the study (Figure 1) has been revised to show the 
screening period (-6 Weeks to Week 0) and safety follow -up period (Week 244 to 
Week 252).
Rationale: This subsection has been reorganized [Week 0 through Week 58 28] for clarity and therefore the 
deletion .
Section 3.1.1 Week 0 
through Week 28Through Week 28 subjects will be monitored and disease activity and safety will be 
assessed at the investigative site every 4 weeks. From  Week 28 through Week 52, 
subjects will be monitored and disease activity and safety will be assessed at the 
investigat ive site every 8 weeks.
After all subjects complete the Week 28 visit, the database will be locked to assess PK, 
safety and efficacy. An additional safety, efficacy, and PK database lock is currently 
planned for Week 52. Final data base lock will be perfor med at Week 252.
No changes should be made to background medications (ie, DMARDs, corticosteroids, 
and NSAIDs) in terms of increases or decreases in BSA -based dosage beyond the 
parameters provided in Section 8(eg, no more than 10 mg/day prednisone or no m ore 
than 0.20 mg/kg/day, whichever is lower) and/or route of administration between 
Weeks 0 and 28, unless there is a safety concern (eg, elevated liver function tests), 
which requires changes to background medications. 
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
42
Status: Approved ,Date: 16 December 2019Applicable Section(s) Description of Change(s)
Rationale: An additional sub sectio nhas been introduced as sub section 3.1.1 w as re -organized for clarity
Section 3.1.2 Week 28 
through Week 52From  Week 28 through Week 52, infusions will continue to be perform ed every 8 
weeks (± 1 week ), however subjects will be actively monitored at theinvestigative 
site and disease activity and safety will be assessed at the investigative site every [ADDRESS_42744] (including agents 
besides MTX), MTX, corticosteroid, and NSAI D use as outlined in Section 8.
Rationale: Clarifications of the availability of study agent have been made
Section 3.1.3 Week 52 
through Week 252 
(Long -term extension)During the long -term extension, all subjects will continue to receive golimumab q8w (± 
1 week )through Week 244. For children who have com pleted the full trial period of 
252 weeks and for whom drug is proven beneficial but the drug is not 
comm ercially available for JIA indication (or patient does not qualify for 
insurance to pay for drug) IV golimumab will continue to be provided by [CONTACT_429]. Betw een Week 52 and Week 252, disease activity will be monitored and 
assessed, and documented in the CRF every  16 weeks; infusions and safety 
measurements will be done every [ADDRESS_42745], MTX, 
corticosteroid, and NSAID use, including increases or decreases in BSA -based dosing 
(where appropriate) for t hese classes of agents as outlined in Section 8.
Rationale: Clarification of the visit window through Week 24 has been made
Section 3.2 .2Dose 
SelectionIn the CNTO148JIA3001 study, BSA -based dosage of SC golimumab was utilized. 
After subjects with pJIA received golimumab 30 mg/m2SC q4w, median steady -state 
trough golimumab levels were similar across different age groups (median 0.73 µg/mL 
to 1.25 µg/mL at Week 48). The median steady -state concentrations in subjects with 
pJIA were also similar to or higher than those seen in adult subjects with RA who 
received golimumab 50 mg SC q4w (0.82 µg/mL at Week 76 and 1.17 µg/mL at Week 
104 in C0524T06 using the same MSD ECLIA assay); both study populations were 
receiving concomitant MTX. The study results confir med that BSA -based doses 
achieved fairly even drug exposure in pediatric subjects at different ages and were 
comparable to the adult exposure.
Data from the Phase 3 IV study in adults with RA (CNTO148ART3001) through [ADDRESS_42746] shown that golimumab 2 mg/kg at Week 0, Week 4, and q8w (±1 week ) 
thereafter is the optimal dose regimen for the treatment of RA in most adults. For a 
child, golimumab 80 mg/m2(2mg/kg/1.73 m2) would be approxim ately equivalent to 2 
mg/kg for an adult subject weighing 70 kg (witha BSA of 1.73 m2). Thus, in the 
current study (CNTO148JIA3003), a dose of golimumab 80mg/m2has been chosen to 
evaluate the safety and efficacy of g olimumab in the JIA population.
Rationale: Clarification of route of administration for S imponi Aria
Section 3.2.3 Rationale The Sponsor will utilize PK/PD data generated from the proposed open -label 
CNTO148JIA3003 study to extrapolate to adult PK and efficacy data from the 
CNTO148ART3001 study in RA, which was the pi[INVESTIGATOR_40939] (SIMPONI ARIA and SIMPONI for 
Intravenous Use) for adult patients with RA.
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
43
Status: Approved ,Date: 16 December 2019Applicable Section(s) Description of Change(s)
Rationale: Several inclusion criteria w ere revised per PRINTO/PRCSG recommendations
Section 4.1
Inclusion criteria #1Pediatric Subjects must be age 2 years to less than 18 years with a body weight >15 kg 
at the time of screening and at Week 0.
Section 4.1
Inclusion criteria #3Active JIA of one of the following subtypes:
a.Rheumatoid factor positive or negative pJIA for ≥3months prior to 
screening , or
b.Systemic JIA with no systemic symptoms for ≥3 months but with 
polyarthritis for ≥3 months prior to screening , or
c.Extended oligoarticular JIA ≥3months prior to screening , or
d.Polyarticular juvenile psoriatic arthritis ≥3 months prior to screening , or,
e.Enthesitis related arthritis ≥3months prior to screening .
Inclusion criteria #[ADDRESS_42747] a 3-month course of MTXbefore 
screening.
Inclusion criteria #[ADDRESS_42748] active JIA despi[INVESTIGATOR_40923], intramuscular or 
subcutaneous MTX (for ≥3months before screening and on a stable dose for 4 weeks 
as noted in Section 8) at a weekly dose of ≥10mg/m2. Subjects currently on MTX 
(weekly 10 to 30 mg/m2), must receive a stable dose of MTX for ≥4weeks before 
screening. Subjects with BSA ≥1.[ADDRESS_42749] receive a minimum of 15mg/week of 
MTX unless documented country or site regulations prohibit use of 15mg of MTX per 
week in subjects with BSA ≥1.67 m2. In situations where there is documented 
intolerance of doses >10mg/m2weekly or for subjects with BSA ≥1.67 m2who do not 
tolerate 15 mg/week for subjects with BSA ≥1.67 m2,subjects may be entered into the 
trial on a low er dose of MTX.
Inclusion criteria #[ADDRESS_42750] be on a stable dose of ≤10 mg/dayprednisone equivalent 
or 0.20 mg/kg/day (whichever is lower) for ≥ 2weeks before first administration of 
study agent (In extreme circumstances, a subject may receive <0.20 mg/kg/ day if there 
is documented intolerance or AEs due to higher doses of corticosteroids ). If currently 
not using corticosteroids, the subject must have not received corticosteroids for at least 
2weeks before the first dose administration. Subjects with syste mic onset JIA but 
without system ic symptoms must be on a stable dose of corticosteroids for at least 3 
days screening .
Inclusion criteria #[ADDRESS_42751] be on a stable dose for ≥[ADDRESS_42752] administration of study agent screening .
Rationale: Several ex clusion criteria w ere revised per PRINTO/PRCSG recommendations
Section 4.2
Exclusion c riteria #1Subject has initiated DMARDs and/or immunosuppressive therapy (with the exception 
of MTX ) within [ADDRESS_42753] study agent administration. 
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
44
Status: Approved ,Date: 16 December 2019Applicable Section(s) Description of Change(s)
Exclusion criteria #[ADDRESS_42754] study agent administration.
Exclusion criteria #[ADDRESS_42755] has had a Bacille Calmette -Guérin (BCG) vaccinatio n within [ADDRESS_42756] 
study drug administration.
Exclusion criteria #[ADDRESS_42757] dose of study agent.
Exclusion criteria #[ADDRESS_42758] 
administration of study agent.
Exclusion criteria #[ADDRESS_42759] study dose 
administration.
Exclusion criteria #[ADDRESS_42760] has a history of lymphoproliferative disease, including lymphoma, or signs 
suggestive of possible lymphoproliferative disease, such as lymphadenopathy of 
unusual size or location, or clinically significant splenomegaly not consistent with 
pJIA  or systemic onset JIA  without system ic symptoms.
Exclusion criteria #[ADDRESS_42761] has a pasthistory of macrophage activation syndrome.
Exclusion criteria #45 Active uveitis within 3 m onths prior to screening 
Exclusion criteria #[ADDRESS_42762] with BSA >3.0 m2
Rationale: Clarification of prohibitions and restrictions hasbeen made.
Section 4.3
Prohibitions and 
Restrictions #1Subjects must not receive a live virus or live bacterial vaccination [ADDRESS_42763] administration of study 
agent.
Prohibitions and 
Restrictions #2Subjects must not receive a BCG vaccination for [ADDRESS_42764] administration of study agent.
Prohibitions and 
Restrictions #5Intramuscular administration of corticosteroids for the treatment of pJIA is not allowed 
during the study. Corticosteroids administered by [CONTACT_40985] e 
of the study. For additional details, see Section 8.
Prohibitions and 
Restrictions #6Subjects must not receive investigational drugs, other immunosuppressants (such 
as, but not exclusively, cyclophosphamide), or other biologics for pJIA during the 
study. 
Rationale: Clarification of the visit windows through Week 24 and through Week 244 has been made
Section 5 Treatment 
Allocation and BlindingThis is an open -label study . Beginning at Week 0, all subjects will receive golimumab 
80mg/m2at Week 0, W eek 4 and q8w  (± 3 days ) through W eek 28 and q8w  (± 1 week ) 
up to W eek 244. 
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
45
Status: Approved ,Date: 16 December 2019Applicable Section(s) Description of Change(s)
Rationale: Clarifications on the maximum single dose have be en made.
Section 6.[ADDRESS_42765] 1 active treatment group and all subjects will receive 80 mg/m2
golimumab ( maximu m single d ose 240 mg) IV infusions at Week 0, Week 4, and q8w 
(±3 days )through Week 28 and q8w (±1 week )thereafter through Week 244. The 
golimumab infusions will be prepared by a pharmacist under sterile conditions using 
golimumab 50mg/4 mL liquid in vials and a 100 mL infusion bag of 0.9% saline. 
Subjects will receive 80mg/m2golimumab IV infusions over 30±10 minutes. Infusions 
may be slowed down for evidence of infusion reactions as deem ed appropriate by [CONTACT_1275], and all changes in the infusion rate should be recorded in the CRF. Body 
surface area will be calculated at each visit and the dose of golimumab will be adjusted 
as needed to maintain the dose at 80mg/m2. Body  surface area will be calculated using 
the Mosteller equation: BSA (m2) = ([height (cm) x weight (kg)]/3600)1/2. For 
additional details, see the Site IP Manual.
Rationale: Clarification on the use of the MTX has been made .
Section 6.2 Dosage and 
Administration
MethotrexateSubjects will receive commercial MTX at the same BSA -based dose (10 to 30mg/m2
per week of MTX) as at time of study entry through Week 28. Body  surface area will 
be calculated at each visit and the dose of MTX will be adjusted as needed to maintain 
the dose at the same mg/m2per week dose as the subject was receiving at time of study 
entry. Absolute dose should rem ain stable from  baseline through Week 28.
Every effort should be made to ensure that subjects remain on the same BSA -based 
dose and route of administration of MTX through the Week 28safety and efficacy 
database lock, unless intolerance or AEs due to MTX occur (Section 8). Guidelines for 
adjustin g MTX dosage in the event of MTX toxicity are provided in the Trial Center 
File.
Subjects will also receive a total dose of commercial folic acid ≥5 mg weekly or folinic 
acid (at half the MTX dose) given the day after the weekly MTX dose. In children 
<12 years of age, the adm inistration of folic acid or folinic acid will be at the 
discretion of the physician.
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
46
Status: Approved ,Date: 16 December 2019Applicable Section(s) Description of Change(s)
Rationale: Clarifications on the use of corticosteroids during participation in this study have been made
Section 8
Prestudy and 
Concomitant TherapyAll therapi[INVESTIGATOR_014] (prescription or over-the-counter medications, including vaccines, 
vitamins, herbal supplements; non-pharmacologic therapi[INVESTIGATOR_40940], and acupuncture special diets, exercise regimens ) different from the study 
drug must be recorded in the CRF. Recorded information will include a description of 
the type of the drug, treatment period, dosing regimen, route of administration, and its 
indication. Modification of an ef fective pre-existing therapy should not be made forthe 
explicit purpose of entering a subject into the study .
If using corticosteroids or NSAID s, subjects must have been on stable doses of these 
medications prior to study entry  per Inclusion Criteria 8 and 9 (Section 4.1). Subjects 
may have been previousl y treated with no more than 1 therapeutic agent targeted at 
reducing TNF α prior to study entry per Inclusion Criterion 19 (Section 4.1). Subjects 
may not have initiated or been treated with prohibited therapeutic agents as outlined in 
Exclusion Criteria 1 through 20(Section 4.2).
Subjects must have received MTX at a w eekly dose of ≥10 mg/m2for ≥3months before 
screening. Subjects with BSA ≥1.[ADDRESS_42766] receive a minimum of 15 mg/week of 
MTX. The dose must have been stable and betw een 10 to 30 mg/m2weekly (or at least 
15mg/week in subjects with BSA ≥1.67 m2) for ≥4 weeks before screening. For 
exceptions to this rule, see Inclusion Criterion 7. Subjects ( with the exception of those 
with sJIA ) receiving corticosteroids at the time of study entry must have been 
receiving a stable dose for ≥2weeks before screening , and that dose must have been 
≤10 mg/day prednisone or prednisone equivalent or 0.20 mg/kg/day (whichever is 
lower). Subjects with systemic onset JIA but without systemic symptoms for ≥[ADDRESS_42767] been 
stable for ≥2 w eeks before screening.
No changes should be made to background medications (ie, DMARDs, MTX, 
corticosteroids, and NSAIDs) in terms of increases or decreases in BSA -based dosage 
(eg, no more than 10 mg /dayprednisone or no more than 0.20 mg/kg/day, whichever is 
lower) and/or route of administration between Weeks 0 and 28, unless there is a safety 
concern (eg, elevated liver function tests), which requires changes to background 
medications. Beginning at Week 28, subjects will be permitted to change/ add new
DMARD, MTX, corticosteroid, and NSAID use, including increases or decreases in 
dosage, changes of route of adm inistration ,or discontinuations in BSA -based 
dosage (where appropriate) for these classes of agents.
Subjects may receive intra-articular injections of a corticosteroid, if clinically required, 
during the study up to Wee k 52. How ever, the number of intra-articular injections 
should be limited to 2over any 24-week period. That is, if a subject has received [ADDRESS_42768] be notified in advance (or as soon as possible 
thereafter) of any instances in which prohibited therapi[INVESTIGATOR_23730] 
(Section 4.3).
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
47
Status: Approved ,Date: 16 December 2019Applicable Section(s) Description of Change(s)
Rationale: Clarifications regarding visit -specific PRO assessments have been made.
Section 9.1.1
Overvie wThe Time and Events Schedules summarize the frequency and timing of efficacy, PK, 
immunogenicity, and safety measurements applicable to this study (Table 1, Table 2, 
and Table 3).All scheduled study visits should occur within ±3 days of the intended 
visit through Week 28 and ±[ADDRESS_42769] be 
contact[CONTACT_40986] a visit.
All visit-specific PRO assessments should be conducted before any tests, 
procedures, or other consultations for that visit to prevent influencing subjects’ 
perceptions. For additional details, refer to the PRO user m anual.
The total blood volume to be collected from each subject for the study is approximately 
146.4 mL(Table 4). Repeat or unscheduled samples may be taken for safety reasons or 
for technical issues with the samples.
Table 4: Approxim ate Volume of Blood to be Collected From  Each Subject 
Through Week 252
Type of SampleApproximate
Volume per 
Sample 
(mL)No. of 
Samples 
per 
SubjectApproximate
Total 
Volume of 
Blood 
(mL)a,b
Safety (including screening and 
posttreatment assessments )
-Hem atology 1.2 1817 21.6 20.4
-Serum chemistry 1.1 1817 19.8 18.7
Serology (hepatitis B and hepatitis 
C)2.0 1 2.0
Serum -hCG pregnancy tests 1.1 1 1.1
-QuantiFERON®-TB Gold test 3.0 56 15.0 18.0
-Rheum atoid factor 1.1 1 1.1
-Anti-dsDNA antibody 1.1 1611 17.6 12.1
-ANA antibodies 1.1 11 12.1
Efficacy (CRP) 1.1 24 26.4
PK and immunogenicity (antibodies to 
golimumab) 2.5 15 37.5
Approximate Total 154.2 149.4
a.Calculated as the number of samples multiplied by [CONTACT_40987].
b.Repeat or unscheduled samples may be taken for safety reasons or technical issues with the samples.
Note: An indwelling intravenous cannula may be used for blood sample collection. 
Abbreviations: ANA = antinuclear antibodie s; β-hCG = β-human chorionic gonadotropin; CRP = C-
reactive protein; dsDNA = double -stranded deoxyribonucleic acid; PK = pharmacokinetic; TB = 
tuberculosis. 
Rationale: 
Section 9.1.[ADDRESS_42770] undergo testing for TB (Attachment 1 and Attachment 2) at screening 
and their medical history assessment must include specific questions about a history of 
TB or known occupational or other personal exposure to individuals with active TB. 
The subject should be asked about past testing for TB, including chest radiograph 
results and responses to tuberculin skin or other TB testing.
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
48
Status: Approved ,Date: 16 December 2019Applicable Section(s) Description of Change(s)
Rationale: Reorganizations noted in Sections 3.1.1 and 3.1.2 resulted in the revisions in Sections 9.1.3 
Section 9.1.3
Treatment Phase: Week 0 
through Week 28Beginning at Week 0, eligible subjects will receive 80 mg/m2 golimumab administered 
as IV infusions over 30±10 minutes at Weeks 0, 4 and q8w (±3 days )through Week 28 
(Section 6.1). Subjects will also receive commercial MTX weekly at the same BSA -
based dosage (10 to 30mg/m2per week of MTX) as at time of study entry at least
through Week 28and commercial folic acid ≥5 mg weekly or folinic acid (at half the 
MTX dose) given the day after the MTX dose (Section 6.2). In children <12 years of 
age, the adm inistration of folic acid or folinic acid will be at the discretion of the 
physician.
Rationale: Additional details have been as a result of reorganization noted in Sections 3.1.1 and 3.1.2
Section 9.1.4 Treatment 
Phase: Week 28 through 
Week 52Beginning at Week 28, eligible subjects will receive 80 mg/m2 golimumab 
administered as IV infusions over 30±10 minutes at Week 28 and q8w (±1week) 
through Week 52 (Section 6.1). Subjects may also receive commercia l MTX 
weekly at the same BSA -based dosage (10 to 30mg/m2per week of MTX) as at 
time of study entry through Week 28 and commercial folic acid ≥5 mg weekly or 
folinic acid (at half the MTX dose) given the day after the MTX dose, however, 
increases, decreas es or discontinuations of MTX, corticosteroids and/or NSAIDs 
are permissible after Week 28. All changes and reasons for changes for these 
medications need to be documented in the eCRF.
Subjects will have safety, efficacy, PK, and immunogenicity evaluations perform ed 
according to the Tim e and Events Schedule (Table 1). 
Rationale: Clarification of the visit windows from Week 52 through Week 244 has been made.
Section 9.1.5
Long -Term  Extension 
Phase: After Week 52 
through Week 252Subjects who enter the long-term extension after the Week 52 visit will continue to 
receive 80mg/m2 golimumab administered as IV infusions over 30±10 minutes q8w 
(±1 week ) through Week 244. 
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
49
Status: Approved ,Date: 16 December 2019Applicable Section(s) Description of Change(s)
Rationale: Clarifications for joint evaluations have been made.
Section [IP_ADDRESS]
Joint EvaluationEach of [ADDRESS_42771] 
PRINTO/PRCSG joint evaluation . A consistent joint assessor, with at least [ADDRESS_42772] enrollment; the training is mand atory unless the site’s joint assessor has 
taken certified training provided by [CONTACT_40988]. If a consistent joint assessor 
was trained by [CONTACT_21411] a previous clinical study, he or she may receive a waiver 
for this training. Documentation of Spon sor or PRINTO/PRCSG training will be 
maintained in the Trial Center File. If possible, the consistent joint assessor for the 
study should not be changed during the study. How ever, the assessor from each site 
who attends the consistent joint assessor traini ng provided by [CONTACT_40989] 1 
additional assessor at the site for coverage during their absences.
Nonevaluable Joints
While it may be reasonable in clinical practice to identify as “nonevaluable” any joint 
which in the past or during study partici pation has been surgically altered (ie, prosthesis 
placement) or medically treated (ie, intra-articular injection), the designation of 
“nonevaluable” for the purposes of this study is slightly different. Joints should only be 
designated as “nonevaluable” by [CONTACT_40990]. if it 
is physically impossible to assess the joint (ie, joint inaccessible due to a cast, joint not 
present due to an amputation, joint deformed so as to make it impossible to assess). 
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
50
Status: Approved ,Date: 16 December 2019Applicable Section(s) Description of Change(s)
Rationale: The definition of CRP has been revised
Section [IP_ADDRESS] American 
College of Rheumatology 
Pediatric ResponseThe JIA ACR 30 response criteria4is defined as a 30% improvem ent (ie, a decrease 
in score) from baseline in at least 3 of the following 6 components, with worsening of 
30% or more in no more than 1 of the following components:
 Physician’s Global Assessment of disease activity
 Parent/Subj ect Assessment of Overall Well -being
 Number of active joints (defined as either swelling, or in absence of swelling, 
limited range of motion associated w ith pain on motion or tenderness)
 Number of joints with limited range of motion
 Physical function by [CONTACT_40991] ( CHAQ )
 CRP (Improvement in CRP occurs when the CRP value changes from abnormal to 
norm al or to lower levels within the abnorm al range. Conversely, a worsening 
occurs when the CRP value changes from normal to abnormal or worsens within 
the abnorm al range. Changes within the norm al range are not considered 
improvements or w orsening.)
The JIA ACR 50 response, the JIA ACR 70 response, and the JIA ACR 90 response are 
defined as a 50% improvement, a 70% improvement, and a 90% improvement from 
baseline, respectively, in at least 3 of the above 6 components, with worsening of 30% 
or more in no more than 1 of the above components.
Inactive Disease
Inactive disease is indicated by [CONTACT_40992]:
 No joints with active arthritis
 No fever, rash, serositis, splenomegaly, hepatomegaly, or generalized 
lymphadenopathy attributable to JIA
 No active uveitis
 Normal CRP (≤0.287 mg/dL for subjects without underlying inflamm atory 
disease)
 Physician Global Assessment of disease activity indicating no active disease 
(<0.5 cm)
 Duration of morning stiffness <15 minutes
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
51
Status: Approved ,Date: 16 December 2019Applicable Section(s) Description of Change(s)
Rationale: As the VAS for pain is included in the CHAQ assessment, Sections [IP_ADDRESS] and 9.2.15 w ere merged. 
Clarification of very severe pain has also been made. CHAQ scoring has been aligned with the CHAQ questionnaire
Section [IP_ADDRESS]
Childhood Health 
Assessment 
QuestionnaireThe functional status of subjects will be assessed by [CONTACT_40980] .18Parents/subjects are to complete this 20-question instrument that 
assesses the degree of difficulty the child has in accom plishing tasks in 8 functional 
areas (dressing and grooming, arising, eating, walking, hygiene, reaching, grippi[INVESTIGATOR_007], and 
activities ofdaily living). Responses in each functional area are scored from 0, 
indicating no difficulty, to 3, indicating inability to perform a task in that area (lower 
scores are indicative of better functioning) with an unable to do and not applicable 
response options as well.Responses in each functional area are scored from  0, 
indicating “Without ANY difficulty”, to 3, indicating “With MUCH Difficulty” to 
perform  a task  in that area (lower scores are indicative of better functioning) with 
‘an unable to do’and ‘not applicable ’response options as well. Properties of the 
measure have been evaluated and its validity assessed.18The CHAQ has been shown to 
be responsive to disease change.18A decrease of 0.[ADDRESS_42773] week on a 
VAS. The scale ranges from “no pain” (0 cm) to “very severe pain ” (10 cm). This 
assessment should be completed by [CONTACT_7903]/subjects prior to the tender and swollen 
joint examination. 
Rationale: Clarifications on C -reactive protein evaluations has been made.
Section [IP_ADDRESS]
C-reactive ProteinC-reactive protein has been demonstrated to be useful as a marker of inflammation in 
patients with pJIA and is part of the JIA ACR 30 core assessments. C-reactive protein 
will be assayed by a central laboratory using a validated, high -sensitivity CRP assay . 
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
52
Status: Approved ,Date: 16 December 2019Applicable Section(s) Description of Change(s)
Rationale: An additional sectional on JADAS has been added .
Section [IP_ADDRESS] Juvenile 
Arthritis Disease Activity 
Score (JADAS)Recently, a composite disease activity score for pJIA, the Juvenile Arthritis 
Disease Activity Score (JADAS ), was developed; in validation analyses it was 
found to have good metrologic properties, including the ability to predict disease 
outcom e. The JADAS (modified for using CRP) is computed by [CONTACT_40993]: (1) physician global rating of overall disease activity, 
measured on a 10 -cm horizontal visual analog scale (VAS) (0 no activity; 10 
maximu m activity for both VAS); (2) parent/child ratings of well-being and pain, 
assessed on a [ADDRESS_42774] and 10-Centim eter Horizontal Line Visual 
Analog Scales20; (3) number of active joints, assessed in 71, 27, or 10 joints 
(JADAS 71, JADAS 27, and JADAS 10, respectively); and (4) CRP was truncated 
toa 0 scale according to the following formula: (CRP [mg/L] -10/10), sim ilar to the 
truncated ESR used in JADAS -ESR. Before calculation, CRP values <10 mg/L are 
converted to 10 and CRP values >110 m g/L are converted to 110.10
The JADAS is calculated as the sum of the scores of its 4 com ponents, which yields 
a global score of 0 –101, 0–57, and 0–40 for t he JADAS 71, JADAS 27, and JADAS 
10, respectively.
The state of JADAS 10, 27, and 71 mini mal disease activity2,8was defined as the 
presence of all of the following: physician’s global assessment of disease activity of 
≤3.5, parent’s global rating of well-being of ≤2.5, and swollen joint count of ≤1 in 
patients with polyarthritis.
JADAS physician assessed remission is defined as a total JADAS score of ≤2.
The criteria for JADAS inactive disease is defined as a total JADAS score of ≤1. 
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
53
Status: Approved ,Date: 16 December 2019Applicable Section(s) Description of Change(s)
Rationale: Clarifica tion on major secondary and other endpoints have been made.
Section 9.2.2 Endpoints Major Secondary Endpoints
Major secondary endpoints include:
 PK exposure at Week 52 (the trough concentrations at Week 52)and the 
Baysesian AUCss at Week 52 (from  population PK m odeling and simulation)
Other endpoints
Other endpoints include:
 The proportions of subjects who are JIA ACR 30, 50, 70, and 90 responders over 
time
 The change from baseline in CHAQ over time
 CRP concentrations over time
 The proportion of subjects who have inactive disease over time
 The proportion of subjects in clinical remission on medication for pJIA over tim e
 The improvement from baseline in the pJIA core set at each visit
 The proportions of subjects who are JIA ACR 30, 50, 70, and 90 responders by 
[CONTACT_40994], and/or age over time through Week 52
 The change from  baseline in JADAS 10, 27, and 71 scores over tim e
 The proportion of subjects who achieve JADAS 10, 27, and 71 minimal 
disease activity over tim e
 The proportion of subjects w ho achieve JADAS 10, 27 ,and 71 remission over 
time
Rationale: No biomarker analyses will be done in this study.
Section 9.3.1
EvaluationsSerum samples will be used to evaluate the PK, as well as the immunogenicity of 
golimumab (antibodies to golimumab). Venous blood samples will be collected and 
each serum sample will be divided into 3 aliquots (1 each for pharmacokinetics, 
antibodies to study drug, and a back -up). Sera collected for golimumab serum 
concentration and antibodies to golimumab analyses may additionally be used to 
evaluate biomarkers of safety or efficacy aspects that address concerns that arise during 
or after the study period. Subject confidentiality will be maintained. The sam ple should 
be draw n from a different arm than the IV line, or if using an IV line that is also being 
used to deliver medication, the line should be flushed and cleared of any residual 
medication that may be remaining prior to each PK sample being drawn. When using 
an IV line to draw  PK samples, the first [ADDRESS_42775] of care. At visits where serum concentration and antibodies to golimumab 
will be evaluated, 1 blood draw of sufficie nt volume can be used.
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
54
Status: Approved ,Date: 16 December 2019Applicable Section(s) Description of Change(s)
Rationale: Clarifications on safety evaluations (physical examination and uveitis evaluations) have been made.
Section 9.4
Safety E valuationsSerum Che mistry Panel
cholesterol panel ( total cholesterol and triglycerides )
Physical Examination
Physical examinations, including a skin exam at every physical examination and
Tanner staging at least every [ADDRESS_42776] antinuclear antibodies (ANA) positive at 
screening will be required to undergo slit lamp evaluation by a  q ualified 
ophthalmo logist to evaluate for subclinical uveitis in screening period as well as at 
least every 3months subsequent (Table 1, Table 2 , and Table 3).
If a subject develops uveitis during the study, the subjects’ continued participation in 
the study is at the discretion of the investigator and a qualified ophthalmologist.
Rationale: Revisions to the number and time for the ultrasound assessments have been made.
Section 9.6 Ultrasound 
SubstudyAt selected sites, a total of approximately 20 subjects over the age of 4 years who are 
enrolled in this study and are currently receiving study treatm ent may undergo power 
ultrasounds of their metacarpophalangeal 2 and 3 joints (examining dorsal and volar
surfaces), wrist (dorsal long midline, tendons), knee (suprapatellar long and parapatellar 
images; entheseal evaluations), and ankle (tibula/talar, subtalar medial and lateral 
surfaces, tendon examinations). Up to 5ultrasound assessments may be conducted , at 
Weeks 0, 4, 8, 12, 28, and 52. The primary objective of the substudy is to examine 
Power Doppler response measured as the Power Doppler Sum Score at 6 months 
compared with the score at baseline. Additional details will be presented inthe 
Ultrasound Substudy Protocol.
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
55
Status: Approved ,Date: 16 December 2019Applicable Section(s) Description of Change(s)
Rationale: Uveitis evaluation has been added to the assessment to be performed for each subject w ho discontinue 
study agent administration but does not discontinue study participation.
Section 10.[ADDRESS_42777] the follow ing assessments performed at the final safety follow -
up visit:
 Safety evaluations (eg, vital signs, AE review, study agent infusion reaction 
evalua tion, TB evaluation, uveitis evaluation, and the collection of a blood 
sample for routine laboratory analyses and determination of the presence of 
ANA/anti -double -stranded deoxyribonucleic acid (dsDNA) antibodies and 
antibodies to golimumab).
Rationale: Clarification on major secondary and other endpoint analyses have been made.
Section 11.3
Efficacy AnalysesPrim ary Endpoint Analysis
No primary efficacy endpoint analysis is planned. As the co-prim ary objective of this 
study is PK analyses of IV golimumab, the co-primary clinical evaluation is the 
proportion of subjects meeting JADAS minimal disease activity criteria at Week 28 the 
primary endpoint is not an efficacy endpoint (Section 11.4).
Major Secondary Endpoints Analyses
No m ajor secon dary efficacy endpoints analyses are planned.
Other efficacy endpoints
The follow ing will be summarized for all subjects enrolled in the study:
 The proportion of subjects who are JIA ACR 30, 50, 70, and 90 responders 
over tim e
 The proportion of subjects wh o have inactive disease over time
 The proportion of subjects in clinical remission on medication for JIA (ACR 
criteria ) over time
 The improvement from baseline in the JIA core set over time
 The proportions of subjects who are JIA ACR 30, 50, 70, and 90 responders by 
[CONTACT_40994], and/or age over time through Week 52
 The change from  baseline in CHAQ over tim e
 CRP concentrations over time
 The change from  baseline in JADAS 10, 27, and 71 scores over tim e
 The proportion of subjects who achieve JADAS 10, 27, and 71 minimal 
disease activity over tim e
 The proportion of subjects who achieve JADAS 10, 27, and 71 remission over 
time
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
56
Status: Approved ,Date: 16 December 2019Applicable Section(s) Description of Change(s)
Rationale: An additional PK analysis has been added
Section 11.4
Pharm acokinetic 
AnalysesSummary golimumab concentrations will be summarized and PK exposure will be 
evaluated through Week 52 and through the LTE. 
Rationale: Clarification on the DMC has been made
Section 11.9
Data Monitoring 
CommitteeThis is an open -label study, with all subjects receiving the same dosage of IV 
golimumab. Therefore, an external Data Monitoring Committee will not be utilized. 
Unblinded safety data will be routinely evaluated by [CONTACT_1758]’s medical monitor and 
an interna l Data Review Committee (DRC) as well as the Steering Committee as 
defined in DRC charter.
Rationale: Clarification of time period for the reporting of serious adverse events has been made
Section 12.3.[ADDRESS_42778]'s last study -related procedure (which may include contact [CONTACT_20687] -up o f 
safety). Serious adverse events, including those spontaneously reported to the 
investigator within 30days after the last dose of study drug of the end of the study , 
must be reported using the Serious Adverse Event Form. The Sponsor w ill evaluate any 
safety information that is spontaneously reported by [CONTACT_40995].
Rationale: The study -specific materials that will be provided to all study sites have been revised.
Section [ADDRESS_42779] the following supplies:
 Investigator Brochure
 Trial Center File
 Investigational Product Manual
 Laboratory manual and laboratory supplies
 ePRO device and user manual
 Interactive voice/web response system manual
 Electronic data capture (eDC) Manual (including on -line access)
 Sample ICF and sample assent form
 Subject participation cards (ie, w allet cards)
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
57
Status: Approved ,Date: 16 December 2019Applicable Section(s) Description of Change(s)
Rationale: The storage time for samples collected in this study has been reduced from 15 to 2 years
Section 16.2.5
Long -Term  Retention of 
Samples for Additional 
Future Research Samples collected in this study may be stored for up to 2years (or according to local 
regulations) for additional research. Samples will only be used to understand 
golimumab, to understand pJIA, to understand differential drug responders, and to 
develop tests/assays related to SIMPONI for IV use and pJIA. The research may begin 
at any time during the study or the post -study storage period.
Stored samples will be coded throughout the sample storage and analysis process and 
will not be labeled with personal identifiers. Subjects may withdraw their consent for 
their samples to be stored for research. (refer to Section 10.3, Withdraw al From the 
Study (Withdraw al From  the Use of Samples in Future Research). 
Rationale: An incorrect reference has been deleted.
Section 16.2.[ADDRESS_42780]. unless explicitly addressed as a 
specific ethical consideration in Section 16.1, Study -Specific Design Consideratio ns.
Rationale: Data that w ill be entered into the CRF has been revised
Section 17.4
Source DocumentationThe follow ing data (at a minimum) will be recorded directly into the CRF and will be 
considered source data where allow ed by  [CONTACT_40996]:
 Race
 History of smoking and all nicotine use (eg,cigarettes, cigars, chewing tobacco, 
patch, gum)
 Blood pressure, pulse/heart rate, temperature, and respi[INVESTIGATOR_697]
 Height and weight
 Details of physical examination
 Limited range of motion and active join ts
 PRO assessments: CHQ and CHAQ
 The following parent/subject -and investigator -completed scales and 
assessments designated by [CONTACT_40997]: joint assessments, CHAQ, 
parent/subject assessment of overall well-being , physician global assessment 
of disease activity, and visual analog scale for pain .
Subject and investigator -completed scales and assessments designated by [CONTACT_40998] w ill be considered source data.
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
58
Status: Approved ,Date: 16 December 2019Applicable Section(s) Description of Change(s)
Rationale: Transmission of IWRS and ePRO data has been added.
Section 17.6
Data Quality 
Assurance/Quality 
ControlSteps to be taken to ensure the accuracy and reliability of data include the selection of 
qualified investigators and appropriate study sites, review of protocol procedures with 
the investigator and study site personnel before the study, and periodic monitoring 
visits by [CONTACT_1034], and direct transmission of clinical laboratory data from a central 
laboratory, IWRS, and PRO data into the Sponsor's data base. Written instructions 
will be provided for collection, handling, storage, and shipment of samples. 
Section 17.[ADDRESS_42781] transmission of clinical laboratory data from a central laboratory, IWRS, 
and PRO data into the Sponsor's database. Recruitment performance or specific 
expertise related to the nature and the key assessment parameters of the study will be 
used to determine a coordinating investigator. Results of analyses performed after the 
Clinical Study Report has been issued will be reported in a separate report and will not 
require a revision of the Clinical Study Report. Study subject identifiers will not be 
used in publication of results. Any work created in connection with performance of the 
study and contained in the data that can benefit from copy right protection (except any 
publication by [CONTACT_40999] ) shall be the property of the 
Sponsor as author and owner of copyright in such work.
Rationale: Clarifications to the Table of Events (Tables 1, 2, and 3) have been made
Table 1:Screening 
Through Week 52JADAS assessment has been added at Weeks 0, 4, 8, 12, 16, 20, 24, 28, 36, 44, and 52.
Antibodies to golimumab assessments have been added at Weeks [ADDRESS_42782] every 3months subsequent .
Footnote i To be completed by [CONTACT_40970], preferably the same parent or caregiver 
should complete at every visit. Subjects who are emancipated juveniles (ages 15 to < 18 
years) at study entry may complete the assessments themselves. Ideally the same 
individual (eg, parent, caregiver, or subject) who completes the assessments at the start 
of the study should complete the assessments throughout the study. at least
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
59
Status: Approved ,Date: 16 December 2019Applicable Section(s) Description of Change(s)
Footn ote j All visit-specific PRO assessments should be conducted before any tests, 
procedures, or other consultations for that visit to prevent influencing subjects’ 
perceptions.
Parent/subject assessment of overall well -being has been deleted
Visual analog scale for pain has been deleted
CHQ assessments have been deleted.
Checks for the following assessments during the screening period have been deleted: 
Parent /subject assessment of overall well-being , Physician Global Assessment of 
disease activity, and Visual analog scale for pain
Table 2: From  Week 60 
Through Week 156 
(Long -term Extension)JADAS assessment has been added at Weeks 68, 84, 100, 116, 132, and 148.
Antibodies to golimumab assessments have been added at Weeks [ADDRESS_42783] every 3 months.
Footnote h To be completed by [CONTACT_40970], preferably the same parent or caregiver 
should complete at every visit. Subjects who are emancipated juveniles (ages 15 to <18 
years) at study entry may complete the assessments themselves. Ideally the same 
individual (eg, parent, caregiver, or subject) who completes the assessments at the start 
of the study should complete the assessments throughout the study.
Footnote i All visit-specific PRO assessments should be conducted before any tests , 
procedures, or other consultations for that visit to prevent influencing subjects’ 
perceptions.
Parent/subject assessment of overall well -being has been deleted
Visual analog scale for pain has been deleted
CHQ assessments have been deleted.
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
60
Status: Approved ,Date: 16 December 2019Applicable Section(s) Description of Change(s)
Table 3: From  
Week 164 T hrough Week 
252 (Long -term 
Extension – Continued)JADAS assessment has been added at Weeks 164, 180, 196, 212, 228, and 244.
Antibodies to golimumab assessments have been added at Weeks [ADDRESS_42784] every 3months.
Footnote h To be completed by [CONTACT_40970], preferably the same parent or caregiver 
should complete at every visit. Subjects who are emancipated juveniles (ages 15 to <18 
years) at study entry may complete the assessments themselves. Ideally the same 
individual (eg, parent, caregiver, or subject) who completes the assessments at the start 
of the study should complete the assessments throughout the study.
Footnote i All visit-specific PRO assessments should be conducted before any tests, 
procedures, or other consultations for that visit to prevent influencing subjects’ 
perceptions.
Parent/subject assessment of overall well -being has been deleted
Visual analog scale for pain has been deleted
CHQ assessments have been deleted.
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
61
Status: Approved ,Date: 16 December 2019Applicable Section(s) Description of Change(s)
Rationale: Revision s were made to several sections of the synopsis to reflect the changes made in the protocol
Synopsis
Overvie w of Study 
DesignThis is a Phase 3, open -label, single -arm, multicenter study to evaluate the PK, safety, 
and efficacy of IV golimumab in subjects with active pJIA despi[INVESTIGATOR_40926]/or corticosteroids and/or non-steroidal anti-inflamm atory agents 
and/or prior use of anti-TNFα agents (up to30% of total population) .The study 
population will be comprised of subjects with pJIA receiving MTX, ages [ADDRESS_42785] a 3-month history of pJIA, and active arthritis in ≥[ADDRESS_42786] population 
of approximately 10% aged 2 to up to 6 years, approximately 20% aged 6 to up to 12 
years, and approximately 70% aged 12 to less than 18 years.
All subjects will receive 80 mg/m2golimumab as an IV infusion ( over 30 ±10 
minutes )at Weeks 0, 4, and every 8 weeks (q8w ; ±3 days )through Week 28 and 
q8w (±1 week )thereafter (maximu m single dose 240mg [maximum BSA 3.0m2x 
80mg/m2]), along with commercial MTX at a dose of 10-30 mg/m2/week (unless for 
documented safety reasons, lower doses of MTX are administered). For patients 
greater than 1.67m2, a minimum fixed dose of 15 mg/week is required. Subjects 
who complete the study at Week [ADDRESS_42787] the option to enter into the long-term 
extension phase of the study. During the long-term extension, all subjects will continue 
to receive 80mg/m2IV golimumab q8w (±1 week ; maximu m single dose 240 mg) 
through Week 244. All subjects who complete the Week 244 visit are expected to 
participate in the safety follow -up visit at Week 252. Golimumab after Week 252 (for 
subjects who have completed the full [ADDRESS_42788]) will be p rovided until the 
drug will be approved and marketed for use in JIA in the country of the subject or 
for as long as proven beneficial to the child (in cases where commercial drug is not 
accessible to the subject.
Subject Population The onset of disease mu st have been before the subject’s 16th birthday, must be at least 
3months’ duration, and must have active pJIA of one of the following subtypes: 
rheumatoid factor positive or negative pJIA; systemic JIA with no systemic symptoms 
but with polyarthritis for ≥3months but with polyarthritis for ≥3 months; extended 
oligoarticular JIA; enthesitis related arthritis or polyarticular juvenile psoriatic 
arthritis ( PsA).
Subjects must have ≥5 joints with active arthritis as defined by [CONTACT_41000] (ACR) criteria at screening and enrollment and must have a screening 
C-reactive protein (CRP)of ≥0.1 mg/dL. Subjects must have active pJIA despi[INVESTIGATOR_40941], intramuscular or subcutaneous MTX (for ≥3 months before 
screening) at a weekly do se of ≥10 mg/m2. 
Dosage and 
Administration
GolimumabThe study will have 1 active treatment group and all subjects will receive 80mg/m2
golimumab IV infusions at Week 0, Week 4, and q8w ± 3days through Week 28 and 
q8w ± 1 week thereafter through Week 244. BSA will be calculated at each visit and 
the dose of golimumab will be adjusted as needed to maintain the dose at 80 mg/m2. 
BSA will be calculated using the Mosteller equation: BSA (m2) = ([height (cm) x 
weight (kg)]/3600).1/2The m aximum single dose w ill be golimum ab 240 m g.
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
62
Status: Approved ,Date: 16 December 2019Applicable Section(s) Description of Change(s)
Methotrexate Subjects will receive commercial MTX at the same BSA -based dose (10 to 30 mg/m2
per week of MTX) as at time of study entry at least through Week 28. BSA will be 
calculated at each visit and the dose of MTX w ill be adj usted as needed to maintain the 
dose at the same mg/m2per week dose as the subject was receiving at time of study 
entry . Every effort should be made to ensure that subjects remain on the same 
BSA -based dose and route of administration of MTX at least through the Week 28
safety and efficacy database lock, unless intolerance or AEs due to MTX occur.
Subjects will also receive commercial folic acid ≥5 mg weekly or folinic acid (at half 
the MTX dose) given the day after the weekly MTX dose. In children <12 years of 
age, the adm inistration of folic acid or folinic acid will be at the discretion of the 
physician.
Efficacy/Pharmacokinetic 
Evaluations and 
EndpointsEfficacy evaluations include the following:
 Joint evaluations (num ber of active joints and number of joints with limited range 
of motion)
 Parent/Subject Assessment of Overall Well -being
 Physician Global Assessment of disease activity
 Visual Analog Scale for Pain
 Childhood Health Assessment Questionnaire ( CHAQ )
 JADAS 10, 27, and 71
 CRP
The primary endpoint in this study is PK exposure at Week 28 (the trough 
concentrations at Week 28 )and the Bayesian steady -state area under the curve [AUCss] 
over one dosing interval of 8 weeks (from population PK modeling and simulation).
The major secondary endpoints are as follows:
 PK exposure at Week 52 (the trough concentrations at Week 52)and the 
Baysesian AUCss at Week 52 (from  population PK m odeling and simulation)
Other efficacy endpoints include:
 The proportions of subjects who are JIA ACR 30, 50, 70, and 90 responders over 
time
 The change from baseline in CHAQ over time
 CRP concentrations over time
 The proportion of subjects who have inactive disease over time
 The proportion of subjects in clinical remission on medication for pJI A over time
 The improvement from baseline in the pJIA core set at each visit
 The proportions of subjects who are JIA ACR 30, 50, 70, and 90 responders by 
[CONTACT_40994], and/or age over time through Week 52
 The change from baseline in JADAS 10, 27, and 71 scores over time
 The proportion of subjects who achieve JADAS 10, 27, and 71 minimal disease 
activity over time
 The proportion of subjects who achieve JADAS 10, 27, and 71 remission over 
time
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
63
Status: Approved ,Date: 16 December 2019Applicable Section(s) Description of Change(s)
Serum golimum ab concentration and/or efficacy measures will be evaluated at 
Weeks 0, 4, 8, 12, 20, 28, 52, 100, 148, 196, and 244 and summarized over time. A 
population PK analysis with data through Week 28 will be perform ed to 
characterize the PK of golimu mab as well as to identify important covariates of 
PKin the pediatric population with pJIA. 
Summary golimumab concentrations will be summarized and PK exposure will be 
evaluated through Week 52 and through the LTE.
Immunogenicity 
EvaluationsAntibodies to golimumab will be evaluated in serum samples collected from all 
subjects at Weeks 0, 4, 8, 12, 28, 52, 100, 148, 196, and 244.
Ultrasound substudy Power Doppler Sonography (PDUS) is a non-invasive ultrasound technique to 
assess inflammation at the joint level in RA. At selected sites, subjects over th e age 
of [ADDRESS_42789] been enrolled in the study and are currently receiving study 
treatm ent may undergo PDUS and High Frequency gray scale Ultrasound ( HFUS )
of the 2ndand 3rdmetacarpophalangeal joints, wrist, knee and ankle. Up to [ADDRESS_42790] s enrolled in the study:
 The proportion of subjects who are JIA ACR 30, 50, 70, and 90 responders over 
time
 The proportion of subjects who have inactive disease over time
 The proportion of subjects in clinical remission on medication for JIA (ACR 
criteria) over time
 The improvement from baseline in the JIA core set over time
 The proportions of subjects who are JIA ACR 30, 50, 70, and 90 responders by 
[CONTACT_40994], and/or age over time through Week 52
 The change from baseline in CHAQ over time
 CRP concentrations over time
 The change from baseline in JADAS 10, 27, and 71 scores over time
 The proportion of subjects who achieve JADAS 10, 27, and 71 minimal disease 
activity over time
 The proportion of subjects who achieve JADAS 10, 27, and 71 remission over 
time
Rationale: Minor errors w ere noted and corrected.
Throughout the
protocolMinor grammatical, formatting, or spelling changes were made.
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
64
Status: Approved ,Date: 16 December 2019SYNOPSIS
A Multicenter, Open -Label Trial of Intravenous Golimumab, a Human Anti -TNFα Antibody, in 
Pediatric Subjects With Active Polyarticular Course Juvenile Idiopathic Arthritis Despi[INVESTIGATOR_40942]: CNTO148JIA3003
Golimumab is a fully human monoclonal antibody (mAb) which binds to human tumor necrosis factor 
alpha (TNFα) with high affinity and specificity and neutralizes TNFα bioactivity. TNFα is a key 
inflammatory mediator, with high levels of TNFα implicated in the pathophysiology of diseases such as 
rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA). SIMPONI®(golimumab) for intravenous 
(IV)use is being developed by [CONTACT_41001] (compared with 
other available anti -TNFα agents) and a convenient dose regimen (ie, every 8 week [q8w] administration)
for patients with polyarticular JIA(pJIA).
OBJECTIVE SAND HYPOTHESIS
Primary Objective
The primary objective of this study is to assess the pharmacokinetics (PK)following intravenously 
administered golimumab in subjects (ages 2 to less than 18 years) with pJ IAmanifested by ≥5 joints with 
active arthritis despi[INVESTIGATOR_40943] (MTX )therapy for ≥[ADDRESS_42791] to 
PK,efficacy (relief of signs and symptoms, physical function, and quality of life), safety (adverse events 
[AEs], serious AEs [ SAEs ], and assessment of laboratory parameters), and immunogenicity (antibodies to 
golimumab).
Hypothesis
No formal hypothesis testi ng is planned in this study.
OVERVIEW OF STUDY DESIGN
This is aPhase 3,open -label, single -arm, multicenter study to evaluate the PK, safety, and efficacy of IV 
golimumab in subjects with active pJIA despi[INVESTIGATOR_40944] .The study populatio n will 
comprise subjects with pJIA receiving MTX, ages [ADDRESS_42792] a 3-month history  
of pJIA, and active arthritis in ≥[ADDRESS_42793] population of approximately 10% aged 2 to up to 6 years, approximately 20% aged 6to up to 
12years, and approximately 70% aged 12 to less than 18 years.
All subjects will receive 80 mg/m2golimumab as an IV infusion (o ver 30 ±10 minutes) at Weeks 0, 4, and 
q8w ( ±3 days) through Week 28 and q8w (±1 week) thereafter (maximum single dose 240 mg [maximum 
body surface area (BSA )3.0 m2x 80 m g/m2]). Commercial MTX is to be admini stered at a stable dose of 
10-30 mg/m2/week in subjects with BSA <1.67 m2or a stable minimum dose of 15 mg/week in subjects 
with BSA ≥1.67 m2through Week 28(unless lower doses of MTX are administered for documented 
safety reasons or unless documented country or site regulations prohibit dose of 15 mg/week or above in 
subjects with BSA ≥1.67 m2).Subjects who complete the study at Week [ADDRESS_42794] the option to enter 
into the long-term extension (LTE) phase of the study. During the LTE, all subjects will continue to 
receive 80mg/m2IV golimumab q8w (±1 week; maximum single dose 240mg) through Week 244. All
subjects who complete the Week 244 visit are expected to participate in the safety follow -up visit at 
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
65
Status: Approved ,Date: 16 December 2019Week 252. Subjects <[ADDRESS_42795] the option to continue to receive golimumab (80 mg/m2q8w) in the Extended Treatment Period 
(ETP). The first dose of golimumab in the ETP is administered at Week 252after all assessments have 
been completed.
Since this is an open -label study with all subjects receiving the same BSA -based dose of IV golimumab, 
an external Data Monitoring Committee will not be established.
The end of the study is defined as the last follow -up assessment f or the last subject in the ETP.
SUBJECT POPULATION
Study subjects must be 2 to less than 18 years of age with a body weight >[ADDRESS_42796]’s 16th birthday , must be of at least 3 months’ 
duration, and must be active pJIA of one of the following subtypes: rheumatoid factor positive or negative 
pJIA; systemic JIA with no systemic symptoms for ≥3 months but with polyarthritis for ≥3 months; 
extended oligoarticular JIA; enthesitis -related arthritis or polyarticular juvenile psoriatic arthritis (PsA).
Subjects must have ≥5 joints with active arthr itis as defined by[CONTACT_41002] 
(ACR) criteria at screening and enrollment . Subjects must have active pJIA despi[INVESTIGATOR_40923], 
intramuscular ,or subcutaneous MTX (for ≥2months before screening) at a weekly dose of ≥10mg/m2.
DOSAGE AND ADMINISTRATION
Golimumab
The study will have 1 active treatment group and all subjects will receive 80 mg/m2golimumab IV 
infusions at Week 0, Week 4, and q8w (± 3days) through Week 28 and q8w (± 1 week )thereafter through 
Week 244. BSA will be calculated at each visit and the dose of golim umab will be adjusted as needed to 
maintain the dose at 80 mg/m2. BSA will be calculated using the Mosteller equation: BSA (m2) =([height 
(cm) x weight (kg)]/3600)½.The maximu m single dose will be golimumab 240 mg.
During the ETP, subjects will continue to receive 80 mg/m2golimumab IV infusions q8w starting at 
Week 252. 
Methotrexate
Subjects will receive commercial MTX at least through Week 28 at the same BSA -based dose (10 to
30mg/m2per week for subjects with BSA <1.[ADDRESS_42797] 15mg/week forsubjects with BSA 
≥1.67 m2) as at time of study entry .Every effort should be made to ensure that subjects remain on the 
same dose and route of administration of MTX through the Week 28 visit, unless intolerance or AEs due 
to MTX occur.
Subjects will also receive commercial folic acid ≥5 mg weekly or folinic acid (at half the MTX dose) 
given the day after the weekly MTX dose. In children <12 years of age, the administration of folic acid or 
folinic acid will be at the discretion of the physician .
EFFICACY EVALUATIONS AND ENDPOINTS
Efficacy evaluations include the following:
 Joint evaluations (number of active joints and number of joints with limited range of motion)
 Physician Global Assessment of Disease Activity
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
66
Status: Approved ,Date: 16 December 2019 Childhood Health Assessment Questionnaire (CHAQ; includes the Parent/Subject Assessment of 
Overall Well -being and Parent/Subject Assessment of Pain )
 CRP
No primary efficacy endpoint ormajor secondary endpoints are planned.  Other efficacy endpoints 
include:
 The proportions of subjects who are JIA ACR 30, 50, 70, and 90 responders over time
 The change from baseline in CHAQ over time
 CRP concentrations over time
 The proportion of subjects who have inactive disease over time
 The proportion of subjects in clinical remission on medication for pJIA over time
 The improvement from baseline in the pJIA core set at each visit
 The proportions of subjects who are JIA ACR 30, JIA ACR 50, JIA ACR 70 and JIA ACR 90 
responders by [CONTACT_40994], and/or age over time through Week 52
 The change from baseline in Juvenile Arthritis Disease Activity Score (JADAS ) 10, 27, and 
71scores over time
 The proportion of subjects who achieve JADAS 10, 27, and 71 minimal dise ase activity over time
PHARMACOKINETIC EVALUATIONS AND ENDPOINTS
Serum golimumab concentration will beevaluated at Weeks 0, 4, 8, 12, 20, 28, 52, 100, 148, 196, and 
244 and summarized over time. A population PK analysis with data through Week 28 will be performed 
to characterize the PK of golimumab as well as to identify important covariates of PK in the pediatric 
population with pJIA.
Golimumab concentrations will be summarized and PK exposure will be evaluated through Week 52 and 
through the LTE.
The primary endpoint in this study is PK exposure at Week 28 (the trough concentrations at Week 28 )and 
the Bayesian steady-state area under the curve [AUCss] over one dosing interval of 8 weeks (from 
population PK modeling and simulation).
The m ajor secondary PK endpoint s include:
 PK exposure at Week 52 (the trough concentrations at Week 52)and Bayesian AUCss at Week 52 
(from population PK modeling and simulation) .
SAFETY EVALUATIONS
Safety evaluations include assessments of the following: AEs; infusion reactions; allergic reactions; 
clinical laboratory tests (hematology, chemistry, and pregnancy testing); vital signs; physical 
examination; height and body weight; uveitis; and early detection of tuberculosis.
IMMUNOGENICITY E VALUATIONS
Antibodies to golimumab will be evaluated in serum samples collected from all subjects at Weeks 0, 4, 8, 
12, 28, 52, 100, 148, 196, and 244.
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
67
Status: Approved ,Date: [ADDRESS_42798] e size of 
approximately 100subjects will remain in the study at Week 52. This sample size is thought to be 
sufficient to build a population PK model, given the sp arse sampling of PK time points, as well as provide 
1 year of safety data from approximately 100 subjects.
Efficacy Analys es
No primary efficacy endpoint analysis and no major secondary efficacy endpoint analyses are planned. 
The following will be summarized for all subjects enrolled in the study:
 The proportion of subjects who are JIA ACR 30, 50 , 70, and 90 responders over time
 The change from baseline in CHAQ over time
 CRP concentrations over time
 The proportion of subjects who have inactive disease over time
 The proportion of subjects in clinical remission on medication for pJIA (ACR criteria) over time
 The improvement from baseline in the pJIA core set over time
 The proportions of subjects who are JIA ACR 30, 50, 70, and 90 responders by [CONTACT_40994], 
and/or age over time through Week 52
 The change from baseline in JADAS 10, 27, and 71 scores over time
 The proportion of subjects who achieve JADAS 10, 27, and 71 minimal disease activity over time
Pharmacokinetic Analyses
The primary objective of this study is to characterize golimumab PK exposure (the trough concentrations 
at Week 28 and the Bayesian AUCss over a dosage interval of 8 weeks from population PK modeling and 
simulation) in the JIA population.
Serum golimumab concentrations will be summarized over time.  In addition, a population PK analysis on 
data through Week 28 will be per formed to characterize the PK of golimumab as well as to identify and 
quantify important covariates of PK in the pediatric population with JIA.  Clearance and volume of 
distribution will be estimated using a nonlinear mixed effects modeling (NONMEM) approa ch.
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
68
Status: Approved ,Date: [ADDRESS_42799] appropriate samples collected for 
detection of antibodies to golimumab (ie, subjects with at least [ADDRESS_42800] 
golimumab administration).
Pharmacokinetic /Pharmacodynamic Analy ses
The relationships between serum golimumab concentration and efficacy will be explored. A suitable 
PK/pharmacodynamic (PD) model will be explored and developed to describe the exposure -response 
relationship.
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
69
Status: Approved ,Date: 16 December 2019TIME A ND EVENTS SCHE DULE S
Table 1: Screening Through Week 52
Screen -
ing 
Period
(-6 
weeks)Week
0aWeek
4aWeek
8aWeek 
12aWeek 
16aWeek
20aWeek 
24aWeek 
28aWeek 
36aWeek
44aWeek
52aFinal 
Safety 
Follow -
up 
Visitb
Procedures and 
Evaluations
Administrative
Informed 
consent/AssentX
Medical 
history/demographic 
data X
Concomitant 
medications 
collection X X X X X X X X X X X X X
Inclusion/exclusion 
criteriaX X
Study Agent
IV administration of 
study agent X X X X X X X X
Safety
Revie w of systems X X X X X X X X X X X X X
Physical 
examinationc X X X X
Body  weight 
measurementX X X X X X X X X X X X
Height measurement X X X X X X X X X X X X
Vital signs X XdXdX XdX XdX XdXdXdXdX
Routine laboratory 
analysesX X X X X X X X X X
Hepatitis B virus 
screeningX
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
70
Status: Approved ,Date: 16 December 2019Table 1: Screening Through Week 52
Screen -
ing 
Period
(-6 
weeks)Week
0aWeek
4aWeek
8aWeek 
12aWeek 
16aWeek
20aWeek 
24aWeek 
28aWeek 
36aWeek
44aWeek
52aFinal 
Safety 
Follow -
up 
Visitb
Hepatitis C virus 
screeningX
QuantiFERON-TB 
Gold testeX Xf
TB evaluation 
(questionnaire) X X X X X X X X X X X X X
Chest x -raygX
Uveitis evaluationshX X X X
Rheumatoid factor X
ANA/Anti -dsDNA 
antibodies X X X X
Pregnancy test 
(serum)i X
Pregnancy test 
(urine)i X X X X X X X X
Infusion reaction 
evaluationj X X X X X X X X
Adverse events X X X X X X X X X X X X X
Efficacy
Joint assessments X X X X X X X X X X X X X
JIA a ssessmentsk, lX X X X X X X X X X X X
CRP X X X X X X X X X X X X X
Pharm acokinetics
Golimumab 
concentrationm, n 2X 2X X 2X X X X X
Population PKo← Xo→
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
71
Status: Approved ,Date: 16 December 2019Table 1: Screening Through Week 52
Screen -
ing 
Period
(-6 
weeks)Week
0aWeek
4aWeek
8aWeek 
12aWeek 
16aWeek
20aWeek 
24aWeek 
28aWeek 
36aWeek
44aWeek
52aFinal 
Safety 
Follow -
up 
Visitb
Immunogenicity
Antibodies to 
golimumabn X X X X X X X
a.All scheduled visits should occur within ±3 days of the intended visit through Week 28 and ± [ADDRESS_42801] infusion (Section 10.2).
c.Includes skin examination at every physical examination and Tanner staging approximately every 6 months.
d.Vital signs should be taken pre- infusion; at 15 and 30 minutes (15 -minute interval s during the infusion); and at 60 and 90 minutes (during the 1 -hour 
observation period follow ing the infusion).
e.Tuberculin skin tests should also be performed in countries where the QuantiFERON -TB Gold test is not approved/registered in that country or th e 
tuberculin skin test is mandated by [CONTACT_41003].
f.Testing is not required for subjects w ith a history of latent TB and ongoing treatment for latent TB or documentation of havi ng completed adequate 
treatment.
g.Chest x -ray screening as per local and country regulations for initiation of immunosuppressive agents in children with JIA who are at risk of TB.
h.Evaluations (based on physical examination and intervie w) should be performed by [CONTACT_40974] [ADDRESS_42802] /optometrist during the study at intervals (based on JIA subtype, ANA 
test results, age at JIA onset, and JIA duration) as specified in Attachment 5 . 
i.All female subjects of childbearing potential (ie, post -menarche) must test negative for pregnancy during screening and at all visits prior to study drug 
administration.
j.Subjects will be observed for at least 60 minutes after the administration of study agent for sy mptoms of an infusion reaction.
k.JIA assessments inc lude the follow ing:  Physician Global Assessment of Disease Activity, Childhood Health Assessment Questionnaire (CHAQ), and 
duration of morning stiffness.  CHAQ should be completed before any tests, proced ures, or other consultations for that visit to prevent influencing 
subjects’ perceptions .
l.CHAQ to be completed by [CONTACT_40970]; preferably the same parent or caregiver should complete at every visit. Subj ects who are 15 to <18 years
of age at study entry may complete the assessment jointly with the parent/caregiver . 
m.At the Weeks 0, 4, and 12 visits, 2 samples for serum golimumab concentrations (indicated by “2X” in the schedule above) will be collected: 1 sample w ill 
be collected immediately pri or to the infusion and the other collected approximately 1 hour (eg, ± 10 minutes) after the end of the infusion. For each of the 
remaining visits, only [ADDRESS_42803] be flushed and 
cleared of any residual medication that may be remaining and 1 mL of blood should be drawn and discarded prior to obtaining the sample if using the same 
access line as was used for drug administration .
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
72
Status: Approved ,Date: 16 December 2019Table 1: Screening Through Week 52
Screen -
ing 
Period
(-6 
weeks)Week
0aWeek
4aWeek
8aWeek 
12aWeek 
16aWeek
20aWeek 
24aWeek 
28aWeek 
36aWeek
44aWeek
52aFinal 
Safety 
Follow -
up 
Visitb
n.The same serum samples may be used for the measurement of golimumab concentration and detection of antibodies to golimumab . For visits with study 
agent administration, all blood samples for assessing golimumab concentration and antibodies to golimumab MUST be collected B EFORE the 
administration of the study agent.
o.One additional sample for serum golimumab concentration for po pulation PK w ill be collected from all subjects at any time between Weeks 0 and 8 other 
than at the time of the Week 0, Week 4, and Week 8 visits; this sample must be collected at least [ADDRESS_42804] not b e collected at a regularly scheduled visit (eg ,Week 8).
Abbreviations: ANA = antinuclear antibodies; CHAQ = Childhood Health Assessment Questionnaire; CRP = C -reactive protein; dsDNA = double -stranded 
deoxyribonucleic acid; IV =intravenous; PK = pharmacokinetic; TB = tuberculosis.
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
73
Status: Approved ,Date: 16 December 2019Table 2: From  Week 60 Through Week 156 (Long -term  Extension)
Week
60aWeek
68aWeek
76aWeek
84aWeek
92aWeek
100aWeek
108aWeek
116aWeek
124aWeek
132aWeek
140aWeek
148aWeek
156aFinal 
Safety 
Follow -
up 
Visitb
Procedures and Evaluations
Administrative
Concomitant medications 
collection XcXcXcXcXcXcXcXcXcXcXcXcXcXc
Study Agent
IV administration of study 
agent X X X X X X X X X X X X X
Safety
Revie w of systems Xd
Physical examinationeX X X X X
Body  weight measurement X X X X X X X X X X X X X
Height measurement X X X X X X X X X X X X X
Vital signs Xd
Routine laboratory analyses X X X
ANA/Anti -dsDNA antibodies X
QuantiFERON-TB Gold 
testXd,f
TB evaluation (questionnaire) X X X X X X X X X X X X X X
Chest x -ray Xg
Uveitis evaluations Xh
Pregnancy test (urine)iX X X X X X X X X X X X X
Infusion reaction evaluationjX X X X X X X X X X X X X
Adverse events X X X X X X X X X X X X X X
Efficacy
Annual attestation form Xk
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
74
Status: Approved ,Date: 16 December 2019Table 2: From  Week 60 Through Week 156 (Long -term  Extension)
Week
60aWeek
68aWeek
76aWeek
84aWeek
92aWeek
100aWeek
108aWeek
116aWeek
124aWeek
132aWeek
140aWeek
148aWeek
156aFinal 
Safety 
Follow -
up 
Visitb
Pharm acokinetics
Golimumab concentrationlX X X
Immunogenicity
Antibodies to golimumablX X X
Note : All assessments at each study visit must be completed prior to study drug administration , unless otherwise specified .
a.All scheduled visits should occur ±[ADDRESS_42805] infusion (Section 10.2).Collection of vital signs, review  of symptoms, and uveitis evaluation are performed at the final 
safety follow -up visit at the discretion of the investigator.
c.Revie w concom itant medications with subject and document in source ;update concomitant medication CRF page to include only those medications that are 
associated with AEs and SAEs (ie, used to treat event or suspected in causing event) .
d.Perform a tthe discretion of the investigator.
e.Includes skin examination at every physical examination.
f.Tuberculin skin tests should also be performed in countries where the QuantiFERON -TB Gold test is not approved/registered or the tuberculin skin test is 
mandated by [CONTACT_41003].
g.Chest x -ray screening should be performed at the discretion of the investigator and per local and country regulations for children with JIA who are receiving
immunosuppressive agents andwho are at risk of TB.
h.Evaluations (based on physical examination and intervie w) should be performed at the discretion of the investigator . Slit lamp evaluations performed by [CONTACT_41004]/optometrist at the discretion of the investigator and per standard of care . 
i.All female subjects of childbearing potential (ie, post -menarche) must test negative for pregnancy at all visits prior to study drug administration.
j.Subjects will be observed at the discretion of the investigator after the administration of study agent for symptoms of an infusion reaction.
k.Investigator w ill com plete an a nnual attestation form to document that subject is benefiting from treatment.
l.The same serum samples may be used for the measurement of golimumab concentration and detection of antibodies to golimumab. F or visits with study agent 
administration, all blood samples for assessing golimumab concentration and antibodies to golimumab MUST be collected BEFORE the administration of 
the study agent.
Abbreviations: AE=adverse event; ANA=antinuclear antibodies; dsDNA=double -stranded deoxyribonucleic acid; IV=intravenous; SAE=serious adverse event; 
TB=tuberculosis.
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
75
Status: Approved ,Date: 16 December 2019Table 3: From  Week 164 Through Week 252 (Continuation of Long -term  Extension)
Week
164aWeek
172aWeek
180aWeek
188aWeek
196aWeek
204aWeek
212aWeek
220aWeek
228aWeek
236aWeek
244aWeek
252aFinal 
Safety 
Follow
-up 
Visitb
Procedures and Evaluations
Administrative
Concomitant medications 
collectionXcXcXcXcXcXcXcXcXcXcXcXcXc
Study Agent
IV administration of study agent X X X X X X X X X X X Xd
Safety
Revie w of systems Xe
Physical examinationfX X X X
Body  weight measurement X X X X X X X X X X X Xd
Height measurement X X X X X X X X X X X Xd
Vital signs Xe
Routine laboratory analyses X X X
ANA/Anti -dsDNA antibodies X X
QuantiFERON-TB Gold testXe,g
TB evaluation (questionnaire) X X X X X X X X X X X X X
Chest x -ray Xh
Uveitis evaluations Xi
Pregnancy test (urine)jX X X X X X X X X X X Xd
Infusion reaction evaluationkX X X X X X X X X X X Xd
Adverse events X X X X X X X X X X X X X
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
76
Status: Approved ,Date: 16 December 2019Table 3: From  Week 164 Through Week 252 (Continuation of Long -term  Extension)
Week
164aWeek
172aWeek
180aWeek
188aWeek
196aWeek
204aWeek
212aWeek
220aWeek
228aWeek
236aWeek
244aWeek
252aFinal 
Safety 
Follow
-up 
Visitb
Efficacy
Annual attestation form Xl
Pharm acokinetics
Golimumab concentrationmX X X
Immunogenicity 
Antibodies to golimumabmX X X
Note : All assessments at each study visit must be completed prior to study drug administration , unless otherwise specified .
a.All scheduled visits should occur ± [ADDRESS_42806] infusion (Section 10.2).Collection of vital signs, review  of symptoms, uveitis evaluation are performed at the final 
safety follow -up visit at the discretion of the investigator.
c.Revie w concom itant medications with subject and document in source ;update concomitant medication CRF page to include only those medications that are 
associated with AEs and SAEs (ie, used to treat event or suspected in causing event) .
d.The ETP starts at Week 252. These procedures should only be completed for subject swho enter the E TP.
e.Perform at the discretion of the investigator.
f.Includes skin exam.
g.Tuberculin skin tests should also be performed in countries where the QuantiFERON -TB Gold test is not approved/registered or the tuberculin skin test is 
mandated by [CONTACT_5737] H ealth Authorities.
h.Chest x -ray screening should be performed at the discretion of the investigator and per local and country regulations for children with JIA who are receiving 
immunosuppressive agents and who are at risk of TB.
i.Evaluations (based on physi cal examination and intervie w) should be performed at the discretion of the investigator . Slit lamp evaluations performed by [CONTACT_41004]/optometrist at the discretion of the investigator and per standard of care . 
j.All female subjects of childbearing potential (ie, post -menarche) must test negative for pregnancy at all visits prior to study drug administration.
k.Subjects will be observed at the discretion of the investigator after the administration of study agent for symptoms of an infusion reaction.
l.Investigator w ill com plete an annual attestation form to document that subject is benefit ingfrom treatment.
m.The same serum samples may be used for the measurement of golimumab concentration and detection of antibodies to golimumab. F or visits with study 
agent administration, all blood samples for assessing golimumab concentration and antibodies to golimumab MUST be collected BEFORE the 
administration of the study agent.
Abbreviations: AE=adverse event; ANA=antinuclear antibodies; dsDNA=double -stranded deo xyribonucleic acid; ETP=Extended Treatment Period; 
IV=intravenous; SAE=serious adverse event; TB=tuberculosis.
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
77
Status: Approved ,Date: [ADDRESS_42807] aspartate aminotransferase
BCG Bacille Calmette -Guérin 
-hCG -human chorionic gonadotropin 
BSA body surface area 
CHAQ Childhood Health Assessment Questionnaire
CL/BSA body surface area -norm alized drug clearance
CL/F apparent total systemic clearance
CRF case report form 
CRP C-reactive protein
DAS Disease Activity Index Score
DMARD disease -modifying anti -rheumatic drug
DNA deoxyribonucleic acid
dsDNA double- stranded deoxyribonucleic acid
eDC electronic data capture
ETP Extended Treatment Period
FDA Food and Drug Administration
GCP Good Clinical Practice
HAQ Health Assessment Questionnaire
HAQ -DI Health Assessment Questionnaire Disability Index
HBsAg HBV surface antigen
HBV hepatitis B virus
HIV human immunodeficiency virus
HLA -B27 human leukocyte antigen B27
HLA -DR4 human leukocyte antigen DR4
HLA -DR5 human leukocyte antigen DR5
HLA -DR8 human leukocyte antigen DR8
ICH International Conference on Harmonisation
IEC Independent Ethics Committee
IL-1 Interleukin -[ADDRESS_42808]
LTE long-term extension
mAb monoclonal antibody
MedDRA Medical Dictionary for Regulatory Activities
MTX methotrexate
NSAID non-steroidal anti-inflammatory drug
PD pharmacodynamic(s)
PED pediatric
pJIA polyarticular juvenile idiopathic arthritis
PK pharmacokinetic
PQC Product Quality Complaint
[COMPANY_003] purified protein derivative
PRCSG The Pediatric Rheumatology Collaborative Study Group
PRINTO Pediatric Rheumatology INternational Trials Organisation
PRO patient -reported outcome(s)
PsA psoriatic arthritis
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
78
Status: Approved ,Date: [ADDRESS_42809] infection
US [LOCATION_002]
VAS visual analog scale
vdH-S van der Heijde Modified Sharp
V/F apparent volume of distribution
Vss volume of distribution at steady -state
WBC white blood cell
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
79
Status: Approved ,Date: 16 December [ZIP_CODE]. INTRODUCTION
Golimumab is a fully  human monoclonal antibody  (mAb) with an immunoglobulin G1 heav y 
chain isotype (G1m[z] alloty pe) and a kappa light chain isotype. The molecular weight of 
golimumab ranges from 149,802 to 151,064 daltons. Golimumab binds to human tumor necrosis 
factor alpha (TNFα) with high affinity  and specificity  and neutraliz es TNFα bioactivity .
TNFα is a key inflammatory  mediator, with high levels of TNFα implicated in the 
pathophy siology  of diseases such as rheumatoid arthritis (RA) and juvenile idiopathic arthritis 
(JIA). Blocking TNFα activity ,as demonstrated inclinical studies of anti-TNF αagents ,can 
prevent the deleterious effects caused by [CONTACT_41005]α. SIMPONI®(golimumab) for 
intravenous (IV)use is being developed by [CONTACT_41006] (compared with other available anti -TNFα agents) and a convenient dose regimen 
(ie, every  8 week [q8w] administration) for patients with polyarticular JIA(pJIA).
For the most comprehensive nonclinical and clinical information regarding SIMPONI®refer to 
the latest version of the Investigator's Brochure and Addenda for SIMPONI.
The term "Sponsor " used throughout this document refers to the entities listed in the Contact 
[CONTACT_23774](s), which will be provided as a separate document.
1.1. Backgroun d
1.1.1. Juvenile Idiopathic A rthritis
Juvenile idiopathic arthritis is a diagnosis of exclusion that encompasses all forms of arthritis that 
begin before the age of [ADDRESS_42810] common chronic rheumatic disease in children and is categorized according to the 
International League of Associations for Rheumatology  (ILAR) classification into 7 subty pes 
(systemic arthritis, oligoarthritis, rheumatoid factor [RF]-negative polyarthritis, RF-positive 
polyarthritis, enthesitis-related arthritis, psoriatic arthritis, undifferentiated arthritis) 
characterized b y distinct clinical presentations and fe atures.[ADDRESS_42811] been implicated. 
These include implicating infection as a triggering mechanism, links between human leukocy te 
antigen (HLA) and non-HLA molecules and disease development, and immunological 
abnormalities leading to tissue inflamm ation and joint destruction. The role of infection in 
disease development is still unproven.18However, in JIA, HLA -DR5 and HLA -DR8 locus 
antigens have been implicated as associated contributory  elements in young girls with 
oligoa rticular arthritis, whereas HLA -DR4 has been implic ated in RF-positive polyarticular 
arthritis in older children, and HLA-B27 has been implicated in older boys with oligoarticular 
disease.15,17
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
80
Status: Approved ,Date: [ADDRESS_42812] shown that levels of inflammatory  cytokines (eg, interleukin -1 beta [IL-1β], 
interleukin -6 [IL-6], and TNFα) elevated in adults with RA are also elevated in the sy novial fluid 
and serum of patients with JI A.9,19,12,3,20These studies have also found different cy tokine profiles 
among patients with various JI A subgroups.
Juvenile idiopathic arthritis is an important cause of short -term and long-term disability  in 
children,14but new advances in therapy  have demonstrated clinicall y important steps forward . In 
the past [ADDRESS_42813] shown that 40% to 60% of patients have inactive disease or 
clinical remission while on medication for J IA at follow -up. Functional outcome has improved in 
the last decade, with 2.5% to 10% of patients with serious functional disability .18However, 
particularl y serious complications of JIA include linear growth suppression, osteoporosis, local 
growth disturbances, macrophage activation s yndrome and iridocyclitis.[ADDRESS_42814] been NSAIDs , intra-articular and 
systemic corticosteroids, methotrexate (MTX) ,and other DMARDs . The introduction of 
biological medications has provided animportant new therapeutic option for the treatment of 
patients with JIA who are resistant to conventional anti-rheumatic agents.18Currently  approved 
biologic therapi[INVESTIGATOR_40945], adalimumab ,abatacept , and 
tocilizumab ; canakinumab and tocilizumab have been approved for systemic JI A.
1.1.2. Golimumab Clinical Studies in Rheumatoid A rthritis and Juvenile 
Idiopathic A rthritis
Golimumab given as a SC injection has been demonstrated to be efficacious in adults with RA, 
PsA, anky losing spondy litis (AS),andulcerative colitis. Intravenous golimumab has also proven 
effective in adults with RA. Other anti-TNF αagents have been effective in the treatment of 
subjects with JIA.The Sponsor conducted a study  of BSA -based dosages of SC golimumab 
(CNTO148J IA3001 ) to assess the benefit sand risksassociated with the use of SC golimumab in 
the treatment of multiple subty pes of J IA, including juvenile PsA.
The results of the CNTO148ART3001 study  of IV golimumab in adults and the results of the 
CNTO148JIA3001 study of SC golimumab in subjects with JIA are described below.
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
81
Status: Approved ,Date: 16 December [ZIP_CODE].1.2.1. Intravenous Golimumab in A dult Rheumatoid A rthritis
The primary  objective of CNTO148ART3001, a randomized, placebo- controlled, multicenter, 
double -blind study , was to assess the clinical efficacy  of IV administration of golimumab 
2mg/kg + MTX compared with MTX alone in adult subjects with active RA despi[INVESTIGATOR_40946] y. Approximately [ADDRESS_42815] 
3months prior to screening who had active RA, defined as ≥6 tender and ≥[ADDRESS_42816] 
C-reactive protein ( CRP)measurement of≥1.0 mg/dL (upper limit of normal=1.0 mg/dL) and be 
RF-positive.
Subjects randomized to golimumab received 2 mg/kg of golim umab intravenously  over a 
30±10 minute infusion time. Additionally , subjects were maintained on their stable dose of 
commercial MTX (between 15 mg and 25 mg/week) throughout the stud y.
Randomization was stratified based upon a screening CRP of <1.5 mg/dL or ≥1.5 mg/dL. 
Subjects were randomized 2:1 to golimumab + MTX or placebo + MTX at Week 0, Week 4, and
every  8 w eeks (q8w) thereafter. The duration of treatment for the entire study  was 100 weeks 
with a 12 week safet y follow -up period.
In total, 570 (96%) of 592 subjects completed the 24-week study . The remaining 22 (4%) 
subjects discontinued the study  before Week 24. Most discontinuations were due toAEs: 
9[2.3%] subjects in the golimumab + MTX group and 2 [1.0%] subjects in the placebo + MTX 
group).
A significantl y greater proportion of subjects in thegolimumab + MTX group (58.5%) achieved
the primary  endpoint, anACR20 response at Week 14,compared with subjects in the placebo + 
MTX group (24.9%, p<0.001). The treatment effect wasconsistent in subjects with either a CRP 
≥1.5 mg/dL or <1.5 mg/dL at screening. A significant difference in the proportion of ACR 20 
responders between the golimumab + MTX and placebo + MTX groups was observed as earl y as 
Week 2. Major secondary  efficacy  endpoints were also achieved. A significantl y greater 
proportion of subjects in the golimumab + MTX group had good or moderate Disease Activity 
Index Score (DAS )28 responses (using CRP) at Week 14 (81.3%) compared with subjects in the 
placebo + MTX group (40.1%, p<0.001).
There was a significa ntly greater improvement inHealth Assessment Questionnaire Disability 
Index (HAQ- DI)disability  scores at Week 14 in subjects in the golimumab + MTX group 
(0.500) compared with subjects in the placebo + MTX group (0.125, p<0.001). There was also a 
significant difference in clinically  relevant improvements in HAQ- DI (≥0.25) in the golimumab 
+ MTX group compared with the placebo + MTX group both at Week 14 (68.4% compared with 
43.1%, respectively , p<0.001) and at Week 24 (67.6% compared with 45.2%, respectivel y, 
p<0.001). Subjects who received golimumab + MTX demonstrated significantly  greater ACR 50 
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
82
Status: Approved ,Date: 16 December 2019response rates at Week 24 (34.9%) compared with subjects who received placebo + MTX 
(13.2%, p <0.001).
A consistent treatment benefit was observed within subgroups of demography , baseline clinical 
characteristics, and prior exposure to medications for RA except for subgroups with small 
population size (ie, < 15 subjects) .
Statistically  significant greater improvement in the mental and physical component summary 
scores of the36-item short form health survey (SF-36)as well as all 8 scales of the SF-36 
instrument were observed in golimumab + MTX treatment relative to placebo + MTX treatment 
at Week 12 (p<0.001 for all comparisons). These improvements were maintained through 
Week 24.
Through Week 16 (the placebo -controlled period prior to early  escape) in CNTO148ART3001, 
43.7% of subjects in the placebo group and 47.3% in the golimumab group had an AE; the 
highest incidence of AEs was in the Infections and infestations system organ class (SOC ), 20.8 % 
and 24.3% in the placebo and golimumab groups, respectivel y,with upper respi[INVESTIGATOR_40947] (URTI) being the most frequently  reported AE (5.6% and 5.1% in the placebo and 
golimumab groups, respectively ). Through Week 112, 79.1% of golimumab -treated subjects had 
an AE; the highest incidence of AEs was in the Infections and infestations SOC (50.5%) and 
URTI  was the most frequently  reported AE (11.5%).
Through Week 16 in CNTO148ART3001, 1.0% of subjects in the placebo group and 3.8% of 
subjects in the golimumab group had aserious adverse event (SAE ). The incidence of SAEs 
within each SOC was <1.0%, and no SAE occurred in more than 1subject. Through Week 112, 
18.2% of golimumab -treated subjects had an SAE; the highest incidence of SAEs occurred in the 
infections and infestations SOC (5.5%) and musculoskeletal and connective tissue disorders 
SOC (3.4%) and the most frequentl y reported SAE was RA (2.1%).
Through Week 24, 1 patient died in the CNTO148ART3001 study ;this subject was randomized 
to treatm ent with placebo + MTX, had never received golimumab, and died of a presumed 
cerebrovascular accident (stroke). Through Week 112, an additional 5 subjects died in the 
CNTO148ART3001 study . Two subjects randomized to treatment with placebo +MTX died, 
both after switching to golimumab 2mg/kg +MTX; cause of death was sudden death (n=1) and 
complications of severe dehy dration, Clostridium difficile colitis, and atrial fibrillation (n=1). 
Three subjects randomized to treatment with 2 mg/kg golimumab + MTX died in the study ; 
reported cause of death was acute abdominal syndrome (later diagnosed as peritoneal 
tuberculosis [TB], n=1), presumed myocardial infarction (MI, n=1), and septic shock secondary 
to a py ogenic lung abscess due to Acinetobacter baumann ii(n=1 ).
No malignancies were reported through Week 16 in study  CNTO148ART3001. T here was 1 case 
of nontreatment -emergent lung adenocarcinoma reported in the placebo +MTX group prior to 
receiving study  agent. Through the placebo -controlled period (Week 24), 1 malignancy  (breast 
cancer) was reported in the golimumab group. Through Week 112, 5 additional malignancies
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
83
Status: Approved ,Date: [ADDRESS_42817] with a 
family  history  of chronic lymphocy tic leukemia , cervi x carcinoma in situ, Bowen’s Disease ,and 
basal cell carcinoma . No ly mphomas were reported through Week 112.
Through Week 16 in CNTO148ART3001, 0.8% of subjects in the golimumab group had a 
serious infection, including appendicitis, bacteremia, and (compli cations of) interstitial lung 
disease. No subjects in the placebo group had a serious infection. Through Week 112, 6.2% of 
golimumab -treated subjects had a serious infection. Serious infections occurring in more than 
one subject were pneumonia (n=5), UTI ( n=4), and ery sipelas (n=2).
Through Week 16 in CNTO148ART3001, 0.5% of subjects in the placebo group and 2.5% of 
subjects in the golimumab group had an infusion reaction. Through Week 112, 3.9% of 
golimumab -treated subjects had an infusion reaction and 0.4% of infusions were complicated by 
[CONTACT_40984]. It should be noted that all placebo infusions consisted of 0.9% normal saline 
alone rather than a true matched placebo. No serious infusion reactions requiring studyagent 
discontinuation were noted. There was a case of anaph ylaxis,which was not associated with 
study  drug.
For the most comprehensive nonclinical and clinical information regarding golimumab, refer to 
the latest version of the Investigator's Brochure and Addenda for S IMPONI (golimumab).
The median peak serum golimumab concentration (ie, post-infusion golimumab concentration) 
of 41.56 µg/mL  was observed at Week 4 following IV administration of 2mg/kg golimumab at 
Week 0, Week 4, followed by q8w (±1 week )administration. This peak is highe r than that 
reported for SC golimumab administration of 50 mgevery  4 w eeks (q4w). The median trough 
serum golimumab concentration in subjects receiving IV golimumab at 2 mg/kg q8w with MTX 
was 0.28 µg/mL at Week 12 and 0.22 µg/mL at Week 20; these levels are similar to those 
reported with SC golimumab 50 mg. Overall exposure to golimumab isapproximately  3 times 
that for SC golimumab 50 mg over a similar period of exposure.
Data from the IV golimumab program demonstrated less radiographic progression in subjects 
treated with golimumab compared with subjects who received placebo. There was asignificant 
difference in change from baseline in total van der Heijde Modified Sharp (vdH -S) score at 
Week 24 (placebo + MTX: 1.09 3.194, g olimumab 2 mg/kg + MTX: 0.03 1.899 [ p<0.001] ) 
between the golimumab + MTX treatment group and placebo + MTX. Significant differences in 
favor of IV golimumab were also observed in changes from baseline in erosion and joint space 
narrowing scores. The proportion of subjects with ra diographic progression based on the smallest 
detectable change was significantl y lower for subjects treated with golimumab + MTX when 
compared with placebo + MTX for the total vdH- S score (p<0.001) as well as both erosion 
(p=0.001) and joint space narrowing measurements (p=0.01).
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
84
Status: Approved ,Date: 16 December [ZIP_CODE].1.2.2. Subcutaneous Golimumab in Juvenile Idiopathic A rthritis
CNTO148JIA3001 was a randomized withdrawal, double -blind, placebo- controlled, 
parallel -group, multicenter study  of BSA -based 30 mg/m2(up to a maximum 50 mg/dose) SC 
golimumab givenevery  4weeks (q4w) in pediatric subjects with active pJIA despi[INVESTIGATOR_40948]. The study  population comprised subjects with pJIA receiving MTX, ages [ADDRESS_42818] a 6-month history  of pJIA, and active arthritis in ≥5joints. All 
subjects received SC golimumab in the active treatment portion of the study from Week 0 
through Week 16. At Week 16, JIA ACR 30 responders were randomized to receive placebo or 
golimumab for 32 weeks; subjects randomized to placebo who experienced flares during this 
32-week period had golimumab therapy  re-instituted . The placebo -controlled period was through 
Week 48, and the long -term extension (LTE) was planned from Week 48 through Week 248.
Approxima tely 170 subjects were planned, and 173 subjects were enrolled into the study . All of 
the 173 subjects were included in the Week 48 efficacy  and safet y analy ses. Nineteen of the 
173subjects discontinued study  agent through Week 16 (due to: lack of efficacy  [n = 14];AEs
[n = 4 ];withdrawal of consent [n = 1]), and154 subjects entered randomized withdrawal (76 to 
placebo and 78 continued golimumab).
The baseline disease characteristics of the 173 enrolled subjects constitute da population with 
moderate to severe JIA comparable with other clinical studies of anti-TNF αagents in pJIA,with 
the exception of numerically  lowe r mean and median CRP /ESR levels in CNTO148J IA3001.
The proportion of subjects who were JIAACR 30 responders at Week 16 was 87.3%. 
Additionally ,the proportion of JIA ACR 50, JIAACR 70,and JIAACR 90 responders at 
Week 16 were 79.2%, 65.9%, and 36.4%, respectively .
The study  did not meet its primary  and major secondary  endpoints as the proportion of subjects 
who were JIA ACR 30 responders at Week 16 and did not experience a flare of disease between 
Week 16 and Week 48 was not significantly  different in subjects randomized to continued 
golimumab treatment between Weeks 16 and 48 as compared with subjects randomized to 
receive placebo between Weeks 16 and 48 (59% versus 52.6%, p=0.41). All sensitivity  analyses
and major secondary  endpoints demonstrated the lack of statistically  significant differences 
between treatment groups. The Sponsor terminated the LTE of the study early  as pre-specified 
effica cy endpoints were not met.
Post-hoc analysesthat evaluated flare rates based on Week 0 CRP levels ranging from 
0.1-1.0mg/dL demonstrated that, in general, among subjects with higher baseline CRP levels, 
the subjects who received continued golimumab therap y had significantly fewer flare epi[INVESTIGATOR_40949] 16.
When JIAACR response rates were analyzedbased on obs erved data through Week 48 (using 
Week 0 as baseline and comparing drug/placebo effect at each visit through Week 48), JIA 
ACR 30 response rates of 89%to 95.9% and JIAACR 90 response rates of 53.4%to 56.2% 
were achieved at Week 48. Improvements in the core sets through Week 48 were similar at all 
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
85
Status: Approved ,Date: 16 December 2019visits in subjects randomized to golimumab at Week 16 as compared with subjects randomized to 
placebo at Week 16 and all represent edclinically  meaningful improvement in disease,
eg,median percent improvement of 94.6% and 95.1%in Physician Global Assessment of 
Disease Activity , and median percent improvement of 90.9%and 100% inthenumber of active 
joints.
Pharmacokinetic (PK)and immunogenicit y data were collected through Week 48 in 
CNTO148JIA3001. In subjects with pJIA who received golimumab 30 mg/m2SCand were 
randomized to stay on active treatment, median trough golimumab concentrations at Week 12, 
Week 24, and Week 48 were 1.16 µg/mL, 1.12 µg/mL, and 0.95 µg/mL, respectivel y, indicating 
that stead y-state levels were maintained though Week 48. Furthermore, stead y-state trough 
golimumab concentrations were similar across different age groups, body  weight quartiles, body 
mass index quartiles, and body  weight categories in subjects with pJIA. Overall, these 
concentrations were similar to the PK exposure observed in the adult active RA population
(despi[INVESTIGATOR_40950]) in C0524T06 treated with SC golimumab, and thus supported the hypothe sis that 
the BSA -based golimumab regimen of 30 mg/m2SC q4w was sufficient to produce 
concentrations comparable to that seen in the adult RA population who received golimumab 
50mg SC q4w. Further, PK and efficacy  analysesshowed that similar efficacy  (as measured by 
[CONTACT_41007] 30response ,and flare rates) were seen in subjects with pJIA in the 4 subgroups of 
steady -state trough golimumab concentration quartiles. Additionally , there were no apparent PK 
differences observed between subjects with and without flares.
With regards to immunogenicity , 40.1% of subjects developed antibodies to golimumab using 
the recentl y developed drug tolerant immunoassay analy ses. The new drug tolerant immunoassay 
is more sensitive compared with assay s used previously  in adult golimumab RA studies and 
allows the detection of antibodies to golimumab despi[INVESTIGATOR_40951]. 
Among subjects who were randomized and remained on golimumab 30 mg/m2SC + MTX, 
30.8% developed antibodies to golimumab; antibody  titers tended to be low. When evaluating 
the effects of immunogenicity  on PK, efficacy , and safet y, it was found that positive 
anti-golimumab antibody  status decreased steady -state trough golimumab concentrations when 
the titer levels were >1:[ADDRESS_42819] of antibodies on efficacy  was less sensitive ,
requiring higher titers >1:1000 in order to correlate with apparent reduction s inefficacy . Since 
only approximately  5% of subjects with JIA developed anti-golimumab antibodies with titers 
>1:1000, it was determined that immunogenicity  was not a contributing factor to lack of 
achievement of the primary  endpoint in CNTO148JI A3001. Additionally , positive 
anti-golimumab antibody  status did not appear to be associated with a higher incidence of 
injection -site r eactions.
The proportion of subjects who reported an AE through Week 48 was 87.9%. The most 
commonly  reported SOC of AEs was Infections and infestations (67.1%), and were 
predominantly  URTIs and nasophary ngitis. There was no marked difference in AEs report ed 
between Week 16 and Week 48 for subjects randomized to placebo (82.9%) and those 
randomized to continued golimumab treatment (78.2 %); however, it needs to be noted that all 
subjects in randomized withdrawal portion of the study  were exposed to golimumab for 
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
86
Status: Approved ,Date: 16 December 201916weeks before re-randomization . Serious adverse events were reported by 13.3% of subjects. 
The most commonly  reported SAE was worsening ofJIA (6.4%). Serious infections were 
reported in 2.9% of subjects (pneumonia, urinary  tract infection, herpes zoster, URTI , and 
pyelonephritis), and there were no deaths, malignancies, or demy elination events through 
Week 48. There were no reports of active TB and no serious opportunistic infections. Through 
Week 48, the number of subjects with abnormal alanine aminotransferase ( ALT)measurements 
(and no concomitant treatment for latent TB, which may affect liver function tests [LFTs ]) was 
29.5% (51/167), 39 of the 51 subjects had elevations <3× ULN.
There were 2subject swith ALT elevation to > 8×ULN but neither subject met the criteria for 
Hy’s Law consistent with hepatotoxicity . Subjects were not receiving TB prophy laxis; one of the 
subjects had baseline ALT which was alread y abnormal. All subject s with LFT abnormalities 
were managed conservatively  with changes in MTX dosing but one subject was discontinued for 
elevated LFTs.
The incidence of injections with injection -site reactions through Week 48 was 0.8% ; there was 
one SAE report of serum sickness -like reaction in a subject randomized to placebo who resumed 
golimum ab treatment .
For the most comprehensive nonclinical and clinical information regarding golimumab, refer to 
the latest version of the Investigator's Brochure and Addenda for S IMPONI (golimumab).
Although the CNTO148JIA3001 study  did not meet its endpoints, when JIA ACR response rates 
were analyzed as observed data through Week 48 (using Week 0 as baseline and comparing 
drug/placebo effec t at each visit through Week 48)the study  showed the potential for efficacy  
that could be attained with SC golimumab in children with pJIA.Therefore, itlends support to 
the study  of IV golimumab in subjects with pJIA who have an inadequate response to M TX.
1.2. Overall Rationale for the Study
Intravenous golimumab has been demonstrated to be efficacious inthe treatment ofadults with 
RA(Section [IP_ADDRESS] ). Other biolo gics,including anti-TNFα agents ,have been shown to be 
effective in the treatment of subjects with pJIA. Though biologic infusion therapi[INVESTIGATOR_40952], there arecurrentl y no approved intravenously  administered anti-TNFα 
agents for this condition. The every  8 week, 30-minute infusion paradigm proposed in this study 
for children and studied in adults with RAmay be appropriate for populations of patients where 
greater physician scrutiny  of drug therapy  may be needed or requested. Particularly  in the 
pediatric population, the reduction in the number of drug administrations (ie, to an every  8 week 
maintenance schedule) could provide greater convenience and less pain (due to fewer IV 
administrations) compared with other biologic agents. In addition, switching to a different 
anti-TNF αagent in a patient in whom a previous anti-TNF αagent was not efficacious may 
provide further symptomatic relief of disease.
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
87
Status: Approved ,Date: 16 December 2019The primary  objective of this study  is to characterize the PK of IV golimumab in pJIA, along 
with evaluation sof the safet y and efficacy  of IV golimumab in these subjects .This study  will
also include subjects with multiple subty pes of JIA, including juvenile PsA,as well assubjects
with prior anti- TNF αexperience (up to 30% of the study  population) .
The study  is designed to obtain PKdata in response to BSA -based (80mg/m2,which is expected 
to be equivalent to the 2 mg/kg dose in adult RA patients weighing 70 kg ) IV golimumab for 
subjects with pJIA who have inadequate response to MTX treatment as well as prior treatment 
with non-steroidal anti-inflammatory  agents, corticosteroids ,and/or anti-TNFα agents , with the 
intent to demonstrate its similarit y to the response seen with weight -based (2 mg/kg) doses of IV 
golimumab in adult RA subjects who have inadequate response to MTX treatment. The 
80mg/m2dose for subjects with pJIA is based on the 2 mg/kg dose studied in
CNTO148ART3001 in the adult RA population.
2. OBJECTIVES A ND HYPOT HESIS
2.1. Objectives
Primary Objective
The primary  objective of this study  is to assess the PK following intravenously  administered 
golimumab in subjects (ages 2 to less than 18 years) with pJIA manifested by ≥5 joints with 
active arthritis despi[INVESTIGATOR_40953] y for ≥2months.
Secon dary Objectives
The secondary  objectives of this study  are to evaluate IV golimumab in subjects with pJIA with 
respect toPK,efficacy  (relief of signs and symptoms, physical function ,andquality  of life), 
safet y (AEs, SAEs, and assessment oflaboratory parameters) ,and immunogenicity  (antibodies to 
golimumab) .
2.2. Hypothesis
No formal h ypothesis testing is planned in this study.
3. STUDY DESIGN A ND RA TIONA LE
3.1. Overview  of Study  Design
This is a Phase 3,open -label ,single -arm, multicenter study to evaluate the PK, safety ,and 
efficacy  of IV golimumab in subjects with active pJIA despi[INVESTIGATOR_40944]. The 
study  population will comprise subjects with pJIA receiving MTX, ages [ADDRESS_42820] a 3-month history  of pJIA, and active arthritis in ≥[ADDRESS_42821] population of 
approximately  10% aged 2 to up to 6 years, approximately  20% aged 6 to up to 12 years, and 
approximately  70% aged 12 to less than 18 y ears.
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
88
Status: Approved ,Date: 16 December 2019All subjects will receive 80 mg/m2golimumab (maximum single dose 240 mg ) as an IV infusion 
given over 30±10 minutes at Weeks 0, 4, and every  8 w eeks (q8w ; ±3 days) through Week 28 
and then q8w (±1 week ) thereafter through Week 244. Body surface area will be calculated 
based on the subject’s height and bod y weight measured at each visit, and the BSA -based dose of
golimumab will be adjusted as needed to maintain the dose at 80mg/m2. Subjects will also 
receive commercial MTX weekl y through Week 28at the same BSA -based dosage (10 to 
30mg/m2per week of MTX in subjects with BSA <1.67 m2, ora minimum of 15mg/week in 
subjects with BSA ≥1.67 m2) as at time of study  entry as outlined in Section 6.2.At Week 252, 
subjects who meet the inclusion criteria for the optional Extended Treatment Period (ETP) may 
continue treatment with golimumab (80 mg/m2q8w) after completion of the Week 252 
assessments. 
Every  effort should be made to maintain subjects at a dose of 80 mg/m2of golimumab based 
upon BSA, and decreases below or increases above 80 mg/m2or shortening of the dosing 
interval (eg, from 8 weeks to 6 weeks) will not be permitted at an y visit.
This is an open -label study , with all subjects receiving the same BSA-based dose of IV 
golimumab. Safet ydata will be routinely  evaluated by [CONTACT_1758] ’s medical monitor. Therefore, 
an external Data Monitoring Committee will not be established.
A diagram of the stud y design is provided in Figure 1.
Figure 1: Schematic Overview of the Study
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
89
Status: Approved ,Date: 16 December [ZIP_CODE].1.1. Week 0 Through Week 28
Through Week 28,subjects will be monitored and disease activity  and safety  will be assessed at 
the investigative site every  4 weeks.
If <50% of the study  population achieves an adequate response to the treatment (American 
College of Rheumatology  Pediatric 30% [JIA ACR 30] response) at Week 28, the study  will be 
discontinued.
After all subjects complete the Week 28 visit, the database will be locked to assess PK, safet y 
and efficacy .An additional safet y, efficacy ,and PK database lock is currentl y planned for
Week 52. A database lock will be performed at Week 252, and a final database lock will be 
performed at the end of study .
No changes should be made to background medications (ie, MTX, other DMARDs, 
corticosteroids, and NSAIDs) in terms of increases or decreases in dosage bey ond the parameters 
provided in Section 8(eg, no more than 10 mg/day prednisone or no more than 0.20mg/kg/day ,
whichever is lower ) and/or route of administration between Weeks 0 and 28, unless there is a 
safet y concern (eg, elevated LFTs ), which require schanges to background medications.
Ifa subject is lost to follow -up, every  possible effort must be made by  [CONTACT_41008]/withdrawal. The measures taken 
to follow -up must be documented.
When a subject withdraws before completing the study , the reason for withdrawal is to be 
documented in theCRF and in the source document. Study  drug assigned to the withdrawn 
subject may  not be assigned to another subject. Subjects who withdraw will not be replaced.
3.1.2. Week 28 Through Week 52
From Week 28 through Week 52, infusions will continue to be performed every  8 weeks 
(±1week );however, subjects will be actively  monitored at the investigative site and disease 
activity  and safet y will be assessed at the investigative site every  8  w eeks rather than every  
4weeks as between Weeks 0 and 28. As noted above, after Week 28 subjects will be perm itted 
to change /add MTX, other DMARD s,corticosteroid s, and NSAID sas outlined in Section 8.
3.1.3. Week 52 Through Week 252 (Long- term Extension)
Subjects who complete the study  at Week [ADDRESS_42822] administration of study  agent.
During the LTE, all subjects will conti nue to receive golimumab q8w (±1 week) through 
Week 244. For subjects who have completed the trial period of 252 weeks and for whom drug is 
proven beneficial but is not commerciall y available for pJIA indication (or patient does not 
qualify for insurance to pay for the drug) IV golimumab will continue to be provided by [CONTACT_429] , as described in Section 3.1.4 .Between Week 52 and Week 252, disease activit y will be 
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
90
Status: Approved ,Date: [ADDRESS_42823]’s source documents by [CONTACT_41009] a yearly basis via an attestation form ;infusions 
and safet y measurements will be done at the investigative siteaccording to the Time and Events 
Schedule .
As noted above ,after Week 28, subjects will be permitted to change /addMTX, other DMARD s, 
corticosteroid s, and NSAID s, including increases or decreases in BSA -based dosing (where 
appropriate) for these classes of agents as outlined in Section 8.
All subjects who complete the Week [ADDRESS_42824] 
administration of study  agent.
A database lock will occur at Week 252.
3.1.4. After Week 252 ( Extended Treatment P eriod)
Subjects <[ADDRESS_42825] in the ETP.
3.2. Study Design Rationale
3.2.1. Blinding, Control, Study Phase/Periods, Treatment Groups
This is a single -arm, open -label study  to evaluate the PK of IV golimumab in subjects with pJIA , 
with all subject s receiving the same BSA -based dose of IV golimumab through Week 52.
Subjects who complete the study  at Week [ADDRESS_42826] the option to enter into the LTE phase of 
this study  through Week 252. After Week 252, subjects who meet specific criteria (see 
Attachment 6 ) will have the opportunity  to continue treatment with golimumab in the ETP.
3.2.2. Dose Selection
Unlike adult drug doses, pediatric drug doses (parentera l) are commonl y calculated individually  
asweight -based (mg/kg) or BSA -based (mg/m2)doses to manage the PK variability  observed in 
children across different ages as changes occur in their maturing organ systems.10,22The 
successful outcome of dose extrapolation from adults to pediatric subject s through weight -based 
or BSA -based dose normalization for other approved anti-TNF αagents (eg, adalimumab and 
etanercept) supports the assumption that clinical responses to anti-TNF αagents in rheumatoid 
disease would be similar between adults and childre n. That is, after the PK differences inherent 
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
91
Status: Approved ,Date: 16 December 2019between adults and children are accounted for, similar drug responses would be expected with 
similar drug exposure in both adults a nd children.
Data from the Phase 3 IV study  in adults with RA (CNTO148ART3001) through [ADDRESS_42827] 
shown that golimumab 2 mg/kg at Week 0, Week 4, and q8w (±1 week )thereafter is the optimal 
dose regimen for the treatment of RA in most adults. For a child, golimumab 80 mg/m2
(2mg/kg/1.73 m2) would be approximately  equivalent to 2 mg/kg for an adult subject weighing 
70 kg (with a BSA of 1.73 m2). Thus ,in the current study  (CNTO148JI A3003), a dose of 
golimumab 80mg/m2has been chosen to evaluate the safety  and efficacy of golimumab in the 
pJIA population .
3.2.3. Rationale
The open -label study  design for IV golimumab in the pJIA population isbased on data from
studies ofother anti-TNF αagents in adult RA and pJIA,PK and efficacy  data from the 
Sponsor’s study  of IV golimumab in adult RA(CNTO148ART3001), the Sponsor’s experience 
with SC golimumab in pJIA (CNTO148J IA3001), and feedback from the Pediatric 
Rheumatolo gy International Trials Organisation (PRINTO )and The Pediatric Rheumatology  
Collaborative Study  Group (PRCSG ).
The Sponsor will utilize PK data generated from the proposed open -label CNTO148J IA3003 
study  to extrapolate to adult PK data from the CNTO148ART3001 study in RA, which was the 
pi[INVESTIGATOR_40954] (SIMPONI ARIA/SIMPONI 
for Intravenous Use) for adult patients with RA. Additionally , efficacy  (PD) data will be 
collected to explore the assessment of supportive exposure -response.
4. SUBJECT POPULA TION
Screening for eligible subjects will be perfo rmed within [ADDRESS_42828] safety. Therefore, adherence to the criteria as specified in the protocol is essential.
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
92
Status: Approved ,Date: [ADDRESS_42829] be age 2 years to less than 18 years with a body  weight >[ADDRESS_42830]’s 16th birthday .
3. Active J IA of one of the following subt ypes:
a.Rheumatoid factor positive or negative pJ IA for ≥3 months prior to screening , or
b.Systemic JIA with no systemic symptoms for ≥3 months, but with polyarthritis for 
≥3 months prior to screening , or
c.Extended oligoar ticular JIA ≥3 months prior to screening , or
d.Polyarticular juvenile psoriatic arthritis ≥3 months prior to screening, or,
e.Enthesitis-related arthritis ≥[ADDRESS_42831] ≥5 joints with active arthritis at screening and at Week 0as defined 
by [CONTACT_19665] (ie, a joint with either swelling, or in the absence of swelling, limited 
range of motion associated with pain on motion or tenderness).
6. Subjects must have a screening CRP of ≥0.1 mg/dL with the exception of approximately  
30% of the stud y population .
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
93
Status: Approved ,Date: [ADDRESS_42832] active pJIA despi[INVESTIGATOR_40923], intramuscular ,or 
subcutaneous MTX for ≥2months before screening . For subjec ts with BSA <1.[ADDRESS_42833] be between 10 to 30 mg/m2 per week and stable for≥4weeks before 
screening .For subjects with BSA ≥1.[ADDRESS_42834] be a minimum of 
15mg/week and must be stable for ≥4weeks before screening . In situations where there 
is documented intolerance of doses >10mg/m2weekly  (for subjects with BSA 
<1.67 m2)or ≥15mg/week (for subjects with BSA ≥1.67 m2);or where documented 
country  or site regulations prohibit use of ≥15mg of MTX per week in subjects with 
BSA ≥1.[ADDRESS_42835] be on a stable dose of ≤10 mg/day prednisone equivalent 
or 0.20 mg/kg/day  (whichever is lower ) for ≥[ADDRESS_42836] be on a stable dose for ≥[ADDRESS_42837] 2 weeks before 
screening .
10. Subjects are considered eligible according to the following TB screening criteria:
a.Have no history  of latent or active TB prior to screening. An exception is made 
for subjects currentl y receiving treatment for latent TB with no evidence of 
active TB, or who have a history  of latent TB and documentation of having 
completed appropriate treatment for latent TB within [ADDRESS_42838] no signs or symptoms suggestive of active TB upon medical history 
and/or ph ysical examination.
c.Have had no recent close contact [CONTACT_4490] a person with active TB or, if there has 
been such contact, will be referred to a phy sician specializing in TB to undergo 
additional evaluation and, if warranted, receive appropriate treatment for latent 
TB prior to the first administration of study  agent.
d.Within [ADDRESS_42839] a negative 
QuantiFERON®-TB Gold ( Attachment 1) test result, or have a newly  identified 
positive QuantiFERON®-TB Gold test result in which active TB has been ruled 
out and for which appropriate treatment for latent TB(Sect ion 9.1.2 )has been 
initiated prior to the first administration of study  agent. Within [ADDRESS_42840] 
(Attachment 2), or a newly  identified positive tuberculin skin test in which 
active TB has been ruled out and for which appropriate treatment for latent TB 
has been initiated prior to the first a dministration of study  agent, is additionally  
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
94
Status: Approved ,Date: 16 December 2019required if the QuantiFERON®-TB Gold test is not approved/registered in that 
country  or the tuberculin skin test is mandated by  [CONTACT_41003].
e.Indeterminate results should be handled as outlined in Section 9.1.2 . Subjects 
with persistentl y indeterminate QuantiFERON®-TBGold test results may be 
enrolled without treatment for latent TB, if active TB is ruled out, their chest 
radiograph shows no abnormality  suggestive of TB (active or old, inactive TB), 
and the subject has no additional risk factors for TB as determined by[CONTACT_1275]. This determination must be promptly  reported to the Sponsor ’s 
medical monitor and recorded in the subject's source documents and initialed 
by [CONTACT_093].
f.The QuantiFERON®-TB Gold test and the tuberculin skin testare not required 
at screening for subjects with a history  of latent TB and ongoing treatment for 
latent TB or documentation of having completed adequate treatment as 
described above; Subjects with documentation of having completed adequate 
treatment as described above are notrequired to initiate additional treatment 
for latent TB.
g.Unless country  or local guidelines do not recommend a chest radiograph as a 
necessary  screening process prior to initiation of anti-TNFα therapi[INVESTIGATOR_014], a chest 
radiograph (posterior -anterior view ) must have been taken within [ADDRESS_42841] 
radiographs (both posterior -anterior andlateral view s) must be performed as 
part of the screening process in all cases when either the tuberculin skin test 
and/or QuantiFERON®-TB Gold testing for TB is positive. 
11. Subjects must be medically  stable on the basis of phy sical examination, medical history, 
and vital signs performed at screening. If there are abnormalities, they must be 
consistent with the underly ing illness in the study  population.
12. G irlsmust be either:
Not of childbearing potential: premenarchal; permanentl y sterilized (eg, tubal 
occlusion, hysterectom y, bilateral salpi[INVESTIGATOR_1656]); or otherwise be incapable of 
pregnancy ,
OR
Of childbearing potential, and if sexually  active , practicing a highl y effective 
method of birth control consistent with local regulations regarding the use of birth 
control methods for subjects participating in clinical studies: eg, established use of 
oral, injected or implanted hormonal methods of contraception; placement of an 
intrauterine device (IUD) or intrauterine system (IUS); barrier methods: condom 
with spermicidal foam/gel/film/cream/suppository or occlusive cap (diaphragm or 
cervical/vault caps) with spermicidal foam/gel/film/cream/suppository ; male partner 
sterilization (the vasectomized partner should be the sole partner for that subject); 
true abstinence (when this is in line with the preferred and usual lifesty le of the 
subject and at the discretion of the investigator/per local regulations). Girls of 
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
95
Status: Approved ,Date: [ADDRESS_42842] agree not to donate eggs (ova, oocy tes) for the purposes 
of assisted reproduction du ring the study  and for [ADDRESS_42843] 
dose of study  drug.
Note: If the childbearing potential changes after start of the study  (eg, girl who is 
not heterosexually  active becomes active, premenarchal girlexperiences menarche) 
a girl must begin a highly  effective method of birth control, as described above.
13. Girls of childbearing potential must have a negative serum -human chorionic 
gonadotropin (-hCG )test at screening and a negative urine pregnancy  test ateach 
study  visit where golimumab infusion is to take place.
14. Boys must practice abstinence, or if sexually  active with agirlof childbearing potential 
and has not had a vasectomy  must agree to use a barrier method of birth control eg, 
either condom with spermicidal foam/gel/film/cream/suppository  or partner with 
occlusive cap (diaphragm or cervical/vault caps) with spermicidal 
foam/gel/film/cream/suppository , and allboysmust also not donate sperm during the 
study and for [ADDRESS_42844] dose of study  drug.
15. Subjects’ s creening laboratory  tests must meet the following criteria:
a.Hemoglobin: ≥8.0 g/dL (SI: ≥80 g/L; girls and boy s, ages 2 to 11)
≥8.5 g/dL (SI: ≥85 g/L ; girls, ages 12 to 18)
≥9.0 g/dL (SI: ≥90 g/L ; boy s, ages 12 to 18)
b.White blood cells (WBCs) ≥3.0 x 103cells/µL  (SI: ≥3.0 x 109cells/L)
c.Neutrophils ≥1.5 x 103cells/µL  (SI: ≥1.5 x 109cells/L)
d.Platelets ≥140 x 103cells/µL (SI: ≥140 x 109cells/L)
e.Serum transaminase levels not exceeding 1.2 x the upper limit of normal for the 
central laboratory :
– Aspartate aminotransferase ( AST )
o≤67IU/L (girls, ages 2 to <4 )
o≤58IU/L (girls, ages 4 to <7)
o≤48 I U/L (girls, ages 7 to 18)
o≤83 I U/L (boy s, ages 2 to <4)
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
96
Status: Approved ,Date: 16 December 2019o≤71 I U/L (boy s, ages 4 to <7)
o≤48 I U/L (boy s, ages 7 to 18)
–Alanine aminotransferase ( ALT)
o≤41IU/L (girls, ages 2 to 18)
o≤41 I U/L (boy s, ages 2 to <10)
o≤52IU/L (boy s, ages 10 to 18)
f.Serum creatinine not to exceed:
– 0.5 mg/dL (SI: 44 µmol/L; ages 2 to 5)
– 0.7 mg/dL (SI: 62 µmol/L; ages 6 to 10)
– 1.0 mg/dL (SI: 88 µmol/L; ages 11 to 12)
–1.2 mg/dL (SI: 106 µmol/L ; ages ≥13)
16. Subjects must be up to date with all immunizations in agreement with current local 
immunization guidelines for immunosuppressed subjects before Week [ADDRESS_42845] and his/her parent (if applicable) must be able to adhere to the study  visit 
schedule, and understand and comply  with other protocol requirements.
19. Subject must be willing and able to adhere to the prohibitions and restrictions specified 
in this protocol.
20. Each subject (or their legally  acceptable representative) must sign an ICFindicating that 
he or she understands the purpose of and procedures required for the study  and are 
willing to participate in the study .Assent is also required of children capable of 
understanding the nature of the study  (typi[INVESTIGATOR_897]  7years of age and older and per local 
regulations ) as described in Section 16.2.3 , Informed Conse nt.
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
97
Status: Approved ,Date: [ADDRESS_42846] who meets any  of the following criteria will be excluded from participating 
in the study .
Concomitant or  previous medical therapi[INVESTIGATOR_014] r eceived:
1. Subject has initiated DMARD sand/or immunosuppressive therap y within [ADDRESS_42847] has been treated with intra-articular , intramuscular or intravenous 
corticosteroids (including intramuscular corticotropin) during the [ADDRESS_42848] has been treated with natalizumab, efalizumab, or therapeutic agents that 
deplete B or T cells (eg, rituximab, alemtuzumab, or visilizumab) during the 
12months before first study agent administration, or hasevidence at screening of 
persistent depletion of the targe ted ly mphocy te after receiving any  of these agents.
5. Subject has been treated with alefacept within [ADDRESS_42849] study  agent 
administration (irrespective of undergoing a drug elimination procedure), or have 
received leflunomide from [ADDRESS_42850] has received IL -1ra (anakinra) within [ADDRESS_42851] study  agent 
administration.
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
98
Status: Approved ,Date: [ADDRESS_42852] has received a Janus kinase (JAK) inhibitor , including but not limited to 
tofacitinib, within [ADDRESS_42853] (more than 3 of 5 tests elevated within 
6-months period), MTX pneumonitis, severe mucosal ulcers, intractable nausea, 
vomiting/diarrhea, evidence of clinicall y significant bone marrow suppression, 
severe headaches, severe bone pain, or traumatic fractures.
20. Subject has received an investigational drug (including investigational vaccines) or 
used an invasive investigational medical device within [ADDRESS_42854] dose of study  drug or is currentl y 
enrolled in an investigational study .
Infections or  predisposition to infections:
21. Subject has a history  of active granulomatous infection, including histoplasmosis or 
coccidioidomy cosis, prior toscreening. Refer to inclusion criterion (Section 4.1) for 
information regarding eligibility  with a history  of latent TB.
22. Subject tests positive for hepatitis B virus ( Attachment 3).
23. Subject isseropositive for antibodies to hepatitis C virus (HCV) .
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
99
Status: Approved ,Date: [ADDRESS_42855] has aknown history  of infection with human immunodeficiency  virus 
(HIV).
25. Subject has had a nontuberculous mycobacterial infection or opportunistic infection 
(eg, cytomegalovirus, pneumocy stis, or aspergillosis )within [ADDRESS_42856] has or has had a serious infection (including but not limited to hepatitis, 
pneumonia, or pyelonephritis), or have been hospi[INVESTIGATOR_40955] [ADDRESS_42857] infection (eg, 
bronchiectasis), sinusitis, recurrent urinary tract infection (eg, recurrent 
pyelonephritis), open, draining, or infected skin wound, or ulcer .
29. Subject hasa chest radiograph within [ADDRESS_42858] administration of 
study  agent that shows an abnormality  suggestive of a malignancy  or current active 
infection, including TB (if applicable) .
Malignancy or  incr eased potential for  malignancy:
30. Subject has a known malignancy  or a history  of malignancy .
31. Subject has a history  of lymphoproliferative disease, including lymphoma, or signs 
suggestive of possible lymphoproliferative disease, such as lymphadenopathy  of 
unusual size or location, or clinically  significant splenomegaly  not consistent with 
pJIA  or systemic onset J IA without sy stemic s ymptoms.
Coexisting medical conditions or  past medical history:
32. Subject has a history ofsevere progressive or uncontrolled liver or renal 
insufficiency ; or significant cardiac, vascular, pulmonary , gastrointestinal, 
endocrine, neurologic, hematologic, psychiatric, or metabolic disturbances.
33. Subject has known allergies, hypersensitivity , or intolerance togolimumab or its 
excipi[INVESTIGATOR_840] (refer to Investigator's Brochure) or subject has known allergies, 
hypersensitivity , or intolerance to immunoglobulins. 
34. Subject has or has had a substance abuse (drug or alcohol) problem.
35. Subject has a history  of macrophage activation s yndrome.
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
100
Status: Approved ,Date: [ADDRESS_42859] has a history  of,or concomitant diagnosis of , congestive heart failure.
Other: 
40. Subject has any condition for which, in the opi[INVESTIGATOR_871], participation 
would not be in the best interest of the subject (eg, compromise the well-being) or 
that could prevent, limit, or confound the protocol -specified assessments.
41. Subject i s agirlwho is pregnant, or breast- feeding, or planning to become pregnant 
while enrolled in this study  or within [ADDRESS_42860] with BSA >3.0 m2.
NOTE: Investigators should ensure that all study enrollment criteria have been met at screening. 
If a subject's status changes (including laboratory  results or receipt of additional medical records ) 
after screening but before the first dose of study  drug is giv en such that he or she nolonger meet s
all eligibility  criteri a, then the subject should be excluded from participation in the study . 
Section 17.4, Source Documentation, describes the required documentation to support meeting 
the enrollment criteria.
4.3. Prohibitions and Restrictions
Potential subjects must be willing and able to adhere to the following prohibitions and 
restrictions during the course of the study  to be eligible for participation:
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
101
Status: Approved ,Date: [ADDRESS_42861] not 
donate eggs (ova, oocy tes) for the purposes of assisted reproduction during the study  
and for 6months after receiving the last dose of study  agent ,including the LTE phase of 
the study .
4. If sexually active with a girl of childbearing potential and has not had a vasectomy , boy s 
must use a double barrier method of birth control during the study  and for [ADDRESS_42862] not receive investigational drugs, other immunosuppressants (such as, but 
not exclusively , cyclophosphamide), or other biologics for pJ IA during the study . 
5. TREA TMENT ALLOCA TION AND BLINDING
Thisis anopen -label study . All subjects will receive golimumab 80mg/m2at Week 0, Week 4,
and q8w ( ± 3 day s)through Week 28 and q8w (± 1 week) after W eek [ADDRESS_42863] 1 active treatment group and all subjects will receive 80 mg/m2golimumab 
(maximum single dose 240 mg) IV infusions at Week 0, Week 4,and q8w (±3 days)through 
Week 28 and q8w ( ±1 week ) thereafter through Week 244. The golimumab infusions will be 
prepared by a pharmacist under sterile conditions using golimumab 50mg/4mL liquid in vials 
and a 100 m L infusion bag of 0.9% saline. Subjects will receive 80mg/m2golimumab IV 
infusions over 30±10 minutes. Infusions may be slowed down for evidence of infusion reactions 
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
102
Status: Approved ,Date: 16 December 2019as deemed appropriate by  [CONTACT_093] ,andall changes in the infusion rate should be recorded 
in the CRF . Body surface area will be calculated at each visit and the dose of golimumab will be 
adjusted as needed to maintain the dose at 80mg/m2.Body  surface area will be calculated using 
the Mosteller equation: BSA (m2) =([height (cm) x weight (kg)]/3600)1/2. For additional details, 
see the Site I P Manual.
During the ETP, golimumab will be administered as described in Attachment [ADDRESS_42864] has completed the Week 252 
assessments.
6.2. Methotrexate
Subjects will receive commercial MTX throu gh Week 28at the same BSA -based dose (10 to 
30mg/m2per week for subjects with BSA <1.[ADDRESS_42865] 15 mg/week for subjects with 
BSA ≥1.67 m2)as at time of study  entry. Absolute dose should remain stable from baseline 
through Week 28.
Every  effort should be made to ensure that subjects remain on the same dose and route of 
administration of MTX through theWeek 28visit, unless intolerance or AEs due to MTX occur
(Section 8). Guidelines for adjusting MTX dosage in the event of MTX toxicity  are provided in 
the Trial Center File.
Subjects will also receive a total dose ofcommercial folic acid ≥5mg weekly or folinic acid 
(athalf the MTX dose) given the day after theweekly MTX dose. In children <12 years of age, 
the administration of folic acid or folinic acid will be at the discretion of the physician.
After Week 28, changes in MTX administration are permitted (eg, increase or decrease in 
dosage, change in route of administration, or discontinuation).
7. TREA TMENT COMPLIA NCE
The study  site personnel will ensure compliance with the treatment assignments. Site personnel 
will administer the study  infusion at each visit and record the amount of infusion given.
All subject CRFs will be monitored by a site monitor designated by [CONTACT_1034] . During these 
monitoring visits, all procedures will be evaluated for compliance with the protocol. Treatments 
that are administered outside of the scheduled windows, as well as missed visits, will be recorded 
on the CRF. Subject charts will be reviewed and compared with the data entries on the CRFs to 
ensure accuracy .
8. PRESTUDY AND CONCOMITA NT THERAPY
Prestudy  JIA medications administered before the first dose of study  agent must be recorded at 
screening. All concomitant therapi[INVESTIGATOR_40956] [ADDRESS_42866] on the CRF 
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
103
Status: Approved ,Date: 16 December 2019page only those concomitant medications that are associated with AEs and SAEs (ie, used to 
treat event or suspected in causing even t).
All therapi[INVESTIGATOR_014] (prescription or over-the-counter medications, including vaccines, vitamins, herbal 
supplements; non-pharmacologic therapi[INVESTIGATOR_40957] ) 
different from the study  drug must be recorded in the CRF through Week 52.Recorded 
information will include a description of thetype of the drug, treatment period, dosing regimen,
route of administration, and its indication .Modification of an effective pre-existing therap y 
should not be made for the explicit purpose of entering a subject into the study .
If using corticosteroids or NSAIDS, subjects must have been on stable doses of these 
medications prior to study  entry per Inclusion Criterion 8 and 9 (Section 4.1). Subjects may  have 
been previously  treated with no more than 2therapeutic agent stargeted at reducing TNF αprior 
to study  entry per Exclusion Criterion 12 (Section 4.2). Subjects may not have initiated or been 
treated with prohibited therapeutic agents as outlined in Exclusion Criteria 1 through 20
(Section 4.2).
Subjects must have received MTX for ≥2 months before screening. For subjects with BSA 
<1.[ADDRESS_42867] be between 10 to 30mg/m2 per week and stable for ≥4weeks 
before scree ning. For subjects with BSA ≥1.[ADDRESS_42868] be a minimum of 
15mg/week of MTX and must be stable for ≥4weeks before screening . For exceptions tothis 
rule, see Inclusion Criterion 7 . Subjects (with the exception of those with sJIA) receiving 
corticosteroids at the time of study  entry must have been receiving a stable dose for ≥2weeks 
before screening ,and that dose must have been ≤10 mg /day prednisone or prednisone equivalent 
or 0.20mg/kg/day  (whiche ver is lower). Subjects with systemic onset JIA but without systemic 
symptoms for ≥[ADDRESS_42869] been stable for 
≥2weeks before screening .
No change s should be made to background medications (ie, MTX , other DMARDs , 
corticosteroids, and NSAIDs) in terms of increases or decreases in dosage (eg, no more than 
10mg/day prednisone or no more than 0.20mg/kg/day ,which ever is lower ) and/or route of 
administration between Weeks 0 and 28, unless there is a safet y concern (eg, elevated LFTs ), 
which require schanges to background medications. After Week 28, subje cts will be permitted to 
change/add MTX, other DMARD s,corticosteroids, and NSAID s, including increases or 
decreases in dosage, changes of route of administration, or discontinuations from these classes of 
agents.
Intramuscular administration of corticosteroids for the treatment of pJIA is not allowed during 
the study . Corticosteroids administered by [CONTACT_41010] A may be given as needed throughout the course of the study .
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
104
Status: Approved ,Date: 16 December 2019Every  attempt should be made to avoid the use of IV co rticosteroids. For subjects requiring short 
courses (2 weeks or less) of oral or IV corticosteroids for reasons such as proph ylactic therapy  
prior to surgery  (stress -dose corticosteroids) or therap y for limited infections, exacerbation of 
asthma, or for any condition other than pJIA, corticosteroid therapy  should be limited to 
situations in which, in the opi[INVESTIGATOR_021], there are no adequate alternatives 
and should be documented in the CRF.
Subjects may receive intra-articular injection sof a corticosteroid, if clinically  required, during 
the study up to Week 52. However, the number of intra-articular injections should be limited to 
2over any24-week period. That is, if a subject has received [ADDRESS_42870] be notified in advance (or as soon as possible thereafter) of any instances in 
which prohibited therapi[INVESTIGATOR_23730] (Section 4.3).
After Week 252, concomitant medications are documented as described in Attachment 6 .
9. STUDY EVA LUATIONS
9.1. Study Procedures
9.1.1. Overview
The Time and Events Schedule s summarize the frequency  and timing of efficacy , PK, 
immunogenicit y, and safety  measurements applicable to this study  (Table 1,Table 2, and 
Table 3). All scheduled study  visits should occur within ±3 days of the intended visit through 
Week 28 and ± [ADDRESS_42871] be recorded in source documents. After Week 252, study  procedures will be 
performed as described in Attachment 6 .
The Childhood Health Assessment Questionnaire (CHAQ) should be conducted before any tests,
procedures, or other consultations for that visit to prevent influencing subjects’ perceptions. For 
additional details, refer to the PRO user manual.   
At every  unscheduled visit ,the investigator will perform the following evaluations:
Review of s ystems (after Week 52, at the discretion of the investigator)
Vital signs (after Week 52, at the discretion of the investigator)
TB questionnaire
Adverse events
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
105
Status: Approved ,Date: 16 December 2019Review of concomitant medications (after Week 52, medications should be reviewed and 
documented in source; medications used to treat or associated with AEs and SAEs should be 
recorded on the CRF)
Safety  laboratory  evaluations (after Week 52, at the discretio n of the investigator)
Additional serum or urine pregnancy  tests may be performed, as determined necessary  by [CONTACT_41011], to establish the absence of pregnancy  at any time 
during the subject's participation in the stud y.
The total blood volume to be collected from each subject for the study  is approximately
149.4mL(Table 4). Repeat or unscheduled samples may be taken for safet y reasons or for 
technical issues with the samples.
Table 4: Approxim ate Volume of Blood to be Collected From  Each Subject Through Week 252
Type of SampleApproximate
Volume per 
Sample (mL)No. of Samples 
per SubjectApproximate
Total Volume of 
Blood ( mL)a,b
Safety (including screening and posttreatment 
assessments )
-Hem atology 1.2 17 20.4
-Serum chemistry 1.1 17 18.7
Serology (hepatitis B and hepatitis C ) 2.0 1 2.0
Serum -hCG pregnancy tests 1.1 1 1.1
-QuantiFERON®-TB Gold test 3.0 6 18.0
-Rheum atoid factor 1.1 1 1.1
-Anti-dsDNA antibody 1.1 11 12.1
-ANA antibodies 1.1 11 12.1
Efficacy (CRP) 1.1 24 26.4
PK and i mmunogenicity (antibodies to golimumab) 2.[ADDRESS_42872] during the study ;with 
implementation of Protocol Amendment 4, the volume of blood collected w ill be decreased. 
Note: An indw elling intravenous cannula may be used for blood sample collection.
Abbreviations: ANA = antinuclear antibodies; β-hCG = β -human chorionic gonadotropin ;CRP = C -reactive protein; 
dsDNA = double -stranded deoxyribonucleic acid; PK = pharmacokinetic; TB = tuberculosis. 
9.1.2. Screening Phase
After written informed consent /assent has been obtained (Section 16.2.3 ),and within a period of 
6weeks before Week 0, all screening evaluations establishing subject eligibility  will be 
performed. Subjects who meet all of the inclusion and none of the exclusion criteria will be 
enrolled in the study . Every  effort should be made to adhere to the study  Time and Events 
Schedule for each subject ( Table 1 ).
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
106
Status: Approved ,Date: [ADDRESS_42873] dose of study 
agent . The method(s) of contraception used by  [CONTACT_41012].
Subjects must undergo testing for TB (Attachment 1and Attachment 2) at screening and their 
medical history  assessment must include specific questions about a history  of TB or known 
personal exposure to individuals with active TB. The subject should be asked about past testing 
for TB, including chest radiograph results and responses to tuberculin skin or other TB testing 
(Section 4.1).
Subjects with a negative QuantiFERON®-TB Gold test result (and a negative tuberculin skin test 
result in countries in which the QuantiFERON®-TB Gold test is not approved/registered or the 
tuberculin skin is mandated by [CONTACT_41003]) are eligible to continue with screening 
procedures. Subjects with a newl y identified positive QuantiFERON®-TB Gold ( and/or 
tuberculin skin test)result must undergo an evaluation to rule out active TB and initiate 
appropriate treatment for latent TB. Appropriate treatment for latent TB is defined according to 
local country  guidelines for immunocompromised patients. If no local country  guidelines for 
immunocompromised patients exist, US guideli nes must be followed, or the subject will be 
excluded from the study .
A subject whose first QuantiFERON®-TB Gold test result is indeterminate must have the test 
repeated. In the event that the second QuantiFERON®-TB Gold test result is also indeterminate, 
the subject may be enrolled without treatment for latent TB if active TB is ruled out, their chest 
radiograph shows no abnormality  suggestive of TB (active or old, inactive TB),and the subject 
has no additional risk factors for TB as determined by [CONTACT_093]. This determination must 
be promptly  reported to the Sponsor ’s medical monitor and recorded in the subject's source 
documents and initialed by  [CONTACT_093].
Retesting of an abnormal screening value that leadsto exclusio n isallowed only once using an 
unscheduled visit during the screening period to reassess eligibility . This should only be 
considered if there is no antici pated impact on subject safet y.
9.1.3. Treatment Phase : Week 0 Through Week 28
Beginning at Week 0, eligible subjects will receive 80 mg/m2 golimumab administered as IV 
infusions over 30±10 minutes at Weeks 0, 4 and q8w ( ±3 days)through Week 28 (Section 6.1). 
Subjects will also receive commercial MTX weekl y at least through Week 28 at the same 
BSA -based dosage as at time of study  entry and commercial folic acid ≥5 mg weekl y or folinic 
acid (at half the MTX dose) given the day after the MTX dose (Section 6.2). In children 
<12years of age, the administration of folic acid or folinic acid will be at the discretion of the 
physician.
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
107
Status: Approved ,Date: [ADDRESS_42874] safety, efficacy , PK, and immunogenicity  evaluations performed according to 
the Time and Events Schedule (Table 1). One additional sample for serum golimumab 
concentration for population PK will be collected from all subjects at any time between Weeks 0 
and 8 other than at the time of the Week 0, Week 4, and Week 8 visits; this sample must be 
collected at least [ADDRESS_42875] not be collected 
at a regularl y scheduled visit (eg, Week 8) .
9.1.4. Treatment Phase: After Week 28 Through Week 52
After Week 28, subjects will continue to receive 80 mg/m2 golim umab administered as IV 
infusions over 30±10 minutes q8w (±1 week )through Week 52 (Section 6.1). Subjects may also 
receive commercial MTX weekl y at the same BSA -based dosage as at time of study  entry and 
commercial folic acid ≥5 mg weekl y or folinic acid if administered (at half the MTX dose; 
Section 6.2) given the day  after the MTX dose ;however, increases, decreases or discontinuations 
of MTX, other DMARDs, corticosteroids ,and/or NSAIDs are permissible after Week 28. All 
changes and reasons for changes for these medications need to be docum ented in the eCRF.
Subjects will have safety, efficacy , PK, and immunogenicity  evaluations performed according to 
the Time and Events Schedule ( Table 1).
End of Treatment/ Early Withdrawal
If a subject discontinues study  agent before Week 52, the subject should return approximately
8weeks after the last administration of study  agent for a final safet y follow -up visit
(Section 10.2). If a subject withdraws from study  participation before Week 52, every  effort 
should be made to obtain end-of-treatment assessments prior to the subject’s withdrawal of 
consent.
9.1.5. Long -Term Extension Phase :After Week 52 Through Week 2 52
Subjects who enter the LTE after the Week 52visit will continue to receive 80mg/m2
golimumab administered as IV infusions over 30±10 minutes q8w (±1 week) through Week 244.
Subjects will have safet y, PK, and immunogenicity  evaluations performed according to the Time 
and Events Schedule s (Table 2and Table 3). After Week 52, disease activity  will be monitored 
and assessed by [CONTACT_431]. Investigators will fill out an annual attestation form to document 
that a subject is benefiting from treatment .Subjects who discontinue study  agent administration 
prior to Week [ADDRESS_42876] study  agent infusion (Section 10.2).
Review of systems, collection of vital signs, QuantiFERON®-TB Gold testing, uveitis 
evaluation s (including slit lamp evaluations) , and chest x-ray screening will be performed at the 
discretion of the investigator ;refer to the Time and Events Schedules ( Table 2and Table 3).It is 
the responsibility  of the investigator to carry out all assessments per standard of practice and to 
update the CRF with all information related to AEs and SAEs (eg, concomitant medications).
Subjects should continue to be evaluated for signs and sy mptoms of TB (Section 9.4).
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
108
Status: Approved ,Date: 16 December [ZIP_CODE].1.6. Extende d Treatment Period
Subjects who enter the ETP after completion of the Week 252 assessments will continue to 
receive 80 mg/m2 golimumab IV q8w.
The frequency  and timing of assessments during the ETP are provided in Attachment 6 .
9.2. Efficacy
9.2.1. Evaluations
The Time and Events Schedule summarizes the frequency  and timing of efficacy  measurements 
applicable to this study  (Table 1).After Week 52, investigators will complete an attestation form 
annually  to document that the subject is benefit ingfrom treatment.
[IP_ADDRESS]. Joint Evaluation
Each of [ADDRESS_42877] PRINTO/PRCSG joint evaluation . A 
consistent joint assessor, with at least [ADDRESS_42878] enrollment; thetraining is mandatory  unless the site’s joint assessor has taken certified 
training provided by [CONTACT_40988]. If a consistent joint assessor was trained by [CONTACT_41013] a previous clinical study , he or she may receive a waiver for this training. 
Documentation of Sponsor or PRINTO/PRCSG training will be mainta ined in the Trial Center 
File. If possible, the consistent joint assessor for the study  should not be changed during the 
study . However, the assessor from each site who attends the consistent joint assessor training 
provided by [CONTACT_40989] [ADDRESS_42879] 1 or 
more years of experience as joint assessors or be approved by [CONTACT_13099] r. If the designated 
consistent joint assessor from the site trains any additional assessors at the site, a letter 
documenting the training should be filed in the site’s Trial Center File. In addition, if more than 
[ADDRESS_42880] for all subsequent visits through the 
final efficacy  assessment at Week 52.
Nonevaluable Joints
While it may be reasonable in clinical practice to identify  as “nonevaluable” any joint which in 
the past or during study participation has been surgically  altered (ie, prosthesis placement) or 
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
109
Status: Approved ,Date: 16 December 2019medically  treated (ie, intra-articular injection), the designation of “nonevaluable” for the 
purposes of this stud y is slightly  different. Joints should only  be designated as “nonevaluable” by  
[CONTACT_41014] y impossible to assess the joint 
(ie, joint inaccessible due to a cast, joint not present due to an amputation , joint deformed so as 
to make it impossible to assess).
[IP_ADDRESS]. American College of Rheumatology  Ped iatric Response
The JIA ACR 30 response criteria5is defined as a 30% improvement (ie, a decrease in score)
from baseline in at least 3 of the following 6 components, with worsening of 30% or more in no 
more than 1 of the following components:
Physician Global A ssessment of D isease Activity
Parent /Subject Assessment of Overall Well- being
Number of active joints (defined as either swelling, or in absence of swelling, limited range 
of motion associated with pain on motion or tenderness)
Number of joints with limited range of motion
Physical function by  [CONTACT_41015]
CRP
The JIA ACR 50 response, the JIA ACR 70 response, and the JIA ACR 90 response are defined 
as a 50% improvement, a 70% improvement, and a 90% improvement from baseline, 
respectivel y, in at least 3 of the above 6 components, with worsening of 30% or more in no more 
than 1 of the above components.
Inactive Disease
Inactive disease is indicated by  [CONTACT_41016]:
No joints with active arthritis
No fever, rash, serositis, splenomegal y, hepatomegaly , or generalized lymphadenopathy  
attrib utable to JIA
No active uveitis
Normal CRP (≤0.287 mg/dL  for subjects without underly ing inflammatory disease )
Physician Global Assessment of D isease Activity indicating no active disease (<5mm)
Duration of morning stiffness <15 minutes
Clinical Remission While on Medication for JIA
Clinical remission while on medication for JIA is defined as inactive disease at each visit for a 
period of ≥6 months while on medication.
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
110
Status: Approved ,Date: 16 December [ZIP_CODE].2.1.3. Physician Global A ssessment of Disease A ctivity
The Physician Global Assessment of Disease Activity  is a 100 mm VAS . Physicians are to 
complete the VAS that has them assess the patient’s current arthritis activity . Theanchors of the 
scale are “no arthritis activity ” to “extremely  active arthritis.” Lower scores indicate less disease 
activity . The process for including this measure in the core set of variables for the assessment of 
children has been captured in the literature.5
[IP_ADDRESS]. Childhood Health A ssessment Questionnaire
The functional status of subjects will be assessed by [CONTACT_41017].21Parents/subjects will complete 
this questionnaire to assess the degree of difficulty  the subject has in accomplishing tasks in 
8functional areas (dressing and grooming, arising, eating, walking, hygiene, reaching, grippi[INVESTIGATOR_007], 
and activities of daily living ).  Responses in each functional area are scored as0(without any 
difficulty ), 1 (with some difficulty ), 2 (with much difficulty ), 3 (unable to do), or 4 (not 
applicable) .  Lower scores are indicative of improved functioning and task performance in 
specific functional areas . 
Additionally , the CHAQ includes 2 VAS questions —one used to assess the subject’s level of 
pain, and one used to assess the subject’s overall well-being. Properties of the CHAQ have been 
evaluated and its validity assessed.21The CHAQ has been shown to be responsive to disease 
change.21A decrease of 0.188 h as been determined to be a meaningful clinical improvement.1
Parent/Subject Assessment of Pain
Pain will be assessed as average pain experienced by[CONTACT_41018] a 
VAS scale that ranges from “no pain” (0 mm) to “very  severe pain” (100 mm). This assessment 
should be completed by [CONTACT_7903] (caregiver)/subjects prior to the tender and swollen joint 
examination.   
Parent/Subjec t Assessment of Overall Well- being
The Parent/Subject Assessment of Overall Well- being is a 0-100 mm VAS. Parents/subjects will 
complete the VAS that asks them to consider all the way s arthritis impacts their child/themselves 
and then indicate how the subject is doing. The anchors of the scale are “very  well” (0 mm) to 
“very  poor” (100 mm) . Lower scores indicate better well-being. The process for including this 
measure in the core set of variables for the assessment of children has been captured in the 
literature.5
Subjects who are 15 to <18 yearsof ageat study  entry may complete the CHAQ jointly  with the 
parent/caregiver . Preferably , the same individual (eg, parent, caregiver, or subject) who 
completes the assessment at the start of the study  should complete the ass essment throughout the 
study . 
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
111
Status: Approved ,Date: 16 December [ZIP_CODE].2.1.5. C-reactive Protein
C-reactive protein has been demonstrated to be useful as a marker of inflammation in patients 
with pJIAand is part of the JIA ACR 30core assessments . C-reactive protein will be assay ed by 
a central laboratory  using a validated, high -sensitivity  CRP assay .
[IP_ADDRESS]. Juvenile A rthritis Disease A ctivity  Score (JA DAS)
Recently , a composite disease activity  score for pJIA, the Juvenile Arthritis Disease Activity 
Score (JADAS), was developed; in validation analyses it was found to have good metrologic 
properties, including the ability to predict disease outcome. The JADAS (modified for using 
CRP) is computed by [CONTACT_41019]: (1) physician global rating of overall 
disease activity , measured on a 100-mm horizontal VAS (0 no activity ; 100maximum activity  
for both VAS); (2) parent/child ratings of well-be ing and pain, assessed on a [ADDRESS_42881] and 100-Millimeter Horizontal Line Visual Analog Scales4;(3) number of active joints, 
assessed in 71, 27, or 10 joints (JADAS 71, JADAS 27, and JADAS 10,respectively); and 
(4)CRP was truncated toa 0 scale according to the following formula: (CRP [mg/L ]-10/10 ), 
similar to the truncated ESR used in JADAS -ESR. Before calculation, CRP values <10 mg/L are
converted to 10 and CRP values >110 mg/L are converted to 110.13
The JADAS is calculated as the sum of the scores of its 4 components, which yields a global 
score of 0 to 101, 0 to 57, and 0to 40for the JADAS 71, and JADAS 27, and JADAS 10,
respectivel y.
The state of JADAS 10,27, and 71 minimal disease activity2,11was defined as the presence of all 
of the following: P hysician Global Assessment of Disease A ctivity  of ≤3.5, parent’s global rating 
of well -being of ≤2.5, and swollen joint count of ≤1 in patients with poly arthritis.
The criteria for JADAS inactive disease is defined as a total JADAS score of ≤1.
9.2.2. Endpoints
Primary Endpoint
The primary  endpoint in this study  is PK exposure at Week 28 (the trough concentrations at 
Week 28) and the Bayesian AUCss over one dosing interval of 8 weeks (from population PK 
modeling and simulation) .
Major Secondary Endpoints
Major secondary  endpoints inc lude:
PK exposure at Week 52 (the trough concentrations at Week 52 )and the Bayesian AUCss at 
Week 52 (from population PK modeling and simulation)
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
112
Status: Approved ,Date: 16 December 2019Other E ndpoints
Other endpoints include:
The proportions of subjects who are JIA ACR 30, 50, 70, and 90 respo nders over time
The change from baseline in CHAQ over time
CRP concentrations over time
The proportion of subjects who have inactive disease over time
The proportion of subjects in clinical remission on medication for pJ IA over time
The improvement from baseline in the pJ IA core set at each visit
The proportions of subjects who are JIA ACR 30, 50, 70, and 90 responders by [CONTACT_41020], and/or age over time through Week 52
The change from baseline in JADAS 10, 27 ,and 71 scores over time
The proportion of subjects who achieve JADAS 10, 27, and 71 minimal disease activity  over 
time
9.3. Pharmacokinetics and Immunogenicity
9.3.1. Evaluations
Serum samples will be used to evaluate the PK, as well as the immunogenicity  of golimumab 
(antibodies to golimumab). Venous blood samples will be collected and each serum sample will 
be divided into 3 aliquots (1 each for pharmacokinetics, antibodies to study  drug, and a back -up).
Subject confidentiality  will be maintained. The sample should bedrawn from a different arm 
than the IV line,or if using an IVline that is also being used to deliver medication ,the line 
should be flushed and cleared of any  residual medication that may  be remaining prior to each PK 
sample being drawn. When using an IVline to draw PKsamples, the first [ADDRESS_42882] of care. At visits where serum concentration and antibodies to 
golimumab will be evaluated, 1 blood dra w of sufficient volume can be used.
9.3.2. Analytical Procedures
Pharmacokinetics
Serum samples will be analyzed to determine concentrations ofgolimumab using a validated, 
specific, and sensitive method by  [CONTACT_23788] .
Immunogenicity
The detection and characterization of antibodies togolimumab will be performed using a 
validated assay  method by [CONTACT_23788] . All samples collected for 
detection of antibodies togolimumab will also be evaluated forgolimumab serum concentration 
to enable interpretation of the antibody  data.
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
113
Status: Approved ,Date: 16 December [ZIP_CODE].3.3. Pharmacokinetic Parameters
Serum golimumab concentrations will be evaluated at Weeks 0, 4, 8, 12, 20, 28, 52, 100, 148, 
196, and 244 and summarized over time.
Pre-infusion (immediately  before infusion) and post-infusion ( 1hour after infusion) samples will 
be drawn at Weeks 0, 4,and 12,and an additional random population PK sample will be drawn 
at any time between Weeks [ADDRESS_42883] be flushed and cleared of any residual medication that may be remaining 
and 1 mL of blood should be drawn and dis carded prior to obtaining the sample if using the same 
access line as was used for drug administration.
A population PK anal ysiswith data through Week 28 will be performed to characterize the PK of 
golimumab as well as to identify  important covariates of PK in the pediatric population with 
pJIA. Additionally  the population PK model will be used to assess the similarity  of the PK in 
pediatrics and adults. The clearance and volume of distribution will be estimated using a 
NONMEM approach. In addition, an exp osure -response analysis will be performed toexplore 
andcharacterize the relationship between exposure and efficacy .
9.3.4. Immunogenicity  Assessments (Antibodies to Golimumab)
Antibodies togolimumab will be evaluated in serum samples collected from all subject s 
according to the Time and Events Schedule (ie, Weeks 0, 4, 8, 12, 28, 52,100, 148, 196, and 
244). Additionally , serum samples should also be collected at the final visit from subjects who 
are discontinued from treatment or withdrawn from the study . These samples will be tested by 
[CONTACT_13679] 's designee.
Serum samples will be screened for antibodies binding togolimumab and the titer of confirmed 
positive samples will be reported. Other analy ses may be performed to verify  the stability  of 
antibodies to golimumab and/or further characterize the immunogenicity  ofgolimumab .
The incidence of antibodies to golimumab during the study  will be determined.
9.4. Safety  Evaluations
Any clinically  relevant changes occurring during the study must be recorded on the Adverse 
Event section of the CRF.
Any clinically  significant abnormalities persisting at the end of the study/earl y withdrawal will 
be followed b y the investigator until resolution or until a clinically  stable endpoint is reached.
The study  will include the following evaluations of safet y and tolerability  according to the time 
points provided in the Time and Events Schedule s:
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
114
Status: Approved ,Date: [ADDRESS_42884] (or, when appropriate, by a caregiver, surrogate, 
or the subject's legall yacceptable representative) for the duration of the study . Adverse events 
will be followed by  [CONTACT_23803] 12, Adverse Event Reporting.
Clinical Laboratory Tests
Blood samples for serum chemistry  and hematology  will be collected. The investigator must 
review the laboratory  report, document this review, and record any clinically  relevant changes 
occurring during the study  in the adverse event section of the CRF. The laboratory  reports must 
be filed with the source documents.
The following tests will be performed by [CONTACT_2237] :
Hematology  Panel
-hemoglobin -WBC (neutrophils, lymphocy tes, monocy tes, 
eosinophils, basophils [%, absolute])
-hematocrit -platelet count
-RBC -mean corpuscular volume
-mean corpuscular hemoglobin -mean corpuscular hemoglobin concentration 
-RBC morphology -WBC morphology  (if present)
Serum Chemistry  Panel
-sodium -total bilirubin
-potassium -bilirubin (direct and indirect)
-urea nitrogen -calcium
-creatinine -phosphorous
-glucose -albumin
-AST -total protein
-ALT 
-alkaline phosphatase -uric acid
-bicarbonate -chloride
Serum pregnancy  testing for girls of childbearing potential will be conducted at screening.
Urine pregnancy  testing for girls of childbearing potential will be performed according to 
the Time and Events Schedules.
Additional serum or urine pregnancy  tests may beperformed, as determined necessary  by 
[CONTACT_31837], to establish the absence of pregnancy  
throughout the stud y.
Serology for hepatitis B surface antigen (HBsAg), hepatitis B surface antibody  (anti-HBs), 
and hepatitis B core antibody  (anti -HBc total) at screening .
Serology  for HCV antibody  at screening.
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
115
Status: Approved ,Date: 16 December 2019Vital Signs
Pulse /heart rate, respi[INVESTIGATOR_2842], temperature, and blood pressure measurements will be 
performed according to the Time and Events Schedule s (Table 1 , Table 2, and Table 3).
Vital signs should be taken pre-infusion; at 15 and 30 minutes (15-minute intervals during the 
infusion); and at 60 and 90 minutes (during the 1 -hour observation period following the infusion)
through Week 52 .After Week 52, vital signs should be taken at the discretion of the investigator.
Physical Examination
Physical examinations, including a skin exam at every  physical examination and Tanner staging
for sexual maturit y will be performed (through Week 52 only ) according to the Time and Events 
Schedule. Review of sy stems will be performed at all visits through Week [ADDRESS_42885]/optometrist through Week 52 at intervals (based on JIA subty pe, ANA test 
results, age at JIA onset, and JIA duration) as specified in Attachment 5. After Week 52, slit 
lamp evaluations will be performed at the discretion of the investigator and per standard of care.
If a subject develops uveitis during the study , the subje ct’s continued participation in the study  is 
at the discretion of the investigator and Sponsor.
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
116
Status: Approved ,Date: 16 December 2019Infusion Reaction Evaluations
Before an infusion is started, the appropriate personnel, medications (eg, epi[INVESTIGATOR_238], inhaled 
beta agonists, antihistamines andcorticosteroids), and other requirements to treat anaphy laxis 
should be available. The subject may be premedicated with prophy lactic drugs 
(eg,diphenh ydramine) prior to starting the infusion based on investigator’s discretion but this is 
not mandatory . However, corticosteroids for prophy laxis are not allowed. Premedications should 
be recorded in the eCRF.
The investigator or qualified designee will evaluate the subject for infusion reactions accordin g 
to the Time and Events Schedule.
An infusion reaction is any unfavorable or unintended sign that occurs during the infusion or 
within [ADDRESS_42886] should be treated at the investigator’s discretion.
The investigator will record the infusion reaction in the AE page. If no infusion reaction is 
observed, the investigator will note this in the subject’s medical records (source data).
Allergic Reactions
Throug h Week 52, all subjects must be observed carefully  for symptoms of an allergic reaction 
(eg, urticaria, itching, hives) for at least [ADDRESS_42887] be observed carefully  for symptoms of an allergic reaction at the 
discretion of the investigator after completion of the infusion. If mild or moderate allergic 
reaction is observed, acetaminophen or NSAIDs and diphenh ydramine at approved pediatric
doses may  be administered.
Subjects with severe reactions following an infusion that result in bronchospasm with 
wheezing and/or dyspnea and require ventilatory support , or symptomatic hypotension 
with a decrease in systolic blood pressure greater than 40 mm mercury (Hg) ,will not be 
permitted to receive any additional study agent infusions. In the case of such reactions, 
appropriate medical treatment should be administered.
Early Detection of Active T uberculosis
To aid in the early detection of TB, reactivation, or new TB infection during study  participation, 
subjects must be evaluated for signs and symptoms of active TB at scheduled visits (refer to 
Time and Events Schedule) or by [CONTACT_41021] 8 to 12 weeks through 
Week 252. After Week 252, TB evaluation will be carried out at investigator discretion and 
according to local and country  guidelines for immunosuppressed patients . The following series 
of questions is suggested for use during the evaluation.
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
117
Status: Approved ,Date: 16 December 2019“Has your child had a new cough of >14 day s’ duration or a change in a chronic cough?”
“Has your child had an y of the following s ymptoms ”:
Persistent fever?
Unintentional weight loss?
Night sweats?”
“Has your child had close contact [CONTACT_41022]?” (If there is 
uncertaint y as to whether a contact [CONTACT_41023] “close,” a physician specializing in 
TB should be consulted.)
If the evaluation raises suspi[INVESTIGATOR_40958] a subject may have TB reactivation or new TB infection, 
study  agent administrat ion should be interrupted and an immediate and thorough investigation 
should be undertaken, including, where possible, consultation with a physician specializing in 
TB.
Investigators should be aware that TB reactivation in immunocompromised subjects may  present 
as disseminated disease or with extrapulmonary  features. Subjects with evidence of active TB 
must immediately  discontinue study  agent and should be referred for appropriate treatment.
QuantiFERON®-TB Gold (andtuberculin skin)testing at Week [ADDRESS_42888] radiograph, a repeat QuantiFERON®-TB Gold test, a repeat 
tuberculin skin test in countries in which the QuantiFERON®-TB Gold test is not
approved/registered, and, if possible, referral to a physician specializing in TB to determine the 
subject’s risk of developi[INVESTIGATOR_40959]. The 
QuantiFERON®-TB Gold test (andtuberculin skin test )does not need to be repeated for subjects 
with a history  of latent TB, and ongoing treatment for latent TB,or documentation of having 
completed adequate treatment for TB. If the QuantiFERON®-TB Gold test result is 
indeterminate, the test should be repeated as outlined in Section 9.1.[ADDRESS_42889] be recorded in the CRF or laboratory 
requisition form.
Refer to the T ime and Events Schedule for the timing and frequency  of all sample collections.
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
118
Status: Approved ,Date: [ADDRESS_42890] COMPLETION/W ITHDRA WAL
Subject completion/withdrawal during the ETP is d escribed in Attachment [ADDRESS_42891]'s study  treatment must be discontinued before the end of the treatment regimen, this 
will not result in automatic withdrawal of the subject from the stud y.
A subject's study  treatment should bepermanentl ydiscontinue d ifanyof the following occur:
The investigator believes that for safet y reasons (eg,adverse event) it is in the best interest 
of the subject to discontinue study treatment .
The subject becomes pregnant.
Reaction resulting in bronchospasm (both new- onset study  agent-related and severe 
exacerbation of pre -existing asthma) with and without wheezing, and/or dyspnea requiring 
ventilatory  support, and/or symptomatic hypotension that occurs following a study  agent 
administration.
Reaction resulting in myalgia and/or arthralgia with fever and/or rash (suggestive of serum 
sickness and not representative of signs and symptoms of other recognized clinical 
syndromes) occurring 1 to 14 days after an infusion of study  agent. These may be 
accompanied by [CONTACT_41024], facial, hand, or lip edema, dysphagia, 
urticaria, sore throat, and/or headache.
Opportunistic infection.
Malignancy .
The subject develops congestive heart failure at any  time during the tri al.
Demy elinating disease.
The subject withdraws consent for administration of study  agent.
The initiation of protocol -prohibited medications.
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
119
Status: Approved ,Date: 16 December 2019Subject is deemed ineligible according to the following TB screening criteria .
A diagnosis of active TB is made.
A subject has symptoms suggestive of active TB based on follow -up assessment 
questions and/or physical examination, or has had recent close contact [CONTACT_4490] a person 
with active TB, and cannot or will not continue to undergo additional evaluation.
A subject undergoing evaluation has a chest radiograph with evidence of current active 
TB and/or a positive QuantiFERON®-TB Gold test result (or a positive tuberculin skin 
test result in countries in which the QuantiFERON®-TB Gold test is not 
approved/registered or the tuberculin skin test is mandated by [CONTACT_41003]), 
unless active TB can be ruled out and appropriate treatment for latent TB can be 
initiated prior to the next administration of study agent and continued to completion. 
Indeterminate QuantiFER ON®-TB Gold test results should be handled as in 
Section 9.1.2 . Subjects with persistently  indeterminate QuantiFERON®-TB Gold test 
results may continue without treatment for latent TB if active TB is ruled out, their 
chest radiograph shows no abnormalit y suggestive of TB (active or old, inactive TB) 
and the subject has no additional risk factors for TB as determined by [CONTACT_093]. 
This determination must be promptly  reported to the Sponsor’s medical monitor and 
recorded in the subject's source documents and initialed by  [CONTACT_093].
A subject receiving treatment for latent TB discontinues this treatment prematurely  or is 
noncompliant with the therap y.
All subjects who discontinue study  agent infusion s during the study  will be followed for 
approximately  [ADDRESS_42892] infusion is administered.
Note: The visit that is approximately [ADDRESS_42893] study agent infusions is referred 
to as the “final safety follow -up visit,” which may occur at a scheduled or an unscheduled 
visit.
Subjects who discontinue study  agent infusions but do not terminate study  participation will have 
the following assessments performed at the final safet y follow- up visit:
Safety  evaluation including AE review , TB evaluation, and the collection of a blood sample 
for routine laboratory  analy ses,determination of the presence of ANA/anti -double -stranded 
deox yribonucleic acid (dsDNA )antibodies, and antibodies to golimumab ;after Week 52, 
other safet y evaluations are performed at the discretion of the investigator (vital signs, 
review of s ystems, uveitis evaluation).
Concomitant medication review (after Week 52, medications should be reviewed and
documented in subject’s sourcerecords ; medications used to treat or associated with AEs 
and SAEs should be recorded in the source document as well as the CRF) .
Efficacy  evaluations (joint assessment s,JIA assessments, and collection of blood sample for 
CRP )through Week 52 only .
Blood samples drawn for measurement of golimumab concentration for all subjects at the 
final safet y follow- up visit.
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
120
Status: Approved ,Date: [ADDRESS_42894] will be withdrawn from the stud y for any of the following reasons:
Lost to follow -up
Withdrawal of consent
Death
If a subject discontinues study  treatment before the end of the study , end-of-treatment 
assessments should be obtained approximately [ADDRESS_42895] and determine the reason for discontinuation/withdrawal. The measures 
taken to follow -up must be documented.
When a subject withdraws before completing the study , the reason for withdrawal is to be 
documented in the CRF and in the source document. Study  drug assigned to the withdrawn 
subject may  not be assigned to another subject. Subjects who withdraw will not b e replaced.
If a subject withdraws from the study  before the end of the study , end-of-treatment assessments 
should be obtained prior to the withdrawal of consent.
11. STATISTICA L METHODS
Statistical analy sis will be done by [CONTACT_23815] . A general 
description of the statistical methods to be used to anal yze the efficacy  and safet y data is outlined 
below. Specific details will be provided in the Statistical Analy sis Plan.
In general, descriptive statistics, such as mean, median, standard deviation, interquartile range, 
minimum and maximum for continuous variables, and counts and percentages for categorical 
variables will be used to summarize data.
11.1. Subject Information
All subjects who are enrolled in th e study  will have baseline descriptive statistics provided.
Subject baseline data, demographic and baseline disease characteristics will be summarized. The 
baseline measurement is defined as the closest measurement taken before the time of the Week [ADDRESS_42896] 
received study  agent administration. Pharmacokineti c data will be summarized for all subjects 
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
121
Status: Approved ,Date: [ADDRESS_42897] a sample size that will be sufficient to build a population PK and,
if feasible ,an exposure -response model. Additionally , a sample size that will provide reasonable 
safet y assessments was also taken into consideration. With these considerations, a sample s ize of 
approximately  120 subjects has been chosen assuming that if 20 subjects were to drop out or if 
they do not provide PK samples, a sample size of approximately  100 subjects is thought to be 
sufficient to build a population PK model, given the sparse sampling of PK time points, as well 
as provide 1 year of safety  data from approximately  100 subjects.
11.3. Efficacy  Analyses
Primary Endpoint Analysi s
No primary  efficacy  endpoint analy sis is planned.
Major Secondary Endpoints Analyses
No major secondary  efficacy  endpoints analysesare planned.
Other E fficacy Endpoints
The following will be summarized for all su bjects enrolled in the study :
The proportion of subjects who are J IA ACR 30, 50, 70 ,and 90 responders over time
The proportion of subjects who hav e inactive disease over time
The proportion of subjects in clinical remission on medication for pJIA (ACR criteria) over 
time
The improvement from baseline in the pJIA core set over time
The proportions of subjects who are JIA ACR 30, 50, 70, and 90 respon ders by [CONTACT_41020], and/or age over time through Week 52
The change from baseline in CHAQ over time
CRP concentrations over time
The change from baseline in JADAS 10, 27 ,and 71 scores over time
The proportion of subjects who achieve JADAS 10, 27, and 71 minimal disease activity  over 
time
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
122
Status: Approved ,Date: 16 December 201911.4. Pharmacokinetic Analyses
The primary  objective of this study  is to characterize golimumab PK exposure (the trough 
concentrations at Weeks 28 and the Bayesian AUCss over adosing interval of 8 weeks from 
population PK modeling and simulation) in the pJIA population.
Serum golimumab concentrations will be summarized over time. In addition, a population PK 
analysis on data through Week 28 will be performed to characterize the PK of golimumab as 
well as to identify  and qua ntify  important covariates of PK in the pediatric population with pJIA. 
Clearance and volume of distribution will be estimated using a NONMEM approach. Details will
be provided in a population PK analy sis plan and the results of the anal ysis will be p resen ted in a 
separate report.
Measures of PK exposure will begraphically evaluated in the pediatric populations after 
administration of IV golimumab (including but not limited to steady -state Cmax, Cminand AUC ) 
and compared to PK exposure from adults in CNTO148ART3001. Similarity between pediatric 
and adult subjects will be assessed by [CONTACT_41025].
Summary  golimuma b concentrations will be summarized and PK exposure will be evaluated 
through Week [ADDRESS_42898] appropriate samples 
collected for detection of antibodies to golimumab (ie, subjects with at least [ADDRESS_42899] golimumab administration).
11.6. Pharmacokinetic/Pharmacody namic Analyses
The relati onships between serum golimumab concentration and efficacy will be explored. A
suitable PK/PD model will be explored and developed to describe the exposure -response 
relationship.
11.7. Safety  Analyses
Adverse Events
The verbatim terms used in the CRF by [CONTACT_41026] (MedDRA). All reported adverse events 
with onset during the treatment phase (ie, treatment -emergent adverse events, and adverse events 
that have worsened since baseline) will be included in the analysis. For each adverse event, the 
percentage of subjects who experience at least 1occurrence of the given event will be 
summarized by  [CONTACT_1570].
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
123
Status: Approved ,Date: [ADDRESS_42900] narratives may be provided, as appropriate, for those 
subjects who die, who discontinue treatment due to an adverse event, or who experience a severe 
or a serious adverse event.
The following analyseswill be used to assess the safet y of subjects in this trial:
The occurren ce and t ype of AEs
The occurrence and t ype of SAEs
The occurrence and type of reasonably  related AEs
The occurrence of infusion reactions
The occurrence of ANA and anti -dsDNA antibodies
The occur rence of antibodies to golimumab
The occurrence of markedly  abnormal laboratory  (hemat ology  and chemistry ) parameters
Clinical Laboratory Tests
Laboratory  data will be summarized by [CONTACT_23821]. Reference ranges and markedl y 
abnormal results (specified in the Statistical Analy sis Plan) will be used in the summary  of 
laboratory  data. Changes from baseline results will be presented in pre-versus posttreatment
cross -tabulations (with classes for below, within, and above normal ranges). Frequency 
tabulations of the abnormalities will be made. A listing of subjects with any markedl y abnormal 
laboratory  results will also be provided.
Vital Signs
Descriptive statistics of pulse/heart rate, respi[INVESTIGATOR_2842], temperature, and blood pressure 
(systolic and diastolic) values and changes from baseline will be summar ized at each scheduled 
time point in the Schedule of Events.
11.8. Interim A nalysis
No interim anal ysis is planned.
11.9. Data Monitoring Committee
This is an open -label study , with all subjects receiving the same dosage of IV golimumab. 
Therefore, an external Data Monitoring Committee will not be utilized. Safet ydata will be 
routinely  evaluated by [CONTACT_1758] ’s medical monitor and Sponsor’s internal Safet y Management 
Team as needed. In addition, the data may  be reviewed by  [CONTACT_41027] .
12. ADVERSE EVENT REPORT ING
Timely, accurate, and complete reporting and analy sis of safety  information from clinical studies 
are crucial for the protection of subjects, investigators, and the Sponsor , and are mandated by 
[CONTACT_23824]. The Sponsor has established Standard Operating Procedures in 
conformity  with regulatory  requirements worldwide to ensure appropriate reporting of safet y 
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
124
Status: Approved ,Date: 16 December 2019information; all clinical studies conducted by [CONTACT_23825].
12.1. Definitions
12.1.1. Adverse Event Definitions and Classifications
Adverse Event
An adverse event is any untoward medical occurrence in a clinical study  subject administered a 
medicinal (investigational or non-investigational) product. An adverse event does not necessaril y 
have a causal relationship with the treatment. An adverse event can therefore be any  unfavorable
and unintended sign (including an abnormal finding), sy mptom, or disease temporally  associated 
with the use of a medicin al (investigational or non-investigational) product, whether or not 
related to that medicinal (investigational or non-investigational) product. (Definition per 
International Conference on Harmonisation [I CH])
This includes any occurrence that is new in ons et or aggravated in severit y or frequency  from the 
baseline condition, or abnormal results of diagnostic procedures, including laboratory  test 
abnormalities.
Note: The Sponsor collects adverse events starting with the signing of the ICF (refer to 
Section 12.3.[ADDRESS_42901] adverse event recording).
Serious Adverse Event
An SAE based on ICH and European Union Guidelines on Pharmacovigilance for Medicinal 
Products for Human Use is any  untoward medical occurrence that at an y dose:
Results in death
Is lifethreatening (The subject was at risk of death at the time of the event. It does not refer 
to an event that hypothetically might have caused death if it were more severe )
Requires inpatient hospi[INVESTIGATOR_1081]
Results in persistent or significant disability /incapacity
Is a congenital anomal y/birth defect
Is a suspected tran smission of any  infectious agent via a medicinal product
Is Medicall y Important*
*Medical and scientific judgment should be exercised in deciding whether expedited reporting is 
also appropriate in other situations, such as important medical events that may not be 
immediately  life threatening or result in death or hospi[INVESTIGATOR_23738]. 
These should usually  be considered serious.
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
125
Status: Approved ,Date: 16 December 2019If a serious and unexpected adverse event occurs for which there is evidence suggesting a causal 
relationship between the study  drug and the event (eg, death from anaph ylaxis), the event must 
be reported as a serious and unexpected suspected adverse reaction even if it is a component of 
the study  endpoint (eg, all -cause mortalit y).
Unlisted (Unexpected) Adverse Event/Reference Safety Information
An adverse event is considered unlisted if the nature or severity  is not consistent with the 
applicable product refere nce safet y information. Forgolimumab , the expectedness of an adverse 
event will be determined by  [CONTACT_41028] I nvestigator's Brochure.
For MTX , which hasa marketing authorization, the expectedness of an adverse event will be 
determined b y whether or not it is listed in the package label supplied by  [CONTACT_33641]’s manufacturer 
in that country .
Adverse Event Associated With the Use of the Drug
An adverse event is considered associated with the use of the drug if the attribution is possible, 
probable, or very  likel yby [CONTACT_23826] 12.1.2 .
12.1.2. Attribution Definitions
Not Related
An adverse event that is not related to the use of the drug.
Doubtful
An adverse event for which an alternative explanation is more likely, eg,concomitant drug(s), 
concomitant disease(s), or the relationship in time suggests that a causal relationship is unlikely .
Possible
An adverse event that might be due to the use of the drug. An alternative explanation, 
eg,concomitant drug(s), concomitant disease(s), is inconclusive. The relationship in time is 
reasonable; ther efore, the causal relationship cannot be excluded.
Probable
An adverse event that might be due to the use of the drug. The relationship in time is suggestive 
(eg,confirmed by [CONTACT_23827]). An alternative explanation is less likely , eg,concomitant 
drug(s) , concomitant disease(s).
Very Likely
An adverse event that is listed as a possible adverse reaction and cannot be reasonabl y explained 
by [CONTACT_4867], eg,concomitant drug(s), concomitant disease(s). The relationship 
in time is very  suggest ive (eg, it is confirmed b y dechallenge and rechallenge).
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
126
Status: Approved ,Date: 16 December 201912.1.3. Severity Criteria
An assessment of severity  grade will be made using the following general categorical 
descriptors:
Mild : Awareness of symptoms that are easily tolerated, causing minimal discomfort and not 
interfering with every day activities.
Moderate : Sufficient discomfort is present to cause interference with normal activity .
Severe : Extreme distress, causing significant impairment of functioning or incapacitation. 
Prevents normal every day activit ies.
The investigator should use clinical judgment in assessing the severit y of events not directly  
experienced b y the subject (eg, laboratory  abnormalities).
12.2. Special Reporting Situations
Safety  events of interest on a Sponsor study  drugthat may require expedited reporting and/or 
safet y evaluation include, but are not limited to:
Overdose of a Sponsor study  drug
Suspected abuse/misuse of a Sponsor study  drug
Inadvertent or accidental exposure to a Sponsor study  drug
Any failure of expected pharmacologic action (ie, lack of effect) of a Sponsor study  drug
Unexpected therapeutic or clinical benefit from use of a Sponsor study  drug
Medication error involving a Sponsor product (with or without subject/patient exposure to 
the Sponsor study  drug , eg, name [CONTACT_2976])
Special reporting situations should be recorded in the CRF. Any special reporting situation that 
meets the criteria of a serious adverse event should be recorded on the serious adverse event page 
of the CRF.
12.3. Proc edures
12.3.1. All Adverse Events
All adverse events and special reporting situations, whether serious or non-serious, will be 
reported from the time a signed and dated ICFis obtained until completion of the subject's last 
study -related procedure (which may include contact [CONTACT_20687] -up of safety ).Serious adverse 
events, including those spontaneously  reported to the investigator within 30days of the end of 
the study , must be reported using the Serious Adverse Event Form. The Sponsor will evaluate 
any safety information thatis spontaneously  reported by [CONTACT_41029].
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
127
Status: Approved ,Date: [ADDRESS_42902] be recorded using medical terminology  in the source document and the CRF. Whenever 
possible, diagnoses should be given when signs and symptoms are due to a common etiology 
(eg,cough, runny nose, sneezing, sore throat, and head congestion should be reported as "upper 
respi[INVESTIGATOR_23739]"). Investigators must record in the CRF their opi[INVESTIGATOR_23740] . All measures required for adverse event 
management must be recorded in the source document and reported according to Sponsor
instructions.
The Sponsor assumes responsibility  for appropriate reporting of adverse events to the regulatory 
authorities. The Sponsor will also report to the investigator (and the head of the investigational
institute where required) all serious adverse events that are unlisted (unexpected) and associated 
with the use of the study  drug. The investigator (or Sponsor where required) must report these 
events to the appropriate Independent Ethics Committee/I nstitutional Review Board (IEC/IRB) 
that approved the protocol unless otherwise required and documented b y the IEC/I RB.
For all studies with an outpatient phase, including open -label studies, the subject must be 
provided with a "wallet (study )card" and instructed to carry  this card with them for the duration 
of the study  indicating the following:
Study number
Statement, in the local language(s), that the subject is participating in a clinical study
Investigator's name [INVESTIGATOR_1238] 24-hour contact [CONTACT_23828]
Local Sponsor 's name [INVESTIGATOR_1238] 24-hour contact [CONTACT_23828] (for medical staf f onl y)
Site number
Subject number
Any other information that is required to do an emergency  breaking of the blind
12.3.2. Serious A dverse Events
All serious adverse events occurring during thestudymust be reported to the appropriate 
Sponsor contact [CONTACT_41030] [ADDRESS_42903] be completed and signed by a physician from the study  site, 
and transmitted to the Sponsor within 24 hours. The initial and follow -up reports of a serious 
adverse event should be made b y facsimile ( fax).
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
128
Status: Approved ,Date: [ADDRESS_42904]'s participation in the study , must be followed until 
any of the following occurs:
The event resolves
The event stabilizes
The event returns to baseline, if a baseline value/status is available
The event can be attributed to agents other than the study  drug or to factors unrelated to 
study  conduct
It becomes unlikely  that any additional information can be obtained (subject or health care 
practitioner refusal to provide additional information, lost to follow -up after demonstration 
of due diligence with follow- up ef forts)
Suspected transmission of an infectious agent by a medicinal product will be reported as a 
serious adverse event. Any event requiring hospi[INVESTIGATOR_059] (or prolongation of hospi[INVESTIGATOR_059]) 
that occurs during the course of a subject's participation in a study  must be reported as a serious 
adverse event , except hospi[INVESTIGATOR_23741]:
Hospi[INVESTIGATOR_40960] e event (eg, social reasons 
such as pending placement in long -term care facility )
Surgery  or procedure planned before entry  into the study  (must be documented in the CRF ). 
Note: Hospi[INVESTIGATOR_23743], and where the 
underly ing condition for which the hospi[INVESTIGATOR_23744] ,will not 
be considered serious adverse events. Any  adverse event that results in a prolongation of the 
originall y planned hospi[INVESTIGATOR_23745] a new serious adverse event.
The cause of death of a subject in a study  within [ADDRESS_42905] be reported to the Sponsor by [CONTACT_41031] 24 hours of their knowledge of the event using the appropriate pregnancy  notification 
form. Abnormal pregnancy  outcomes (eg, spontaneous abortion, stillbirth, and congenital 
anomaly ) are considered serious adverse events and must be reported using the Serious Adverse 
Event Form. Any subject who becomes pregnant during the study  must disc ontinue further study 
treatment .
Because the effect of the study  drug on sperm is unknown, pregnanci es in partners of male subjects 
included in the study  will be reported by [CONTACT_41032] 24 hours of their 
knowledge of the event using the appropriate pregnancy  notification form.
Follow -up information regarding the outcome of the pregnan cy and any  postnatal sequelae in the 
infant will be required .
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
129
Status: Approved ,Date: [ADDRESS_42906] administration of 
study  agent(s) in subjects participating in this clinical study  must be reported by [CONTACT_41033] 12.3. Investigators are also advised that active TB is 
considered a reportable disease in most countries. These events are to be considered serious only 
if they  meet the definition of a serious adverse event.
12.5. Contact[CONTACT_23830] (and corresponding telephone numbers) of the individuals who should be contacte d 
regarding safet y issues or questions regarding the study  are listed on the Contact [CONTACT_23832](s), which will be provided as a separate document.
13. PRODUCT QUA LITY COMP LAINT HA NDLING
A product qualit y complaint (PQC) is defined as any suspi[INVESTIGATOR_1884] a product defect related to 
manufacturing, labeling, or packaging, ie, any dissatisfaction relative to the identity , quality ,
durability , or reliabilit y of a product, including its labeling or package integrity . A PQC may  have 
an impact on the safet y and ef ficacy  of the product. T imely , accurate, and complete reporting and 
analysis of PQC information from studies are crucial for the protection of subjects, investigators, 
and the Sponsor , and are mandated by [CONTACT_23824]. The Sponsor has 
estab lished procedures in conformity  with regulatory  requirements worldwide to ensure 
appropriate reporting of PQC information; all studies conducted by [CONTACT_41034].
13.1. Procedures
All initial PQCs must be reported to the Sponsor by [CONTACT_41032] [ADDRESS_42907] report the 
PQC to the Sponsor according to the serio us adverse event reporting timelines (refer to 
Section 12.3.2 , Serious Adverse Events). A sample of the suspected product should be
maintained for further investigation if requested by  [CONTACT_1034] .
13.2. Contact[CONTACT_23834] (and corresponding telephone numbers) of the individuals who should be contact[CONTACT_41035](s), which will be 
provided as a separate document.
14. STUDY DRUG INFORMA TION
14.1. Physical Description of Study Drug
Thetest product, golimumab, will be supplied as a sterile liquid for IV infusion at a volume of 
4mL (50mg, 12.5 mg/mL) in single -use vials. Each vial will contain golimumab in an aqueous 
medium of histidine, sorbitol and polysorbate 80 at pH 5.5. No preservatives are present. It will 
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
130
Status: Approved ,Date: 16 December 2019be manufactured and provided under the responsibility  of the Sponso r.Refer to the Investigator's 
Brochure for a list of excipi[INVESTIGATOR_840].
MTX (oral or injectabl e) will not be supplied by [CONTACT_41036] a 
commercial pharmacy .
14.2. Packaging
The study  drug will be packaged in individual subject kits. Each kit will consist ofa single vial
packaged within a carton. The packaging is not child -resistant. Both vials and cartons will have a 
booklet label containing local language translations as required for participating countries.
14.3. Labeling
Study  drug labe ls will contain information to meet the applicable regulatory requirements.
14.4. Preparation, Handling, and Storage
Liquid study  agent in glass vials will be supplied ready to use. At the study  site, vials of 
golimumab solution must be stored in a secured refrigerator atcontrolled temperatures ranging 
from 2°C to 8°C (35.6°F to 46.4°F).
The study  agent IV infusions will be prepared according to the subject’s BSA . Details on the 
preparation and storage of study  material are provided in the Pharmacy Manual.
Prepa ration, handling, and storage of study  agent during the ETP is described in Attachment [ADDRESS_42908] be 
documented on the drug accountability  form. All study  drug will be stored and disposed of 
according to the Sponsor 's instructions. Study site personnel must not combine contents of the 
study  drug containers.
Study  drug must be handled in strict accordance with the protocol and the container label, and 
must be stored atthe study  site in a limited -access area or in a locked cabinet under appropriate 
environmental conditions. Unused study  drugmust be available for verification by [CONTACT_1034] 's 
study  site monitor during on-site monitoring visits. The return to the Sponsor of unused study  
drug will be documented on the drug return form. When the study  site is an authorized 
destruction unit and study  drug supplies are destroy ed on-site, this must also be documented on 
the drug return form.
Potentially  hazardous materials such as used ampules, needles, syringes and vials containing 
hazardous liquids, should be disposed of immediately  in a safe manner and therefore will not be 
retained for drug accountability  purposes.
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
131
Status: Approved ,Date: 16 December 2019Study  drug should be dispensed under the supervision of theinvestigator or a qualified member 
of the study site personnel , or b y a hospi[INVESTIGATOR_307]/clinic pharmacist. Study  drug will be supplied onl y to 
subjects participating in the study . Returned study drug must not be dispensed again, even to the 
same subject. Study  drug may not be relabeled or reassigned for use by [CONTACT_23837]. The 
investigator agrees neither to dispense the study  drug from, nor store it at, any site other than the 
study  sites agreed upon with the Sponsor .
Drug accountabilit y during the ETP is desc ribed in Attachment [ADDRESS_42909] the following supplies:
Investigator Brochure
Trial Center File
Investigational Product Manual
Laboratory  manual and la boratory  supplies
ePRO device and user manual
Interactive voice /web response sy stem m anual
Electronic data capture (eDC)Manual (including on -line access)
Sample I CF and sample assent form
Subject participation cards (ie, wallet cards)
16. ETHICA L ASPECTS
16.1. Study -Specific Design Considerations
Potential subjects will be fully informed of the risks and requirements of the study  and, during the 
study , subjects will be given any new information that may affect their decision to continue 
participation. They  will be told that their consent to participate in the study  is voluntary  and may  be 
withdrawn at any time with no reason given and without penalt y or loss of benefits to which they 
would otherwise be entitled. Only subjects who are fully able to understand the risks, benefits, and 
potential adverse events of the study , and provide their consent voluntaril y will be enrolled.
When referring to the signing of the ICF, the terms legal guardian and legall y acceptable 
representative refer to the legall y appointed guardian of the child with authorit y to authorize 
participation in research. For each subject, his or her parent(s) (preferabl y both parents, if 
available) or a legally  acceptable representative(s), as required by [CONTACT_427], must give 
written consent (permission) according to local requirements after the nature of the study  has been 
fully explained and before the performance of any study-related assessments. Assent must be 
obtained from children (minors) capable of understanding the nature of the study ,typi[INVESTIGATOR_1306] y subjects 
[ADDRESS_42910] provided consent (and assent as applicable) refers to the subjects 
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
132
Status: Approved ,Date: 16 December 2019and his or her parent(s) or the subject's legal guardian(s) or legall y acceptable representative(s) 
who have provided consent according to this process. Minors who assent to a study  and later 
withdraw that assent should not be maintained in the study  against their will, even if their paren ts 
still want them to participate.
The total blood volume to be collected isconsidered to benormal for this study  population
(ie,pediatric subjects with >15kg body  weight) and does not exceed >1% of the subject’s blood 
volume per visit.
16.2. Regulatory  Ethics Compliance
16.2.1. Investigator Responsibilities
The investigator is responsible for ensuring that the study  is performed in accordance with the 
protocol, current ICH guidelines on Good Clinical Practice (GCP), and applicable regulatory  and 
country -specific requirements.
Good Clinical Practice is an international ethical and scientific qualit y standard for designing, 
conducting, recording, and reporting studies that involve the participation of human subjects. 
Compliance with this standard provides public as surance that the rights, safety , and well -being of 
study  subjects are protected, consistent with the principles that originated in the Declaration of 
Helsinki ,and that the study  data are credible.
16.2.2. Independent Ethics Committee or Institutional Review  Board
Before the start of the study , the investigator (or Sponsor where required) will provide the 
IEC/IRB with current and complete copi[INVESTIGATOR_23747] (as required by [CONTACT_13125]) :
Final protocol and, if applicable, amendments
Sponsor -approved ICF(and any  other written materials to be provided to the subjects)
Investigator's Brochure (or equivalent information) and amendments/addenda
Sponsor -approved subject recruiting materials
Information on compensation for study -related injuries or payment to subjects for 
participation in the study , if applicable
Investigator's curriculum vitae or equivalent information (unless not required, as 
documented b y the IEC/IRB)
Information regarding funding, name [CONTACT_19618] , institutional affiliations, other potential 
conflicts of interest, and incentives for subjects
Any other documents that the I EC/IRB requests to fulfill its obligation
This study will be undertaken only after the IEC/I RB has given full approval of the final 
protocol, amendments (if any, excluding the ones that are purely  administrative, with no 
consequences for subjects, data or study  conduct ), the ICF, applicable recruiting materials, and 
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
133
Status: Approved ,Date: [ADDRESS_42911] clearly  identify  the IEC/I RB and the documents being 
approved.
During the study  the investigator (or Sponsor where required) will send the following documents 
and updates to the IEC/IRB for their review and approval, where appr opriate:
Protocol amendments (excluding the ones that are purel y administrative, with no 
consequences for subjects, data or study  conduct)
Revision(s) to ICFand any  other written materials to be provided to subjects
If applicable, new or revised subject recruiting materials approved b y the Sponsor
Revisions to compensation for study -related injuries or payment to subjects for participation 
in the study , if applicable
New edition(s) of the Investigator's Brochure and amendments/addenda
Summaries of the status of the study at intervals stipulated in guidelines of the IEC/IRB (at 
least annuall y)
Reports of adverse events that are serious, unlisted/unexpected, and associated with the 
study  drug
New information that may adversel y affect the safet y of the subjects or the conduct of the 
study
Deviations from or changes to the protocol to eliminate immediate hazards to the subjects
Report of deaths of subjects under the investigator's care
Notification if a new investigator is responsible for the study  at the site
Development Safet y Update Report and Line Listings, where applicable
Any other requirements of the IEC/I RB
For all protocol amendments (excluding the ones that are purel y administrative, with no 
consequences for subjects, data or study conduct) , the amendment and applicable ICFrevisions 
must be submitted promptly  to the IEC/I RB for review and approval before implementation of 
the change(s).
At least once a year, the IEC/IRB will be asked to review and reapprove this study . The 
reapproval should be documented in writing (excluding the ones that are purel y administrative, 
with no consequences for subjects, data, or stud y conduct) .
At the end of the study , the investigator (or Sponsor where required) will notify  the IEC/ IRB 
about the study  completion (if applicable, the notification will be submitted through the head of 
investigational institution) .
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
134
Status: Approved ,Date: [ADDRESS_42912] (or a legally acceptable representative) must give written consent according to local 
requirem ents after the nature of the study  has been fully  explained. The ICF(s) must be signed 
before performance of any study-related activity . The ICF(s) and assent form that areused must 
be approved by [CONTACT_19597]/IRB and be in a language that the 
subject can read and understand. The informed consent should be in accordance with principles 
that originated in the Declaration of Helsinki, current ICH and GCP guidelines, applicable 
regulatory  requirements, and Sponsor policy .
Before enrollment in the study , the investigator or an authorized member of the study site 
personnel must explain to potential subjects or their legall y acceptable representatives the aims, 
methods, reasonabl y anticipated benefits, and potential hazards of the study ,and any discomfort 
participation in the study  may entail. Subjects will be informed that their participation is 
voluntary  and that they may withdraw consent to participate at any time. They  will be informed 
that choosing to not participate will not affect the care the subject will receive for the treatment 
of his or her disease . Subjects will be told that alternative treatments are available if they refuse 
to take part and that such refusal will not prejudice future treatment. Finally , they will be told 
that the investigator will maintain a subject identification register for the purposes of long-term 
follow -up if needed and that their records may be accessed by [CONTACT_41037], to the extent permitted by 
[CONTACT_6983](s) or regulations. By [CONTACT_41038], including permission to obtain information ab out his or
her survival status, and agrees to allow his or her study  physician to recontact [CONTACT_41039] y evaluations, if needed, and subsequent disease
related treatments , or to obtain information a bout his or her survival status.
The subject or legally  acceptable representative will be given sufficient time to read the ICF and 
the opportunity  to ask questions. After this explanation and before entry  into the study , consent 
should be app ropriatel y recorded by [CONTACT_41040]'s or his or her legall y acceptable 
representativ e'spersonally  dated signature. After having obtained the consent, a copy of the ICF
must be given to the subject.
If the subject or legally  acceptable repre sentative is unable to read or write, an impartial witness 
should be present for the entire informed consent process (which includes reading and explaining 
all written information) and should personally  date and sign the ICFafter the oral consent of the 
subject or legall y acceptable representative is obtained.
Children (minors) or subjects who are unable to comprehend the information provided can be 
enrolled only after obtaining consent of a legally  acceptable representative. Assent must be 
obtained from children (minors) capable of understanding the nature of the study , typi[INVESTIGATOR_1306] y 
subjects 7years of age and older , depending on the institutional policies. Written assent should 
be obtained from subjects who are able to write. A  separate assent form written in language the 
subject can understand should be developed for adolescents. After having obtained the assent, a 
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
135
Status: Approved ,Date: [ADDRESS_42913]'s parent and/or legall y 
acceptable representative.
16.2.4. Privacy of Personal D ata
The collection and processing of personal data from subjects enrolled in this study will be 
limited to those data that are necessary  to fulfill the objectives of the study .
These data must be collected and processed with adequate precautions to ensure confidentialit y 
and compliance with applicable data privacy  protection laws and regulations. Appropriate 
technical and organizational measures to protect the personal data against unauthorized 
disclosures or access, accidental or unlawful destruction, or accidental loss or alteration must be 
put in place. Sponsor personnel whose responsibilities require access to personal data agree to 
keep the identit y of subjects confidential.
The informed consent obtained from the subject (or his or her legally acceptabl e representative)
includes explicit consent for the processing of personal data and for the investigator /institution to 
allow direct access to his or her original medical records (source data/documents) for study -
related monitoring, audit, IEC/IRB review, and regulatory  inspection. This consent also 
addresses the transfer of the data to other entities and to other countries.
The subject has the right to request through the investigator access to his or her personal data and 
the right to request rectification of any data that are not correct or complete. Reasonable steps 
will be taken to respond to such a request, taking into consideration the nature of the request, the 
conditions of the study , and the applicable laws and regulations.
16.2.5. Long -Term Retention of Samples for Additional Future Research
Samples collected in this study  may  be stored for up to 2 years (or according to local regulations) 
for additional research. Samples will only  be used to understand golimumab, to understand pJIA, 
to understand differential drug responders, and to develop tests/assay s related toSIMPONI for 
IV useand pJIA.The research may begin at any time during the study  or the post-study  storage 
period.
Stored samples will be coded throughout the sample storage and analysis process and will not be 
labeled with personal identifiers. Subjects may withdraw their consent for their samples to be 
stored for research.
16.2.6. Country Selection
This study  will only be conducted in those countries where the intent is to launch or otherwise 
help ensure acc ess to the developed product.
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
136
Status: Approved ,Date: [ADDRESS_42914] not be implemented without prior IEC/I RB 
approval, or when the relevant competent authority  has raised any grounds for non-acceptance, 
except when necessary to eliminate immediate hazards to the subjects, in which case the 
amendment must be promptly  submitted to the IEC/I RB and relevant competent authority . 
Documentation of amendment approval by  [CONTACT_23846]/ IRB must be provided to the 
Sponsor . When the change(s) involves only logistic or administrative aspects of the study , the 
IRB (and IEC where required) onl y needs to be notified.
During the course of the study , in situations where a departure from the protocol is unavoidable, 
the investigator or other physician in attendance will contact [CONTACT_41041] (see Contact [CONTACT_23774](s) provided separatel y). Except in emergency 
situations, this contact [CONTACT_41042]. In 
all cases, contact [CONTACT_41043]. The data recorded in the CRF and source documents 
will reflect any departure from the protocol, and the source documents will describe this 
departure and the circumstances requiring it.
17.2. Regulatory  Documentation
17.2.1. Regulatory  Approval/Notification
This protocol and any amendment(s) must be submitted to the appropriate regulatory  authorities 
in each respective country , if applicable. A study may not be initiated until all local regulatory 
requirements are met.
17.2.2. Required Prestudy  Documentation
The following documents must be provided to the Sponsor before shipment of study  drug to the 
study site:
Protocol and amendment(s), if an y, signed and dated by [CONTACT_458]
A copy of the dated and signed (or sealed, where appropriate per local regulations) , writt en 
IEC/IRB approval of the protocol, amendments, ICF, any recruiting materials, and if 
applicable, subject compensation programs. This approval must clearly  identify  the specific 
protocol by [CONTACT_23850] (or sealed, where appropriate per local 
regulations) by [CONTACT_23851]
Name [CONTACT_23875]/IRB, including a current list of the IEC/IRB members and 
their function, with a statement that it is organized and operates according to GCP and the 
applicable laws and regulations. If accompanied by a  letter of explanation, or equivalent, 
from the IEC/I RB, a general statement may be substituted for this list. If an investigator or a 
member of the study site personnel is a member of the IEC/I RB, documentation must be 
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
137
Status: Approved ,Date: 16 December 2019obtained to state that this person did not participate in the deliberations or in the 
vote/opi[INVESTIGATOR_23748]
Regulatory  authority  approval or notification, if applicable
Signed and dated statement of investigator (eg, Form FDA 1572), if applicable
Docum entation of investigator qualifications (eg, curriculum vitae)
Completed investigator financial disclosure form from the principal investigator, where 
required
Signed and dated clinical trial agreement, which includes the financial agreement
Any other documentation required b y local regulations
The following documents must be provided to the Sponsor before enrollment of the first subject:
Completed investigator financial disclosure forms from all subinvestigators
Documentation of subinvestigator qualifications (eg, curriculum vitae)
Name [CONTACT_23876] , and a dated copy  of 
current laboratory  normal ranges for these tests, if applicable
Local laboratory  documentation demonstrating competence and test reliability 
(eg,accreditation/license), if applicable
17.3. Subject Identification, Enrollment, and Screening Logs
The investigator agrees to complete a subject identification and enrollment log to permit easy 
identification of each subject during and after the study . This document will be reviewed by [CONTACT_41044].
The subject identification and enrollment log will be treated as confidential and will be filed by 
[CONTACT_23854]. To ensure subject confide ntiality , no copy  will be made. All 
reports and communications relating to the study  will identify  subjects by [CONTACT_23855]. In cases where the subject is not enrolled into the study , the date seen and date 
of birth will be used .
The investigator must also complete a subject screening log, which reports on all subjects who 
were seen to determine eligibility  for inclusion in the study .
17.4. Source Documentation
At a minimum, source documentation must be available for the following to confirm data 
collected in the CRF: subject identification, eligibility , and study  identification; study  discussion 
and date of signed informed consent; dates of visits; results of safety  and efficacy  parameters as 
required by [CONTACT_760]; record of all adverse events and follow -up of adverse events; 
concomitant medication; drug receipt/dispensing/return records; study drug administration 
information ; and date of study  completion and reason for early discontinuation of study  drug or 
withdrawal from the study , if applicable.
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
138
Status: Approved ,Date: [ADDRESS_42915] medical care. 
Specific details required as source data for the study  will be reviewed with the investigator 
before the study  and will be described in the monitoring guidelines (or other equivalent 
document).
The following data (at a minim um)will be recorded directl y into the CRF and will be considered 
source data where allowed by  [CONTACT_41045]:
Race
History  of smoking and all nicotine use (eg,cigarettes, ciga rs, chewing tobacco, patch, gum)
Blood pressure ,pulse/ heart rate, temperature, and respi[INVESTIGATOR_2842]
Height and weight
Details of ph ysical examination
The following parent/subject -and investigator -completed scales and assessments designated 
by [CONTACT_41046] y into an electronic device and will be considered 
source data: joint assessments, CHAQ, Physician Global Assessment of Disease Activity , 
and duration of morning stiffness. These assessments should not be record edon paper first.
The minimum source documentation requirements for Section 4.1,Inclusion Criteria and 
Section 4.2, Exclusion Criteria that specify  a need for documented medical history  are as 
follows:
Referral letter from treating ph ysician or
Complete history  of medical notes at the site
Discharge summaries
Inclusion and exclusion criteria not requiring documented medical history must be verified at a 
minimum by [CONTACT_41047] (eg, physical examination, 
laboratory  assessment) and documented in the source documents.
17.5. Case Report Form Completion
Case report forms are provided for each subject in electronic format.
Electronic Data Capture (eDC) will be used for this study . The study  data will be transcribed by 
[CONTACT_41048], and transmitted in a 
secure manner to the Sponsor within the timeframe agreed upon between the Sponsor and the 
study  site. The electronic file will be considered to be the CRF.
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
139
Status: Approved ,Date: [ADDRESS_42916]'s source documentation. All data relating to the 
study  must be recorded in CRFs prepared by [CONTACT_1034] . Data must be entered into CRFs in 
English. Study site personnel must complete the CRF as soon as possible after a subject visit, and 
the forms should be available for review at the next scheduled monitoring visit.
All subjective measurements (eg, pain scale informat ion or other questionnaires) will be 
completed by [CONTACT_23856]. The investigator must verify that all data entries in the CRF s are accurate and correct.
All CRF entries, corrections, and alterations must be made by  [CONTACT_41049]. If necessary , queries will be generated in the eDC tool. The investigator or 
study site personnel must adjust the CRF (if applicable) and complete the query .
If correct ions to a CRF are needed after the initial entry  into the CRF, this can be done in 
3different way s:
Study site personnel can make corrections in the eDC tool at their own initiative or as a 
response to an auto query (generated b y the eDC tool) .
Study sitemanager can generate a query  for resolution by  [CONTACT_3991].
Clinical data manager can generate a query  for resolution by  [CONTACT_3991].
17.6. Data Quality  Assurance/Quality  Control
Steps to be taken to ensure the accuracy  and reliability of data include the selection of qualified 
investigators and appropriate study  sites, review of protocol procedures with the investigator and 
study sitepersonnel before the study , andperiodic monitoring visits by [CONTACT_1034] , and direct 
transmission of clinical laboratory  data from a central laboratory ,IWRS, and PRO data into the 
Sponsor 's data base. Written instructions will be provided for collection, handling, storage, and 
shipment of samples.
Guidelines for CRF completio n will be provided and reviewed with study sitepersonnel before 
the start of the stud y.
The Sponsor will review CRFs for accuracy  and completeness during on-site monitoring visits 
and after transmission to the Sponsor ; any  discrepancies will be resolved with the investigator or 
designee, as appropriate. After upload of the data into the study database they  will be verified for 
accuracy  and consistency with the data sources.
17.7. Record Retention
In compliance with the ICH/GCP guidelines, the investigator/instit ution will maintain all CRFs 
and all source documents that support the data collected from each subject, as well as all study  
documents as specified in ICH/GCP Section 8, Essential Documents for the Conduct of a 
Clinical Trial, and all study  documents as specified by [CONTACT_23859](s). 
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
140
Status: Approved ,Date: 16 December 2019The investigator/institution will take measures to prevent accidental or premature destructio n of 
these documents.
Essential documents must be retained until at least 2years after the last approval of a marketing 
application in an ICH region and until there are no pending or contemplated marketing 
applications in an ICH region or until at least 2years have elapsed since the formal 
discontinuation of clinical development of the investigational product. These documents will be 
retained for a longer period if required by [CONTACT_23860] . It is the responsibility  of the Sponsor to inform the 
investigator/institution as to when these documents no longer need to be retained.
If the responsible investigator retires, relocates, or for other reasons withdraws from the 
responsibility  of keepi[INVESTIGATOR_13274], custody  must be transferred to a person who will 
accept the responsibility . The Sponsor must be notified in writing of the name [CONTACT_23877]. Under no circumstance shall the investigator relocate or dispose of any study  
documents before having obtained written approval from the Sponsor .
If it becomes necessary  for the Sponsor or the appropriate regulato ry authority  to review any 
documentation relating to this study , the investigator /institution must permit access to such 
reports.
17.8. Monitoring
The Sponsor will perform on-site monitoring visits as frequently  as necessary . The monitor will 
record dates of thevisits in a study  site visit log that will be kept at the study site. The first post-
initiation visit will be made as soon as possible after enrollment has begun. At these visits, the 
monitor will compare the data entered into the CRFs with the hospi[INVESTIGATOR_40961] (source 
documents). The nature and location of all source documents will be identified to ensure that all 
sources of original data required to complete the CRF are known to the Sponsor and study site 
personnel and are accessible for verifi cation by [CONTACT_41050]. If electronic 
records are maintained at the study site, the method of verification must be discussed with the 
study site personnel .
Direct access to source documentation (medical records) must be allowed for the purpose of 
verify ing that the data recorded in the CRF are consistent with the original source data. Findings 
from this review of CRFs and source documents will be discussed with the study site personnel . 
The Sponsor expects that, during monitoring visits, the relevant study site personnel will be 
available, the source documentation will be accessible, and a suitable environment will be 
provided for review of study -related documents. The monitor will meet with the investigator on a 
regular basis during the studyto provide feedback on the study conduct.
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
141
Status: Approved ,Date: 16 December 201917.9. Study Completion/Termination
17.9.1. Study Completion
The study  is considered completed with the last study  assessment for the last subject 
participating in the study . The final data from the study site will be sent to the Sponsor
(ordesignee) after completion of the final subject assessment at that study  site, in the time frame 
specified in the Clinical Trial Agreement.
17.9.2. Study Termination
The Sponsor reserves the right to close the study site or terminate the study  at any time for any 
reason at the sole discretion of the Sponsor .Study sites will be closed upon study  completion. A
study site is considered closed when all required documents and study  supplies have been 
collected and a study site clos ure visit has been performed.
The investigator may initiate study site closure at any time, provided there is reasonable cause 
and sufficient notice is given in advance of the intended termination.
Reasons for the earlyclosure of astudy site by [CONTACT_23863]:
Failure of the investigator to comply  with the protocol, the requirements of the IEC/I RB or 
local H ealth A uthorities, the Sponsor 's procedures, or GCP guidelines
Inadequate recruitment of subjects by  [CONTACT_093]
Discontinuation of further study  drug development
17.10. On-Site A udits
Representatives of the Sponsor 's clinical quality  assurance department may visit the study  site at 
any time during or after completion of the study  to conduct an audit of the study  in compliance
with regulatory  guidelines and company  policy . These audits will require access to all study 
records, including source documents, for inspection and comparison with the CRFs. Subject 
privacy  must, however, be respected. The investigator and study site personnel are responsible 
for being present and availabl e for consultation during routinel y scheduled study site audit visits 
conducted b y the Sponsor or its designees.
Similar auditing procedures may also be conducted by [CONTACT_23865], either as 
part of a national GCP compliance program or to review the results of this study  in support of a 
regulatory  submission. The investigator should immediately  notify  the Sponsor if he or shehas
been contact[INVESTIGATOR_530] b y a regulatory agency  concerning an upcoming inspection.
17.11. Use of Information and Publication
All information, including but not limited to information regarding golimumab or the Sponsor 's 
operations (eg,patent application, formulas, manufacturing processes, basic scientific data, prior 
clinical data, formulation information) supplied by [CONTACT_41051] 
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
142
Status: Approved ,Date: 16 December 2019previously  published, and any data, including research data, generated as a result of this study , 
areconsidered confidential and remain the sole property  of the Sponsor . The investigator agrees 
to maintain this information in confidence and use this information only to accomplish this 
study , and will not use it for other purposes without the Sponsor 's prior written consent.
The investigator understands that the information developed in the study will be used by [CONTACT_41052]. To permit the information 
derived from the clinical studies to be used, the investigator is obligated to provide the Sponsor
with all data obtained in the study .
The results of the study  will be reported in a Clinical Study  Report generated by [CONTACT_41053] , and direct transmission 
of clinical laboratory  data from a central laboratory , IWRS, and PRO data into the Sponsor 's 
database . Recruitment performance or specific expertise related to the nature and the key 
assessment parameters of the study  will be used to determine a coordinating investigator . Results 
of analysesperformed after the Clinical Study  Report has been issued will be reported in a 
separate report and will not require a revision of the Clinical Study  Report. Study  subject 
identifiers will not be used in publication o f results. Any work created in connection with 
performance of the study  and contained in the data that can benefit from copyright protection 
(except any publication by [CONTACT_40999]) shall be the propert y of the 
Sponsor as author and owner of cop yright in such work.
Consistent with Good Publication Practices and International Committee of Medical Journal 
Editors guidelines, the Sponsor shall have the right to publish such primary  (multicenter) data 
and information without approval from the investigator. The investigator has the right to publish 
study  site-specific data after the prim ary data are published. If an investigator wishes to publish 
information from the study ,a copy  of the manuscript must be provided to the Sponsor for review 
at least 60days before submission for publication or presentation. Expedited reviews will be 
arran ged for abstracts, poster presentations, or other materials. If requested by [CONTACT_41054], the investigator will withhold such publication for up to an additional 60days to allow 
for filing of a patent application. In the event that issues arise regarding scientific integrity  or 
regulatory  compliance, the Sponsor will review these issues with the investigator. The Sponsor
will not mandate modifications to scientific content and does not have the right to suppress 
information. Formulticenter study designs and substudy approaches, secondary  results generall y 
should not be published before the primary  endpoints of a study  have been published. Similarly , 
investigators will recognize the integrity  of a multicenter study by [CONTACT_41055], within 12 months of the availability  of the final data (tables, 
listings, graphs), or the Sponsor confirms there will be no multicenter study  publication. 
Authorship of publications resulting from this study  will be based on the guidelines on 
authorship, such as those described in the Uniform Requirements for Manuscripts Submitted to 
Biomedic al Journals, which state that the named authors must have made a significant 
contribution to the design of the study  or analy sis and interpretation of the data, provided critical 
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
143
Status: Approved ,Date: 16 December 2019review of the paper, and given final approval of the final version. PRINTO and PRCSG 
guidelines available on the irrespective websites should be followed.
Registration of Clinical Studies and Disclosure of Results
The Sponsor will register and/or disclose the existence of and the results of clinical studies as 
required b y law.
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
144
Status: Approved ,Date: 16 December 2019REFERENCES
1. Brunner HI, Klein -Gitelman MS, Miller MJ, et al. Minimal clinically important differences of the childhood 
health assessment questionnaire. J Rheumatol. 2005;32(1):150 -161.
2. Consolaro A, Bracciolini G, Ruperto N, et al. Remission, minimal disease activity, and acceptable symptom 
state in juvenile idiopathic arthritis. Arthritis Rheum. 2012;64(7):2366 -2374.
3. De Benedetti F, Pi[INVESTIGATOR_40962] P, Gerloni V, et al. Differences in synovial fluid cytokine levels betw een juvenile and 
adult rheumatoid arthritis. J Rh eumatol. 1997;24(7):[ADDRESS_42917] and 10-centimeter horizontal line 
visual analog scales for physician and parent subjective ratings in juvenile idiopathic arthritis. J Rheumatol. 
2010;37 (7):1534 -1541.
5. Giannini EH, Ruperto N Ravelli A, Lovell DJ, Felson DT, Martini A. Preliminary definition of improvement in 
juvenile arthritis. Arthritis Rheum. 1997; 40:1202 -1209.
6. Grossman JM, Brahn E. Rheumatoid arthritis: current clinical and research directions. J Womens Health. 
1997;6(6):627 -638.
7. Heiligenhaus A, Minden K, Föll D, Pleyer U: Uveitis in juvenile idiopathic arthritis. Dtsch Arztebl Int. 2015; 
112: 92 –100. DOI: 10.3238/arztebl.2015.0092
8. Heiligenhaus A, Niewerth M, Ganser G, Heinz C, Minden K; Germ an Uveitis in Childhood Study Group. 
Prevalence and complications of uveitis in juvenile idiopathic arthritis in a population -based nation -wide study 
in [LOCATION_013]: suggested modification of the current screening guidelines. Rheum atology (Oxford). 
2007;46(6):1015 -1019. 
9. Lepore L, Pennesi M, Saletta S, Perticarari S, Presani G, Prodan M. Study of IL-2, IL-6, TNF alpha, IFN 
gamma and beta in the serum and synovial fluid of patients with juvenile chroni c arthritis. Clin Exp 
Rheumatol. 1994;12(5):561 -565.
10. Levin RH, associate ed. Principles of drug disposition and therapy in neonates, infants, and children. In: 
Rudolph AM, ed; Hoffman JLE, co-ed; Axelrod S, assistant ed. Pediatrics. 18th ed. Norwalk, Ct: Appleton & 
Lange; 1987:[ADDRESS_42918].
11. Magni -Manzoni S, Ruperto N, Pi[INVESTIGATOR_40963] A, et al. Development and validation of a  preliminary definition of 
minimal disease activity in patients with juvenile idiopathic arthritis. Arthritis Rheum. 2008;5 9(8):1120 -1127.
12. Mangge H, Kenzian H, Gallistl S, et al. Serum cytokines in juvenile rheum atoid arthritis. Correlation with 
conventional inflammation parameters and clinical subtypes. Arthritis Rheum. 1995;38(2):211 -220.
13. Nordal EB, Zak M, Aalto K, et al. Validity and predictive ability of the juvenile arthritis disease activity score 
based on CRP versus ESR in a Nordic population -based setting. Ann Rheum Dis. 2012;71(7):[ADDRESS_42919] 
Practice and Res Clin Rheumatol. 2002;16(3):347 -360.
15. Petty RE, Cassidy JT. Oligoarthritis. In: Cassidy JT, Petty  RE, Laxer RM, Lindsley CB. Textbook of Pediatric 
Rheumatology. 5th ed. Philadelphia, Pa: Elsevier Saunders; 2005b:[ADDRESS_42920].
16. Petty RE, Southwood TR, Manners P, et al. International League of Associations for Rheumatology 
classification of juvenile idiopathic arthritis: second revision, Edm onton, 2001. J Rheumatol. 2004;31(2):390 -
392.
17. Prahal ad S, Glass DN. Is juvenile rheumatoid arthritis/juvenile idiopathic arthritis different from rheumatoid 
arthritis? Arthritis Res2002, 4(Suppl 3):303-310. Available at: http://arthritis -research.com/content/4/S3/303. 
Accessed June 13, 2008.
18. Ravelli A, Mar tini A. Juvenile idiopathic arthritis. Lancet. 2007;369(9563):767 -778.
19. Rooney M, David J, Symons J, Di Giovine F, Varsani H, Woo P. Inflammatory cytokine responses in juvenile 
chronic arthritis. Br J Rheumatol. 1995;34(5):454 -460.
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
145
Status: Approved ,Date: [ADDRESS_42921] PR, Day er JM, Woo P. Tum or necrosis factor alpha and its soluble 
receptors in juvenile chronic arthritis. Rheumatology. 2000;39(4):432 -438.
21. Singh G, Athreya BH, Fries JF, Goldsmith DP. Measurement of health status in children with juvenile 
rheumatoid arthritis. Arthritis Rheum. 1994;37(12):1761 -1769.
22. Zenk KE. Methods of parenteral drug delivery. In: Rudolph AM, ed; Hoffman JLE, co -ed; Axelrod S, assistant 
ed. Pediatrics. 18th ed. Norw alk, Ct: Appleton & Lange; 1987:[ADDRESS_42922].
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
146
Status: Approved ,Date: 16 December 2019ATTACHMENT 1QUA NTIFERON®-TB GOLD TESTING
The QuantiFERON®-TB Gold test is one of the interferon -(IFN-based blood assay s for TB 
screening (Cellestis, 2009). It utilizes the recently identified M.tuberculosis- specific antigens 
ESAT -[ADDRESS_42923] format, as well as TB7.7 (p4) in the In-Tube format, to 
detect in vitro cell-mediated immune responses in infected individuals. The QuantiFERON®-TB 
Gold assay  measures the amount of IFN-produced by [CONTACT_41056] T-cells when stimulated with 
the synthetic M. tuberculosis- specific antigens. In M. tuberculosis -infected persons, sensitized 
Tlymphocy tes will secrete IFN-in response to stimulation with the M. tuberculosis -specific 
antigens and, thus, the QuantiFERON®-TB Gold test should be positive. Because the antigens 
used in the test are specific to M. tuberculosis and not found in BCG, the test is not confounded 
by [CONTACT_14400], unlike the tuberculin skin test. However, there is some cross -reactivity  with 
the [ADDRESS_42924] 
could be the result of infection with one of these 3species of Mycobacterium, in the absence of 
M. tuberculosis infection.
In a study  of the QuantiFERON®-TB Gold test (standard format) in subjects with active TB, 
sensitivity  has been shown to be approximately  89% (Mori et al, 2004). Specificity  of the test in 
healthy  BCG -vaccinated individuals has been demonstrated to be more than 98%. In contrast, the 
sensitivity  and specificity  of the tuberculin skin test was noted to be only about 66% and 35% in 
a study  of Japanese patients with active TB and healthy  BCG-vaccinated young adults, 
respectivel y. However, sensitivity  and specificity  of the tuberculin skin test depend on the 
population being studied, and the tuberculin skin test performs best in healthy  young adults who 
have not been BCG -vaccinated .
Data from a limited number of published studies examining the performance of the 
QuantiFERON®-TB Gold assay  in immunosuppresse d populations suggest that the sensitivity  of 
the QuantiFERON®-TB Gold test is better than the tuberculin skin test even in 
immunosuppressed patients (Ferrara et al, 2005; Kobashi et al, 2007; Matulis etal, 2008). The 
ability  of IFN--based tests to detec t latent infection has been more difficult to study  due to the 
lack of a gold standard diagnostic test; however, several TB outbreak studies have demonstrated 
that the tests correlated better than the tuberculin skin test with the degree of exposure that 
contacts had to the index TB case (Brock et al, 2004; Ewer et al, 2003). In addition, TB contact 
[CONTACT_41057] a positive QuantiFERON®-TB Gold test result 
and were not treated for latent TB infection were much more likely to develop active TB during 
longitudinal follow -up than those who had a positive tuberculin skin test and a negative 
QuantiFERON®-TB Gold test result (Higuchi et al, 2007; Diel et al, 2008).
Although the performance of the new IFN--based blood tests for a ctive or latent M.tuberculosis
infection have not been well validated in the immunosuppressed population, experts believe 
these new tests will be at least as, if not more, sensitive, and definitel y more specific, than the 
tuberculin skin test (Barnes, 200 4; personal communication, April, [ADDRESS_42925]).
Performing the QuantiFERON®-TB Gold Test
The QuantiFERON®-TB Gold test In-Tube format will be provided for this study . The In-Tube 
format contains 1 additional M. tuberculosis -specific antigen, TB7.7 (p4), which is thought to 
increase the specificity  of the test.
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
147
Status: Approved ,Date: [ADDRESS_42926], each requiring 1 mL of blood. One tube contains the M. tuberculosis -
specific antigens, while the remaining tubes contain positive and negative control reagents. 
Thorough mixing of the blood with the antigens is necessary  prior to incubation. The blood is 
then incubated for 16 to 24 hours at 37°C, after which tubes are centrifuged for approximately  
15minutes at 2000 to 3000 g. Following centrifugation, plasma is harvested from each tube, 
frozen, and shipped on dry ice to the central laboratory . The central laboratory  will perform an 
ELISA to quantify  the amount of IFN-present in the plasma using spectrophotometry and 
computer software anal ysis.
The central laboratory  will analy ze and report results for each subject, and s ites will be informed 
of the results. Under certain circumstances as approved by [CONTACT_1034], a local laboratory  may 
be used to process the QuantiFERON®-TB Gold test sample and/or analy ze the results.
Subjects who have an indeterminate result should have the test repeated.
Adherence to Local Guidelines
Local country  guidelines for immunocompromised patients should be consulted for acceptable 
anti-tuberculous treatment regimens for latent TB. If no local country  guidelines for 
immunocompromised patients exi st, US guidelines must be followed.
In countries in which the QuantiFERON®-TB Gold test is not considered approved/registered, a 
tuberculin skin test is additionally  required.
References
Barnes PF. Diagnosing latent tuberculosis infection: Turning glitter to gold [editorial]. Amer J Respir Crit Care 
Med. 2004;170:[ADDRESS_42927] in 
tuberculosis contacts. Am J Respir Crit Care Med. 2004;170:65 -69.
Cellestis. QuantiFE RON -TB Gold clinicians guide and QuantiFERON -TB Gold In -Tube Method package insert. 
Downloaded from www.cellestis.com, February 2009.
Diel R, Loddenkemper R, Meywald -Walter K, Niemann S, Nienhaus A. Predictive value of a whole blood IFN -
assay for the dev elopment of active tuberculosis disease after recent infection with mycobacterium tuberculosis. Am 
J Respir Crit Care Med . 2008;177:[ADDRESS_42928] for diagnosis of 
Mycobacterium tuberculosis infection in a school tuberculosis outbreak. Lancet. 2003;361:1168 -73.
Ferrara G, Losi M, Meacci M, et al. Routine hospi[INVESTIGATOR_40964] a new commercial whole blood interferon -assay for 
the diagnosis of tuberculosis infection. Am J Re spir Crit Care Med . 2005; 172:631 -635.
Higuchi K, Nobuyuki H, Mori T, Sekiya Y. Use of QuantiFERON -TB Gold to investigate tuberculosis contacts in a 
high school. Respi[INVESTIGATOR_16921] . 2007;12:[ADDRESS_42929] for immunocompromised 
patients. Eur Respir J . 2007; 30:945 -950.
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
148
Status: Approved ,Date: 16 December 2019Matulis G, Jüni P, Villiger PM, Gadola SD. Detection of latent tuberculosis in immunosuppressed patients with 
autoimmune diseases: performance of a My cobacterium tuberculosis antigen -specific interferon assay. Ann 
Rheum Dis . 2008;67:84 -90
Mori T, Sakatani M, Yamagishi F, et al. Specific detection of tuberculosis infection: An interferon --based assay 
using new antigens. Am J Respir Crit Care Med. 2004;170:59 -64.
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
149
Status: Approved ,Date: [ADDRESS_42930] (CDC, 2000) is the standard method of identify ing persons 
infected with Mycobacterium tuberculosis. Multiple puncture tests (Tine and Heaf) should not be 
used to determine whether a person is infected because the amount of tuberculin injected 
intradermall y cannot be precisel y controlled. Tuberculin skin testing is both safe and reliable 
throughout the course of pregnancy .The Mantoux tuberculin test is performed by [CONTACT_41058] 0.1mL of tuberculin into the inner surface of the forearm. The test must 
be performed with tuberculin that has at least the same strength as either 5tuberculin units (TU) 
ofstandard purified protein derivative ([COMPANY_003]) -S or 2TU of [COMPANY_003]-RT23, Statens Seruminstitut, as 
recommended by [CONTACT_38375]. [COMPANY_003] strengths of 1TU or 250TU are not 
acceptable (Menzies, 2000). Using a disposable tuberculin syringe with the needle bevel facing 
upward, the injection should be made just beneath the surface of the skin. This should produce a 
discrete, pale elevation of the skin (a wheal) 6mm to 10mm in diameter. To prevent needle -
stick injuries, needles should not be recapped, purposely  bent or broken, removed from 
disposable syringes, or otherwise manipulated by [CONTACT_35681]. After they are used, disposable needles 
and syringes should be placed in puncture -resistant containers for disposal. Institutional 
guidelines regarding universal precautions for infection control (eg, the use of gloves) should be 
followed. A trained health care worker, preferably  the investigator, should read the reaction to 
the Mantoux test [ADDRESS_42931], tuber culin testing should be repeated. The area of 
induration (palpable raised hardened area) around the site of injection is the reaction to 
tuberculin. For standardization, the diameter of the induration should be measured transversel y 
(perpendicular) to the long axis of the forearm. Erythema (redness) should not be measured. All 
reactions should be recorded in millimeters, even those classified as negative.
Interpreting the Tuberculin Skin Test Results
In the US and many other countries, the most conservative definition of positivity  for the 
tuberculin skin test is reserved for immunocompromised patients, and this definition is to be 
applied in this study  to maximize the likelihood of detecting latent TB, even though the subjects 
may not be immunocompromised a t baseline.
In the US and Canada, an induration of [ADDRESS_42932] be followed.
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
150
Status: Approved ,Date: 16 December 2019References
Centers for Disease Control and Prevention. Core curriculum on tuberculosis: What the clinician should know 
(Fourth Edition). Atlanta, GA: Department of Health and Human Services; Centers for Disease Control and 
Prevention; National Center for HIV, STD, and TB Prevention; Division of Tuberculosis Elimination; 2000:25 -86.
Menzies RI. Tuberculin skin testing. In: Reichman LB, Hershfield ES (eds). Tuberculosis, a comprehensive 
international approach . 2nd ed. N ew York, NY: Marcel Dekker, Inc; 2000:279 -322.
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
151
Status: Approved ,Date: 16 December 2019ATTACHMENT 3HEPA TITIS B VIRUS (H BV) SCREENING
Subjects must undergo screening for HBV . At a minimum, this includes testing for HBsAg 
(HBV surface antigen), anti- HBs (HBV surface antibody ), and anti -HBc tot al (HBV core 
antibody  total):
Subjects who test negative for all HBV screening tests (ie, HBsAg -, anti -HBc-, and 
anti-HBs-) areeligible for this study .
Subjects who test negative for surface antigen (HBsAg -) and test positive for core 
antibody  (anti -HBc+) andsurface antibod y (anti -HBs+) areeligible for this study .
Subjects who test positive only for surface antibody (anti-HBs+) areeligible for this 
study .
Subjects who test positive for surface antigen (HBsAg+) areNOT eligib lefor this study , 
regardless of the results of other hepatitis B tests.
Subjects who test positive only for core antibody (anti -HBc+) areNOT eligible for this 
study .
For subjects who are not eligible for this study due to HBV test results , consultation with a 
physician with expertise in the treatment of hepatitis B virus infection is recommended.
Eligibility based on hepatitis B virus test results
Hepatitis B test result
ActionHepatitis B surface 
antigen
(HBsAg)Hepatitis B surface 
antibody
(anti -HBs)Hepatitis B core 
antibody
(anti -HBc total)
Include— — —
— + +
— + —
Exclude+ —or+ —or+
— — +
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
152
Status: Approved ,Date: 16 December 2019ATTACHMENT 4: A NTICI PATED EVENTS
An anticipated event is an adverse event (serious or non-serious) that commonly  occurs as a 
consequence of the underly ing disease or condition under investigation (disease related) or 
background regimen.
For the purposes of this study , the following events will be considered anticipated events:
Events related to the progression of the disease und er study .
These events will be captured on the CRF and in the database, and will be reported to the 
Sponsor as described in Section 12.3.1 , All Adverse Events. Any event that meets serious 
adverse event criteria will be reported to the Sponsor within the appropriate timeline as described 
in Section 12.3.2 , Serious Adverse Events. These anticipated events are exempt from expedited 
reporting as individual single cases to Health Authorities. However, if based on an aggregate 
review, it is determined that an anticipated event is possibly  related to study  drug, the Sponsor 
will report these events in an expedited manner.
Anticipated Event Review Committee (ARC)
An A RCwill be established to perform reviews of pre- specified events at an aggregate level. The 
ARC is a safet y committee within the Sponsor’s organi zation that is independent of the 
Sponsor’s study  team. The ARC will meet to aid in the recommendation to the Sponsor’s study  
team as to whether there is a reasonable possibility  that an anticipated event is related to the 
study  drug.
Statistical Analysis
Details of statistical analy sis of anticipated events, including the frequency  of review and 
threshold to trigger an aggregate analysis of anticipated event will be provided in a separate 
Anticipated Events Safety Monitoring Plan (ASMP).
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
153
Status: Approved ,Date: 16 December 2019ATTACHMENT 5: SLIT L AMP EVALUATIONS
Through Week 52, a ll subjects are required to have slit lamp evaluations performed by [CONTACT_41059]/optometrist during the study  at intervals (based on JIA subty pe, ANA test 
results, age at JIAonset, and JIA duration) as specified in the table below . After Week 52, slit 
lamp evaluations will be performed at the discretion of the investigator and per standard of care. 
The date of the screening visit and the ANA test results during screening (as applicable
depending on the JIA subty pe) should be used to determine when the first slit lamp evaluation 
should be performed during the study . The interval for the slit lamp evaluations may be adjusted 
thereafter based on the subject’s ANA test results and JIA disease duration after screening. 
However, once a subject tests positive for ANA at any time during the study  (and regardless if 
the subject subsequentl y tests negative for ANA), the subject should be considered ANA positive 
when determining the frequ ency  of slit lamp evaluations. 
If a subject develops uveitis during the study , the subject’s continued participation in the study  is 
at the discretion of the investigator and Sponsor , and slit lamp evaluations should be performed 
according to disease course.  
Intervals for Slit Lamp Evaluations
JIA Subtype ANAAge at JIA 
onset (in years)JIA duration
(in years)Slit Lamp 
Evaluation
Interval
(in months)
OA extended
Polyarticular RF -negative 
Juvenile PSAPositive (+)≤6≤4 ≤3
>4and <7 ≤6
≥7 ≤12
>6≤2 ≤6
>2 ≤12
Negative ( -)≤6≤4 ≤6
>4 ≤12
>6 N/A ≤12
ERA N/A N/A N/A ≤12
Polyarticular RF -positive
Systemic with polyarticular course 
without systemic symptomsN/A N/A N/A ≤12
ANA = antinuclear antibody; ERA = enthesitis -related arthritis; JIA=  juvenile idiopathic arthritis; N/A = not 
applicable; OA = oligoarticular; PSA = psoriatic arthritis; RF = rheumatoid factor
Adapted from: Heiligenhaus et al, 20078and Heiligenhaus et at, [ZIP_CODE]
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
154
Status: Approved ,Date: 16 December 2019ATTACHMENT 6: EXTEND ED TREA TMENT PERIOD
INTRODUCTION
As indicated in Section 3.1.[ADDRESS_42933] completed the full trial period of 252 weeks and 
for whom drug is proven beneficial but is not commercially  available for the pJIA indication (or 
subject does not qualify  for insurance to pay for the drug), will continue to be provided with IV 
golimumab by [CONTACT_1034]. This attachment outlines the procedures and assessments that should 
be followed, for provision of golimumab to eligible subject s after completion of the main study , 
in the ETP . 
Eligible subject s are <[ADDRESS_42934] , in their opi[INVESTIGATOR_1649], will benefit from continued golimumab treatment, 
and it is not commerciall y available for the pJIA indication (or subject does not qualify  for 
insurance to pay for the drug). TheETP begins at Week [ADDRESS_42935] ’s 
respective country  and subject qualifies for insurance to pay  for the drug. Subject s may  decide to 
stop golimumab treatment (withdraw consent) at any  time.
Subject s will receive the same golimumab treatment (80 mg/m2every  8 weeks administered 
intravenously ; maximum dose 240 mg) that they  received prior to Week [ADDRESS_42936] visits and monitoring (eg, laboratory  evaluation, TB evaluation) should occur at the 
investigator’s discretion and as per usual clinical practice for a subject with pJIA receiving a 
TNFα inhibitor. Phy sicians participating in this ETP must agree to take full responsibility  forthe 
use of this product.
Local regulations and guidelines related to participation in the ETP, including but not limited to 
period approvals, and re -approvals are the responsibility  of the ph ysician.
The physician must ensure that any local requirements for safet y reporting to Health Authorities 
and/or Independent Ethics Committees/I nstitutional Review Boards, if appropriate, are met. 
During the ETP, concomitant medications including those for pJIA will be administered at the 
discretion of the investigator for all subject s. During the course of the ETP, in situations where a 
departure from the protocol or standard of care is unavoidable, the investigator or other phy sician 
in attendance will contact [CONTACT_41060] (see Contact [CONTACT_23774][s] provided 
separately ). Except in emergency  situations, this contact [CONTACT_41061]. In all cases, contact [CONTACT_41062]. 
The data recorded in the subject ’s medical records should reflect any departure from the 
protocol/standard of care.
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
155
Status: Approved ,Date: [ADDRESS_42937] ’s medical records the necessity  of 
continuing golimumab treatment in the ETP and that switching to another commerciall y 
available treatment is not in the best interest of the subject . Additionally , for subject s to be 
eligible for the ETP, the investigator must document that golimumab is not commerciall y 
available for the pJIA indication (and subject does not qualify  for insurance to pay for the drug). 
Documentation should be done at the following timepoints:
At Week 252, after the subject has completed participation in the study  (ie, the Week [ADDRESS_42938] been comp leted)
At each subsequent year the subject participates in the ETP(via attestation form) .
Each subject must continue to satisfy  specified inclusion and exclusion criteria as well as 
prohibitions and restrictions as noted in Sections 4.1, 4.2, and 4.3, respectively . For questions 
related to eligibility , the i nvestigator should contact [CONTACT_41063].
In addition, specific criteria for the ETP are noted below.
Inclusion Criteria
Each potential subject must satisfy  the following criteria to continue to receive golimumab as 
part of the ETP . Criteria from Section 4.1that apply  are referenced below.
1. Subject s must be l ess than [ADDRESS_42939] (or their legally  acceptable representative) must sign an ICF indicating that 
he or she understands the purpose of and the procedures required for the ETP. Assent is 
also required of children capable of understanding the nature of the study  (typi[INVESTIGATOR_1306] y 
7years of age and older and per local regulations) as described in Section 16.2.[ADDRESS_42940] pJI A as specified in inclusion criterion #[ADDRESS_42941] continue to meet eligibility  criteria for TB (Inclusion criterion #10 in 
Section 4.1)
6. Subjects must continue to avoid pregnancy  (Inclusion criteria #12, #13, and #14 in 
Section 4.1).
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
156
Status: Approved ,Date: [ADDRESS_42942] meets these criteria, he/she will be excluded from continued
participation in the ETP.
1. Pregnancy  (in a female) or plans for pregnancy  (in females or males) are exclusionary 
(Exclusion criteria #41 and #42 in Section 4.2).
2. Subject s with a BSA >3.0 m2(Exclusion criterion #46 in Section 4.2).
Prohibitions and Restrictions
All subject s must continue to compl y with all the prohibitions and restrictions as noted in 
Section 4.3, with the exception of the prohibition regarding intramuscular corticosteroids. 
Contrary  to the main study , subject s may receive intramuscular administration of corticosteroids 
for the treatme nt of pJIA as deemed necessary  by [CONTACT_41064]. However, these 
occurrences should be limited. If needed for ongoing control of pJI A, thought should be given to 
the need to change to a different medication and the subject stoppi[INVESTIGATOR_40965]. 
PROCEDURES AND ACTIVITIES
Subjects who enter the ETP at the Week 252 visit will continue to receive 80mg/m2golimumab 
(maximum dose 240 mg) administered as IV infusions over 30±10 minutes q8w (±1 week) until 
discontinuation of golimumab tr eatment, as described below.
The following procedures and activities must be performed b y the investigator during the ETP:
Completion of the attestation form to document that a subject is benefiting from treatment -
annually .
Record AEs considered to be related to golimumab, all SAEs (regardless of causality  to 
golimumab), pregnancy , and events of special interest (ie, malignancy  and TB) on the CRF. 
Refer to Section 12.3.1 for procedures for reporting these events.
Record concomitant medications associated with or used to treat AEs and SAEs on the CRF.
Subject visits and monitoring (eg, laboratory  evaluation, TB evaluation) should occur at the 
investig ator’s discretion and as per usual clinical practice for a subject with pJIA receiving a 
TNFα inhibitor. Phy sicians participating in this ETP must agree to take full responsibility  for the 
use of this product.
GOLIMUMAB STORAGE, PREPARATION, DOSAGE, ADMINISTRATION, and 
ACCOUNTABILITY
Golimumab will be supplied by [CONTACT_41065]. The first dose of golimumab in the 
ETP will be administered at Week [ADDRESS_42943] s 
will receive 80 mg/m2golimumab (maximum dose 240 mg) IV infusions q8w. The q8w
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
157
Status: Approved ,Date: 16 December 2019(±1week) dosing regimen should be adhered to and infusions may onlybe missed for safety 
reasons. Exceptions to the q8w (±1week) dosing regimen should only be made if infusions are 
off-schedule for safety  reasons. In these instances, the minimum time between infusions can be 
4weeks to enable the subject to resume the q8w dosing regimen.
Refer to Sections 14.1, 14.2, and 14.3 for details about the physical description, packaging, and 
labeling of golimumab, respectivel y. 
Investigators will be responsible for ensuring that golimumab is stored according to the 
specifications outlined in Section 14.4. 
Investigators/site personnel will also be responsible for scheduling golimumab infusions and 
ensuring correct administration. 
Prior to preparing a dose for infusion, the subject ’s current weight and height should be used to 
obtain the subject ’s body surface area (BSA). The subject ’s BSA will be calculated prior to each 
infusion using the Mosteller equation and the dose of golimumab adjusted as needed to maintain 
the dose at 80 mg/m2. A maximum dose of [ADDRESS_42944] ’s BSA is large enough to yield a higher calculated dose.
The golimumab infusions should be prepared and administered by a healthcare professional as 
noted in the Golimumab Preparation and Administration I nstructions.
The investigator is responsible for ensuring that all golimumab received at the site is inventoried 
and accounted for throughout the ETP. All study  drug should be stored and disposed of
according to the Sponsor 's instructions. Site personnel must not combine contents of the study  
drug containers.
Golimumab should be handled in strict accordance with the Golimumab Preparation and 
Administration Instructions and the container label and should be stored in a limite d-access area 
or in a locked cabinet under appropriate environmental conditions. When the site is an authorized 
destruction unit and study  drug supplies are destroy ed on-site, this must also be documented on 
the drug return form.
Potentially  hazardous mate rials such as used ampules, needles, syringes and vials containing 
hazardous liquids, should be disposed of immediately  in a safe manner and therefore will not be 
retained for drug accountability  purposes.
Golimumab should be dispensed under the supervisio n of the investigator or a qualified member 
of the site personnel, or by a hospi[INVESTIGATOR_307]/clinic pharmacist. Golimumab will be supplied only to 
subject s participating in the ETP. Golimumab returned to the site/I WRS stock must not be 
dispensed again, even to the same subject . Golimumab may not be relabeled or reassigned for 
use by  [CONTACT_6494] s.
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
158
Status: Approved ,Date: 16 December 2019CONCOMITANT MEDICATIONS
Concomitant medications including medications for pJIA may be administered and adjusted at 
the discretion of the investigator but should not viola te any prohibitions and restrictions noted in 
Section 4.3, Prohibitions and Restrictions, with the exception noted in Section 4.3concerning IM
corticosteroids.
Concomitant medications associated with, or used to treat, AEs and SAEs should be recorded in 
the CRF.
Methotrexate will not be supplied b y the Sponsor.
DISCONTINUATION OF GOLIMUMAB/TREATMENT WITHDRAWAL CRITERIA
The subject s may at any time withdraw consent and discontinue treatment with golimumab. If a 
subject ’s golimumab treatment is discontinued, this will result in automatic permanent 
withdrawal of the subject from the ETP. A subject ’s golimumab treatment provided via this ETP
will be permanentl y discontinued when an y of the following occur:
The subject is no longer benefiting from golimumab treatment.
The subject turns 18 y ears of age.
Golimumab becomes commercially  available in the subject ’s respective country  and the 
subject ’s insurance will pay  for the drug .
A subject ’s golimumab treatment should also be permanentl y discontinued if any of the criteria 
in Section 10.2.Discontinuation of Study  Treatment, are met. 
When a subject discontinues study  treatment, a follow -up evaluation should occur approximately  
[ADDRESS_42945] infusion of study  agent to ensure that there are no safety concerns.
ADVERSE EVENT REPORTING
AEs considered by [CONTACT_41066] (as defined in Section 12.3.1 ), 
SAEs (as defined in Section 12.1.1 ), pregnancy , and events of special interest (ie, malignancy 
and TB) are required to be reported in the ETP on the CRF . Refer to the following sections for 
procedures for reporting these events: Section 12.3.[ADDRESS_42946] report the PQC to the Sponsor according to the 
timelines and procedures for an SAE.
The names (and corresponding telephone numbers) of the individuals who should be contact[CONTACT_41035](s), which will be 
provided as a separate documen t.
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
159
Status: Approved ,Date: [ADDRESS_42947] ’s medical records available for a subject
participating in the ETP should be consistent with that commonly  recorded at the site as a basis 
for standard medical care. Subject records must be available for review of AEs considered to be 
related to study  drug and SAEs. The author of an entry  in the subject ’s me dical records should be 
identifiable.
Record Retention
Refer to Section 17.[ADDRESS_42948] ’s 
medical records will be identified to ensure that all sources of original data are known to the 
Sponsor and site personnel and are accessible for verification by [CONTACT_41067]. If 
electronic records are maintained at the site, the method of verification must be discussed with 
the site personnel.
Direct access to subject ’s medical records must be allowed for the purpose of verification of the 
data reported to the Sponsor. Findings from this review of the subject ’s medical records will be 
discussed with the site personnel. The Sponsor expects that, during monitoring visits, the 
relevant site personnel will be available, the subject ’s medical records will be accessible, and a 
suitable environment will be provided for review of ETP-related documents. The monitor will 
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
160
Status: Approved ,Date: 16 December 2019meet with the investigator as needed during the ETP to provide feedback o n the administration of 
the ETP .
Extended Treatment Period Completion/Termination
Extended Treatment Period Completion
The ETP is considered completed when the youngest subject enrolled in the ETP is [ADDRESS_42949] participating in the ETP discontinues. 
Extended Treatment Period Termination
The Sponsor reserves the right to close the study site or terminate the ETP at any time for any 
reason at the sole discretion of the Sponsor. Study sites will be closed by [CONTACT_41068]. Refer to Section 17.9.2 for further details regarding site closure and reasons for early 
closure of a site by [CONTACT_1034]. 
Use of Information and Publication
Refer to Section 17.11 for details regardin g the use of information and publication of data 
generated as a result of this ETP. 
[STUDY_ID_REMOVED]
SIMPONI®(golimumab) for Intravenous Use
Clinical Protocol CNTO148JIA3003 Amendment INT-4
161
Status: Approved ,Date: 16 December 2019INVESTIGA TOR AGREEME NT
[STUDY_ID_REMOVED]
[COMPANY_003]